New compounds derived from schweinfurthines G, E, F
New schweinfurthin derivatives targeting OSBP offer a more selective and stable treatment for cancers and neurodegenerative diseases, addressing the limitations of current therapies by enhancing metabolic stability and reducing side effects.
Patent Information
- Application Number
- FR2021007302
- Authority / Receiving Office
- FR · FR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-07-06
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing cancer treatments, such as chemotherapy, cause significant side effects due to a lack of selectivity, leading to damage to healthy cells, while there is a need for more targeted therapies. Additionally, there are no effective treatments for neurodegenerative diseases and emerging viral diseases like dengue, Zika, and SARS-CoV-2, and current schweinfurthin derivatives like G suffer from metabolic instability and short half-life.
Development of new compounds derived from schweinfurthins E, F, and G, specifically targeting oxysterol binding protein 1 (OSBP), which are synthesized through a process involving intramolecular cyclization and esterification, offering improved metabolic stability and selectivity for cancer cells, and potential applications in treating cancers, neurodegenerative diseases, and viral diseases.
The new compounds demonstrate effective inhibitory biological activity against cancer cells, particularly glioblastoma, and validate cytotoxic activity on human cell lines, providing a more targeted approach with reduced side effects and potential therapeutic benefits for neurodegenerative and viral diseases.
Abstract
Description
Title of the invention: New compounds derived from schwein-furthins G, E, F Technical field
[0001] The present invention relates to novel schweinfurthin derivatives. It also relates to the pharmaceutical application of these novel schweinfurthin derivatives, in particular on the basis of their anti-cancer biological action as well as their biological action on oxysterol-binding protein 1 (OSBP or OSBP1), for the prevention and / or treatment in particular of cancers, viral diseases and neurodegenerative diseases. It also relates to the synthesis process for obtaining them as well as to the medicaments containing them. It further relates to novel intermediate compounds. Prior art
[0002] Schweinfurthins (SWs) are natural products isolated from plants of the genus Macaranga (Euphorbiaceae). They exhibit potent and selective cytotoxic activity on the panel of 60 human cancer cell lines of the National Cancer Institute (NCI). They are particularly active on glioblastoma, kidney, and certain leukemia lines (acute lymphoblastic leukemia or myeloma). Their cytotoxicity profile bears no resemblance to the profiles of molecules currently used in cancer chemotherapy, indicating that they act via a new biological target. This targeted biological activity makes schweinfurthins attractive because they are the leaders of a new series of original anticancer agents.
[0003] The paper Dipesh S. Harmalkar et al., “Schweinfurthins AQ: isolation, synthesis, and biochemical properties,” RSC. Adv., 2018, 8, 21191-21209, discusses various schweinfurthin derivatives, including schweinfurthins E, F, and G (SW-E, SW-F, and SW-G), and their plant origin.
[0004] The document Anthony WG Burgett et al, Nature Chemical Biology, 2011, 7, 639-647 reports the affinity, among other natural molecules, of schweinfurthin A, towards OSBP, as well as its anti-proliferative activity with regard to the HCT116 and Hela lines and highlights a potential link between this target and said anti-proliferative activity.
[0005] The involvement of OSBP in certain pathologies has also recently been highlighted, notably in Antonietta Pietrangelo et al., “Bridging the molecular and biological functions of the oxysterol-binding protein family”, Cellular and Molecular Life Sciences, Springer International Publishing AG, part of Springer Nature 2018.
[0006] Even more recently, the mechanism of action of schweinfurthin G (SW-G) has been investigated in relation to protein targets constituted by intracellular lipid transfer proteins of the oxysterol-binding protein (OSBP) family (Bruno Mesmin et al, “Molecular and cellular dissection of the oxysterol-binding protein cycle through a fluorescent inhibitor”, JBC, First Published on February 19, 2020, doi: 10.1074 / jbc.RAl 19.012012, jbc.RAl 19.012012).
[0007] However, it has been shown that Schweinfurthin G has a lack of metabolic stability and a short half-life. This peculiarity is one of the reasons why Schweinfurthin G has never been used in vivo so far. Only two publications report studies on SW derivatives. (Stevens, JW, et al, Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society, 36:2017; 1283-1293; Kathleen M. Kokolus et al. Oncolmmun. 2019; 8(2): el539614). Statement of the invention
[0008] The main types of cancer treatments are surgery, radiotherapy, so-called conventional chemotherapy (involving cytotoxic agents), targeted therapies (specifically targeting certain mechanisms involved in cell regulation and growth), hormone therapy (adapted in the case of cancers sensitive to the action of hormones naturally produced by the body), and immunotherapy (aimed at stimulating the patient's immune system against tumor cells).
[0009] More specifically, chemotherapy, which remains one of the most effective treatments, is based on a cytotoxic effect: a molecule kills cancer cells in order to stop tumor growth.
[0010] However, these treatments cause serious side effects for patients due to the lack of selectivity, which leads to damage to healthy cells. In order to limit these effects, drugs are often dosed at minimal levels, to the detriment of their effectiveness.
[0011] Consequently, it remains important to find a way to target tumor cells more specifically.
[0012] Furthermore, the risk of the emergence of new viral diseases such as dengue fever or Zika virus infection, or more recently SARS-CoV-2, remains a concern. Indeed, nowadays, there are both imported and indigenous cases of these types of diseases, the latter implying that the virus is circulating in the territory concerned. Although in most cases, these diseases are asymptomatic, a significant proportion of people (20-30%) develop flu-like symptoms (fever, headaches, joint and muscle pain, or even skin rash) which can lead to sometimes severe complications.
[0013] Neurodegenerative diseases are, for their part, frequent, and their frequency increases with age even if certain metabolic and degenerative diseases can occur from childhood. Due to the progressive aging of the population and the absence of curative treatments, the number of people suffering from neurodegenerative diseases has increased considerably over the last decades and is expected to grow steadily in the years to come.
[0014] Thus, there remains a need for novel derivatives of vedelianin and schweinfurthins E, F and G, exhibiting biological action on oxysterol binding protein 1, and which can be prepared by a process comprising a reasonable number of steps, which employs readily accessible starting reagents while still allowing the compounds to be obtained in good yields.
[0015] The invention aims precisely to meet these needs. Summary of the invention
[0016] The present invention relates, according to one of its aspects, to new compounds derived from schweinfurthins E, F and G of formula (I), its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures:
[0017] [Chem.l]
[0018] in which:
[0019] [Chem.2]
[0020] represents a single or double bond, - R1 represents a hydroxy group, a (Ci-C5)alkoxy group, a (C2-C5)alkenyloxy group, a (C2-C5)alkynyloxy group, or a group -OCONH(CH2)nCOORa, in which n represents an integer between 2 and 6, and Ra represents a (Ci-C4)alkyl group, - R2 represents a hydrogen atom or a (C2-C5)alkenyl group, or alternatively, R1 and R2 together form, with the ring which carries them, a 6-membered ring comprising an oxygen atom and optionally an unsaturation, - R3 and R7 independently represent a hydrogen atom or a halogen atom, for example a bromine atom, - Represents a hydroxy group, a group
[0021] [Chem.3] —Q -^CH ^=CH
[0022] , m being equal to 1, 2 or 3, a group
[0023] [Chem.4]
[0024] , n being equal to 1, 2 or 3, preferably 1 or 2, a group
[0025] [Chem.5] GOLD
[0026] or
[0027] [Chem.6]
[0028] , wherein R is a hydrogen atom or a methyl group and R' and R' ' are independent during a (Ci-C3)alkyl group, a group
[0029] [Chem.7]
[0030] , in which s is equal to 0, 1 or 2, t is equal to 1, 2 or 3, p is equal to 2 or 3, q is equal to 1, 2, 3, 4, 5 or 6, preferably 6, and X is a hydrogen atom, halogen, in particular a chlorine atom, or an amine group, or a group -OCORb, in which Rb represents a (Ci-C4)alkyl group, - R5 represents a group of formula
[0031] [Chem. 8]
[0032] or alternatively, R4 and R5 together form, with the ring which carries them, a 6-membered ring comprising an oxygen atom and optionally substituted by one or two (Ci-C4)alkyl groups, - R6 represents a hydroxy group, a (Ci-C6)alkoxy group, a group
[0033] [Chem.9] —□ -£ch
[0034] , m being equal to 1, 2 or 3, a group [Chem. 10]
[0035]
[0036]
[0037] , n being equal to 1, 2 or 3, preferably 1 or 2, a group [Chem. 11]
[0038]
[0039] Or [Chem. 12] GOLD'
[0040]
[0041]
[0042] , in which R is a hydrogen atom or a methyl group and R' and R” are independently a (Ci-C3)alkyl group, a group [Chem. 13] , in which s is 0, 1 or 2, t is 1, 2 or 3, p is 2 or 3, q is 1, 2, 3, 4, 5 or 6, preferably 6, and X is a hydrogen atom, a halogen atom, in particular a chlorine atom, or an amine group, a -OCORc group, in which Rc represents a (Ci-C4)alkyl group, or a -OCONH(CO)pRd group, in which p represents an integer chosen from 0 or 1, Rd represents a (Ci-C6)alkyl group optionally substituted by a halogen atom, such as a chlorine atom, by a radical sugar, by a -COORe group, in which Re represents a (Ci-C4)alkyl group or a hydrogen atom or by a -OP(=O)-(ORf)(ORg) group, in which Rf and Rg independently represent a (Ci-C4)alkyl group, - R8 and R9 independently represent a hydrogen atom, a hydroxy group, or a group -OCORh, in which Rh represents a hydrogen atom or a (Ci-C5)alkyl group, and in which at least: a. R4 and R5 together form, with the ring which carries them, a 6-membered ring comprising an oxygen atom and optionally substituted by one or two (CrC4)alkyl groups, or b. R5 represents a group of formula
[0043] [Chem. 14]
[0044] and at least one of the following conditions is verified: i. R1 and R2 together form, with the ring which carries them, a 6-membered ring comprising an oxygen atom and optionally an unsaturation, ii. at least one of R1, R4 and R6 is a (C2-C5)alkenyloxy group or a (C2-C5)alkynyloxy group, iii. R8 represents a group -OCORh, in which Rh represents a hydrogen atom or a (Ci-C5)alkyl group, iv. R2 represents a (C2-C5)alkenyl group, or v. at least one of R3 and R7 is a halogen atom.
[0045] The present invention also relates, according to another of its aspects, to a compound of formula (I) according to the present invention, or at least one compound (1) to (56) as defined below, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, the mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures or pharmaceutical composition containing them, for its use as a medicament.
[0046] The present invention also relates, according to another of its aspects, to a compound of formula (I) according to the present invention, or at least one compound (1) to (56) as defined below, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, the mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures or pharmaceutical compositions containing them, for use as an inhibitor of oxysterol binding protein 1 (OSBP).
[0047] The present invention also relates, according to another of its aspects, to a compound of formula (I) according to the present invention, or at least one compound (1) to (56) as defined below, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, the mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures or pharmaceutical composition containing them, for its use for the prevention, inhibition and / or treatment of cancers, neurodegenerative diseases, dyslipidemia, hypercholesterolemia, and / or viral diseases.
[0048] The present invention also relates, according to another of its aspects, to a process for preparing a compound of formula (Ia”)
[0049] [Chem. 15]
[0050] in which R1 and R6 are as defined above and at least one of R8 and R9 represents a -OCORh group as defined above, and in particular a -OCHO group or a -OCOCH3 group, and in which R2 is a hydrogen atom, or a (C2-C5)alkenyl group, such as an allyl group or any of its pharmaceutically acceptable salts, comprising at least one step of intramolecular cyclization of the geranyl chain into pyran, of a compound of general formula (II), accompanied by the esterification of the secondary alcohol of the hexahydroxanthene unit
[0051] [Chem. 16]
[0052] (II)
[0053] , in which R1, R6 and R8 are as defined above, or a compound of formula (Ibiv)
[0054] [Chem. 17] R4 R8 I XR2 7 " '■'K 'c ,-KX\ R8^ 'X^' j X / X^' X>X / \ hhi R6 1
[0055] (Ibiv)
[0056] in which R1, R2, R4, R6, R8 and R9 are as defined above, in particular in the presence of a catalyst, in particular in the presence of a palladium catalyst and in particular in the presence of a base which may be chosen from sodium acetate (NaOAc), sodium formate (HCOONa) or sodium tetraborate (Na 2B4O7) and mixtures thereof, preferably sodium acetate, optionally followed by a step of saponification of the ester function of the hexahydroxanthene unit, to lead to the compounds of general formula (Ia”), in which at least one of the groups R1, R6, R8 or R9 is a hydroxy group.
[0057] The present invention finally relates, according to another of its aspects, to a pharmaceutical composition comprising at least one compound of formula (I) according to the present invention or at least one compound (1) to (56) as defined below, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, the mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures, and at least one pharmaceutically acceptable excipient.
[0058] The inventors have discovered that the compounds of formula (I) according to the present invention have efficacy against cancer, in particular against glioblastoma. As is evident in the experimental part, the inventors have demonstrated an inhibitory biological activity of oxysterol binding protein 1 (OSBP). They have further validated the cytotoxic activity on cell lines, and more particularly on the U87 and A549 lines. The U87 cells are cells of a human cancerous glioblastoma (GBM) cell line. The A549 cells are human alveolar basal epithelial cells of adenocarcinoma and constitute a cell line of choice for validating the cytotoxic activity because they are known to be less sensitive to schweinfurthins.
[0059] Other characteristics, aspects and advantages of the invention will appear on reading the detailed description which follows. Definitions
[0060] In the present invention, the term "room temperature" means a temperature between 18°C and 30°C, preferably between 18°C and 25°C.
[0061] In the context of the present invention, the following definitions are used:
[0062] - “Ct-Cz” denotes a carbon chain which may have from t to z carbon atoms where t and z can take for example the values from 1 to 25; for example Ci-C3 is a carbon chain which can have from 1 to 3 carbon atoms.
[0063] - An “alkyl” means a linear or branched monovalent saturated aliphatic group, which may for example comprise from 1 to 25 carbon atoms, and preferably from 1 to 5 carbon atoms. Examples which may be mentioned are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertbutyl groups, etc.
[0064] - An “alkenyl” means an unsaturated, linear or branched aliphatic group, comprising at least one double bond; for example, a Cx to Cz alkenyl group represents an unsaturated carbon chain of x to z carbon atoms, linear or branched. Mention may in particular be made of a vinyl, 1-propenyl, 2-propenyl and butenyl group or an allyl group.
[0065] - An “alkynyl” means an unsaturated, linear or branched aliphatic group, comprising at least one triple bond; for example, a Cx to Cz alkynyl group represents an unsaturated carbon chain of x to z carbon atoms, linear or branched. Examples include an ethynyl group, a propynyl group or a pentynyl group.
[0066] - An "alkoxy" denotes an -O-alkyl group. For example, one can cite a methoxy group or an ethoxy group.
[0067] - An “alkenyloxy” denotes an -O-alkenyl group. For example, we can cite a propenyloxy group.
[0068] - An “alkylnyloxy” denotes an -O-alkynyl group. For example, we can cite a propynyloxy or pentynyloxy group.
[0069] - A “halogen” means chlorine, fluorine, bromine or iodine, and means including chlorine, fluorine or bromine, more particularly chlorine.
[0070] - A “sugar radical” designates a furanose radical or hexose radical, natural or not. Unnatural sugar radicals may, for example, comprise alkylated or acylated hydroxyl and / or amine residues on the ring, such as ether, ester, and amide substituents. Other unnatural sugar radicals may comprise H, hydroxyl, ether, ester, or amide substituents at positions on the ring where these substituents are not present in natural sugars. Alternatively, the sugar radical does not comprise a substituent at its usual position on the natural sugar; this case corresponds to the deoxy sugar radical. Other examples of unnatural sugars include oxidized carbohydrates (e.g., -onic and -uronic acids) and reduced (sugar alcohol). The sugar residue can be a monosaccharide, an oligosaccharide or a polysaccharide.
[0071] As natural sugar radicals which may be used in the context of the present invention, mention may be made of glucose, galactose, fucose, mannose, xylanose, ribose, N-acetylglucose (GlcNAc), sialic acid and N-acetylgalactose (GalNAc).
[0072] - A “protecting group” means a functional group introduced into the molecule from a chemical function to mask all or part of its reactivity.
[0073] - The expression "pharmaceutically acceptable" designates that which is useful in the preparation of a pharmaceutical composition, which is generally safe, non-toxic and neither biologically nor otherwise undesirable and which is acceptable for human veterinary and / or pharmaceutical use.
[0074] - By "pharmaceutically acceptable salt" of a compound is meant in the present invention salts which are pharmaceutically acceptable, as defined herein, and which possess the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, glycolic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, p-toluenesulfonic acid, trifluoroacetic acid and the like;and (2) salts formed when an acidic proton present in the parent compound is either replaced by a metal ion, e.g., an alkali metal ion (e.g., Na+, K+, or Li+), an alkaline earth metal ion (such as Ca2+ or Mg2+), or an aluminum ion; or coordinates with an organic or inorganic base. Acceptable organic bases include diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, and sodium hydroxide. ;
[0075] - The term "hydrate or solvate" means forms of associations or combinations with one or more water molecules or with a solvent.
[0076] - Isomeric forms designate racemic, enantiomers, diaste- reisomers, epimers, tautomers as well as conformational isomers. A racemic form refers to a mixture of two enantiomers in a ratio of 55:45 to 45:55. Compounds of formula (I)
[0077] According to one of its aspects, the present application relates to the compound of formula (I) as defined above, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R 1 represents a hydroxy group, a methoxy group, a -OCONH(CH2)nCOOR a group, in which n is equal to 3, 4 or 5, in particular is equal to 3 or 5, and Ra represents a methyl or ethyl group, in particular ethyl, a propenyloxy group, or a propynyloxy group.
[0078] According to another of its aspects, the present application relates to the compound of formula (I) as defined above, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R2 represents a hydrogen atom or a (C2-C5)alkenyl group, such as an allyl group.
[0079] According to another of its aspects, the present application relates to the compound of formula (I) as defined above, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R1 and R2 together form, with the cycle which carries them, a 6-membered cycle comprising an oxygen atom and an unsaturation, in particular a group
[0080] [Chem. 18]
[0081] According to another of its aspects, the present application relates to the compound of formula (I) as defined above, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R4 represents a hydroxy group, a group
[0082] [Chem. 19]
[0083]
[0084]
[0085]
[0086] , m being equal to 1 or 3, a group [Chem. 20] , n being equal to 1 or 2, a group [Chem.21]
[0087]
[0088] Or
[0089]
[0090]
[0091] , in which R is a hydrogen atom or a methyl group and R' and R” are methyl groups, a group [Chem. 23] , in which s is equal to 0, 1 or 2, t is equal to 1 or 3, p is equal to 2 or 3, q is equal to 6, and X is a halogen atom, in particular a chlorine atom, Or a -OCOCH3 group. According to another of its aspects, the present application relates to the compound of formula (I) as defined above, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R5 represents a group of formula
[0093] [Chem.24]
[0094] According to another of its aspects, the present application relates to the compound of formula (I) as defined above, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R4 and R5 together form, with the cycle which carries them, a 6-membered cycle comprising an oxygen atom, and optionally substituted by one or two methyl groups, in particular a group
[0095] [Chem.25]
[0096] According to another of its aspects, the present application relates to the compound of formula (I) as defined above, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R6 represents a hydroxy group, a methoxy or ethoxy group, a group
[0097] [Chem.26]
[0098] , m being equal to 1 or 3, a group
[0099] [Chem.27]
[0100] , n being equal to 1 or 2
[0101] a group [Chem.28]
[0102] or
[0104] , wherein R is a hydrogen atom or a methyl group and R' and R' ' are methyl groups, a group -OCOCH3, a group -OCONHCOCH2C1, or a group -OCONH(CH2)qCOORk, in which q represents an integer chosen from 3, 4 or 5, in particular 3 and 5, and Rk represents a methyl or ethyl group, in particular ethyl.
[0105] According to another of its aspects, the present application relates to the compound of formula (I) as defined above, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R8 and independently represent a hydrogen atom, a hydroxy group, an -OCHO group, or an -OCOCH3 group.
[0106] With regard to the substitution of the (Ci-C6)alkyl group, it can alternatively be located at the end of the chain or at any level of the chain. According to a variant of the invention, the substitution, when present, is located at the end of the chain.
[0107] According to another of its aspects, the present application relates to the compound of formula (I) as defined above, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, pure enantiomers and racemic or non-racemic mixtures, represented by the formula (la):
[0108] [Chem.30] R1 R*
[0109] (the)
[0110] in which [YES] [Chem.31]
[0112] , R1, R2, R3, R6, R7, R8 and R9 are as defined above as well as its pharmaceutical salts ceutically acceptable, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures.
[0113] According to yet another of its aspects, the present application relates to the compound of formula (Ia) as defined above, in which:
[0114] [Chem.32]
[0115] represents a single or double bond, - R3 and R7 are as defined above, and more particularly represent a hydrogen atom, - R1 represents a hydroxy group, a (Ci-C5)alkoxy group, a (C2-C5)alkenyloxy group, a (C2-C5)alkynyloxy group, or a group -OCONH(CH2)nCOORa, in which n represents an integer between 2 and 6, and Ra represents a (Ci-C4)alkyl group, - R2 represents a hydrogen atom or a (C2-C5)alkenyl group, or alternatively, R1 and R2 together form, with the cycle which carries them, a 6-membered cycle comprising an oxygen atom and optionally an unsaturation, - R6 represents a hydroxy group, a (Ci-C6)alkoxy group, a (C2-C5)alkynyloxy group, a group -OCORc, in which Rc represents a (Ci-C4)alkyl group, or a group -OCONH(CO)pRd, in which p represents an integer chosen from 0 or 1, Rd represents a (Ci-C6)alkyl group optionally by a halogen atom, such as a chlorine atom, by a sugar radical, by a group -COORe, in which Re represents a (Ci-C4)alkyl group or a hydrogen atom or by a group -OP(=O)-(ORf)(ORg), in which Rf and Rg independently represent a (CrC4)alkyl group, and - R8 and independently represent a hydrogen atom, a hydroxy group, or a group -OCORh, in which Rh represents a hydrogen atom or a (Ci-C5)alkyl group.
[0116] According to a particular embodiment of this aspect of the invention, the compound of formula (Ia) as defined above, is such that
[0117] - R1 represents a hydroxy group, a methoxy group, a -OCONH(CH2)n group COORa, in which n is 3, 4 or 5, in particular is 3 or 5, and Ra represents a methyl or ethyl group, in particular ethyl, a propenyloxy group, or a propynyloxy group,
[0118] - R2 represents a hydrogen atom or a (C2-C5)alkenyl group, such as a group allyl or R1 and R2 together form, with the ring which carries them, a 6-membered ring comprising an oxygen atom and an unsaturation, in particular a group
[0119] [Chem.33] Here Y
[0120] - R6 represents a hydroxy group, a methoxy or ethoxy group, a pro group pynyloxy, an -OCOCH3 group, an -OCONHCOCH2C1 group, or an -OCONH(CH2)qCOORk group, in which q represents an integer chosen from 3, 4 or 5, in particular 3 and 5, and Rk represents a methyl or ethyl group, in particular ethyl, and - R8 and R9 independently represent a hydrogen atom, a hydroxy group, an -OCHO group, or an -OCOCH3 group
[0121] According to a particular embodiment of this aspect of the invention, the compound of formula (Ia) as defined above, has the formula (Ia')
[0122] [Chem.34]
[0123] (the)
[0124] in which
[0125] [Chem.35]
[0126] is as defined above and is in particular a double bond, R6 is as defined above and represents in particular a hydroxy group, R8 and R9 are as defined above, and in particular independently represent a hydrogen atom, a hydroxy group, an -OCHO group or an -OCOCH3 group, and even more particularly a hydroxy group, an -OCHO group or an -OCOCH3 group, as well as its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures.
[0127] Among the compounds of the invention falling within this general formula (la”), we may notably cite compounds (3) and (4).
[0128] According to yet another particular embodiment of this aspect of the invention, the compound of formula (Ia) as defined above, has the formula (Ia”)
[0129] [Chem.36] H1
[0130] (the”)
[0131] in which
[0132] [Chem.37]
[0133] , R1, R2, R6, R8 and R9 are as defined above, and in particular, - R1 represents a hydroxy group, a methoxy group, a -OCONH(CH2)n COORa group, in which n is equal to 3, 4 or 5, in particular is equal to 3 or 5, and Ra represents a methyl or ethyl group, in particular ethyl, a propenyloxy group, or a propynyloxy group, - R2 represents a hydrogen atom or a (C2-C5)alkenyl group, such as an allyl group - R6 represents a hydroxy group, a methoxy or ethoxy group, a propynyloxy group, an -OCOCO3 group, an -OCONHCOCH2C1 group, or an -OCONH(CH2)qCOORk group, in which q represents an integer chosen from 3, 4 or 5, in particular 3 and 5, and Rk represents a methyl or ethyl group, in particular ethyl, and - R8 and independently represent a hydrogen atom, a hydroxy group, an -OCHO group, or an -OCOCH3 group, as well as its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures.
[0134] Still according to this particular embodiment of this aspect of the invention, the formula (the”) is such that - R1 represents a hydroxy group, or a methoxy group, - R2 represents a hydrogen atom - R6 represents a hydroxy group, and - R8 and independently represent a hydrogen atom, a hydroxy group, or a group -OCHO.
[0135] Among the compounds of the invention falling within this general formula (la”), we may notably cite compounds (1), (2), (5), (6), (7), (8), (9), (10), (11) and (12).
[0136] According to yet another particular embodiment of this aspect of the invention, the compound of formula (Ia) as defined above, has the formula (Ia'”)
[0137] [Chem.38]
[0138] (the”)
[0139] in which
[0140] [Chem.39]
[0141] , R1, R2, R6, R9 and Rh are as defined previously, with in particular at least one of the groups R1 and R6 is a group -OCORc or a group -OCONH(CO)pRd as defined below, and in particular, - R1 represents a hydroxy group, a methoxy group, a group -OCONH(CH2)nCOORa, in which n is equal to 3, 4 or 5, in particular is equal to 3 or 5, and Ra represents a methyl or ethyl group, in particular ethyl, a propenyloxy group, or a propynyloxy group, - R2 represents a hydrogen atom or a (C2-C5)alkenyl group, such as an allyl group, - R6 represents a hydroxy group, a (Ci-C6)alkoxy group, a (C2-C5)alkynyloxy group, an -OCORc group, in which Rc represents a (Ci-C4)alkyl group, or an -OCONH(CO)pRd group, in which p represents an integer chosen from 0 or 1, Rd represents a (Ci-C6)alkyl group optionally substituted by a halogen atom, such as a chlorine atom, by a sugar radical, by a -COORe group, in which Re represents a (Ci-C4)alkyl group or a hydrogen atom or by an -OP(=O)-(ORf)(ORg) group, in which Rf and Rg independently represent a (Ci-C4)alkyl group, - R9 represents a hydrogen atom, a hydroxy group, an -OCHO group or an -OCH3 group, - Rh represents a hydrogen atom or a methyl, as well as its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures.
[0142] Still according to this particular embodiment of this aspect of the invention, the formula (la' ”) is such that - R1 represents a hydroxy group, a methoxy group, a group -OCONH(CH2)nCOORa, in which n is 3, 4 or 5, in particular is 3 or 5, and Ra represents a methyl or ethyl group, in particular ethyl, - R2 and R9 represent a hydrogen atom, and - R6 represents a hydroxy group, a methoxy or ethoxy group, a -OCONHCOCH2C1 group, or a -OCONH(CH2)qCOORb group, in which q represents an integer chosen from 3, 4 or 5, in particular 3 and 5, and Rb represents a methyl or ethyl group, in particular ethyl,
[0143] Among the compounds of the invention falling within this general formula (la”), we may notably cite compounds (13), (14), (15) and (16).
[0144] According to another of its aspects, the present application relates to the compound of formula (I) as defined above, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, represented by the formula (Ib)
[0145] [Chem.40]
[0146] (Ib)
[0147] in which
[0148] [Chem.41]
[0149] , R1, R2, R3, R4, R6, R7, R8 and R9 are as defined previously, as well as its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures.
[0150] According to yet another of its aspects, the present application relates to the compound of formula (Ib) as defined above, in which
[0151] [Chem.42]
[0152] represents a single or double bond, in particular a double bond, - R1 represents a hydroxy group, a (Ci-C5)alkoxy group, a (C2-C5)alkenyloxy group, a (C2-C5)alkynyloxy group, or a group -OCONH(CH2)nCOORa, in which n represents an integer between 2 and 6, and Ra represents a (Ci-C4)alkyl group, - R2 represents a hydrogen atom or a (C2-C5)alkenyl group, such as an allyl group, or alternatively, R1 and R2 together form, with the cycle which carries them, a 6-membered cycle comprising an oxygen atom and optionally an unsaturation, - R3 and R7 independently represent a hydrogen atom or a halogen atom, for example a bromine atom, - Represents a hydroxy group, a group
[0153] [Chem.43] -OH
[0154] , m being equal to 1, 2 or 3, a group
[0155] [Chem.44] — O H2—0 H 2—O —C H2—C^^CH
[0156] , n being equal to 1, 2 or 3, preferably 1 or 2, a group
[0157] [Chem.45] GOLD
[0158] or
[0159] [Chem.46]
[0160] , wherein R is a hydrogen atom or a methyl group and R' and R” are independent during a (Ci-C3)alkyl group, a group
[0161] [Chem.47]
[0162] , in which s is equal to 0, 1 or 2, t is equal to 1, 2 or 3, p is equal to 2 or 3, q is equal to 1, 2, 3, 4, 5 or 6, preferably 6, and X is a hydrogen atom, halogen, in particular a chlorine atom, or an amine group, or a group -OCORb, in which Rb represents a (Ci-C4)alkyl group, - R6 represents a hydroxy group, a (Ci-C6)alkoxy group, a (C2-C5)alkynyloxy group, a group
[0163] [Chem.48] -OH
[0164] , m being equal to 1, 2 or 3, a group
[0165] [Chem.49] — Û^CH2—CHS—
[0166] , n being equal to 1, 2 or 3, preferably 1 or 2, a group
[0167] [Chem.50]
[0168] or
[0170] , wherein R is a hydrogen atom or a methyl group and R' and R” are independent during a (Ci-C3)alkyl group, a group
[0171] [Chem.52]
[0172] , in which s is equal to 0, 1 or 2, t is equal to 1, 2 or 3, p is equal to 2 or 3, q is equal to 1, 2, 3, 4, 5 or 6, preferably 6, and X is a hydrogen or halogen atom, in particular a chlorine atom, or an amine group, or a group -OCORc, in which Rc represents a (Ci-C4)alkyl group, or a group -OCONH(CO)pRd, in which p represents an integer chosen from 0 or 1, Rd represents a (Ci-C6)alkyl group optionally substituted by a halogen atom, such as a chlorine atom, by a sugar radical, by a group -COORe, in which Re represents a (Ci-C4)alkyl group or a hydrogen atom or by a group -OP(=O)-(ORf)(ORg), in which Rf and Rg independently represent a (Ci-C4)alkyl group, and - R8 and Represent independently a hydrogen atom, a hydroxy group, or a group -OCORh, in which Rh represents a hydrogen atom or a (Ci-C5)alkyl group, and in which at least one of the following conditions is verified: i. R1 and R2 together form, with the ring which carries them, a 6-membered ring comprising an oxygen atom and optionally an unsaturation, ii. at least one of R1, R4 and R6 is a (C2-C5)alkenyloxy group or a (C2-C5)alkynyloxy group, iii. R8 represents a group -OCORh, in which Rh represents a hydrogen atom or a (Ci-C5)alkyl group, iv. R2 represents a (C2-C5)alkenyl group, or v. at least one of R3 and R7 is a halogen atom.
[0173] According to a particular embodiment of this aspect of the invention, the compound of formula (Ib) as defined above, is such that
[0174]
[0175] [Chem.53]
[0176] represents a double bond, - R1 represents a hydroxy group, a methoxy group, a group -OCONH(CH2)nCOORa, in which n is 3, 4 or 5, in particular is 3 or 5, and Ra represents a methyl or ethyl group, in particular ethyl, a propenyloxy group, or a propynyloxy group and
[0177] - R2 represents a hydrogen atom or a (C2-C5)alkenyl group, such as a group allyl or
[0178] R1 and R2 together form, with the cycle which carries them, a 6-membered cycle comprising an oxygen atom and an unsaturation, in particular a group 0' - Represents a hydroxy group, a group ■CH , m being equal to 1 or 3, a group -CH?-—CH ■c^ecH , n being equal to 1 or 2, a group Or RO R"0 , in which R is a hydrogen atom or a methyl group and R' and R” are methyl groups, a group ; in which s is 0, 1 or 2, t is 1 or 3, p is 2 or 3, q is 6, and X is a halogen atom, in particular a chlorine atom, Or a group -OCOCH3, - R6 represents a hydroxy group, a methoxy or ethoxy group, a group , m being equal to 1 or 3, a group , n being equal to 1 or 2 a group Or .b GOLD , in which R is a hydrogen atom or a methyl group and R' and R” are methyl groups, a -OCOCH3 group, a group -OCONHCOCH2C1, or a group -OCONH(CH2)qCOORk, in which q represents an integer chosen from 3, 4
[0179]
[0180]
[0181]
[0182]
[0183] or 5, in particular 3 and 5, and Rk represents a methyl or ethyl group, in particular ethyl, and represents in particular a hydroxy group, a methoxy or ethoxy group, a group -OCOCH3, a group [Chem. 54] , m being equal to 1 or 3, a group [Chem. 55] , n being equal to 1 or 2, or a group [Chem. 56]
[0184]
[0185] GOLD Or [Chem.57]
[0186] , in which R is a hydrogen atom or a methyl group and R' and R” are methyl groups, - R8 and Represent independently a hydrogen atom, a hydroxy group, a group -OCHO, or a -OCOCH3 group.
[0187] According to a particular embodiment of this aspect of the invention, the compound of formula (Ib) as defined above, has the formula (Ibi)
[0188] [Chem.58]
[0189] (Ibi)
[0190] in which
[0191] [Chem.59]
[0192] R4, R6'R8 and R9 are as defined above, and in particular,
[0193] [Chem.60]
[0194] represents a double bond, - R4 represents a hydroxy, propynyloxy group or an -OCOCH3 group, in particular a hydroxy group,
[0195] - R6 represents a hydroxy group, a methoxy or ethoxy group, a pro group pynyloxy, an -OCOCH3 group, an -OCONHCOCH2C1 group, or an -OCONH(CH2)q COORk group, in which q represents an integer chosen from 3, 4 or 5, in particular 3 and 5, and Rk represents a methyl or ethyl group, in particular ethyl, with R6 representing in particular a hydroxy group, and - R8 and R9 independently represent a hydrogen atom, a hydroxy group, an -OCHO group, or an -OCOCH3 group, with R8 and R9 independently representing in particular a hydrogen atom or a hydroxy group,
[0196] as well as its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, the mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures.
[0197] Among the compounds of the invention falling within this general formula (Ibi), we may notably cite compound (22).
[0198] According to a particular embodiment of this aspect of the invention, the compound of formula (Ib) as defined above, has the formula (Ibii)
[0199] [Chem.61] R6
[0200] (Ibii)
[0201] in which
[0202] [Chem.62]
[0203] , R1, R4, R6'R8 and R9 are as defined above, and in which at least one of R1, R4 and R6 is a (C2-C5)alkenyloxy group or a (C2-C5)alkynyloxy group,
[0204] and in particular,
[0205] [Chem.63]
[0206] represents a double bond, - R1 represents a hydroxy group, a (C2-C5)alkynyloxy group, or a (C2-C5)alkenyloxy group, - R4 and R6 independently represent a hydroxy group, a group
[0207] [Chem.64] —O-^CH^C^=CH
[0208] , m being equal to 1, 2 or 3, a group
[0209] [Chem.65] — CH2—o^—€H2—C^^CH
[0210] , n being equal to 1, 2 or 3, preferably 1 or 2, a group
[0211] [Chem.66] O । JL RO y R-Ox GOLD
[0212] or
[0213] [Chem.67] NO. IJ ' R'O"
[0214] , wherein R is a hydrogen atom or a methyl group and R' and R” are independent during a (Ci-C3)alkyl group, a group
[0215] [Chem.68]
[0216] , in which s is equal to 0, 1 or 2, t is equal to 1, 2 or 3, p is equal to 2 or 3, q is equal to 1, 2, 3, 4, 5 or 6, preferably 6, and X is a hydrogen atom, halogen, in particular a chlorine atom, or an amine group, and - R8 and R9 independently represent a hydrogen atom, or a hydroxy group, as well as its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures.
[0217] Among the compounds of the invention falling within this general formula (Ibii), mention may in particular be made of compounds (17), (18), (19), (20), (21), (25), and (31) to (56).
[0218] According to a particular embodiment of this aspect of the invention, the compound of formula (Ib) as defined above, has the formula (Ibiii)
[0219] [Chem.69]
[0221] in which
[0222] [Chem.70]
[0223] , R1, R2, R4, R6 and Rh are as defined above, and in particular
[0224] [Chem.71]
[0225] represents a double bond, - R1 represents a methoxy group, a hydroxy group or a (C2-C5)alkenyloxy group, such as an allyloxy group, - R2 represents a hydrogen atom or a (C2-C5)alkenyl group, such as an allyl group, - R4 and R6 independently represent a hydroxy group or an -OCORb group, in which Rb represents a (Ci-C4)alkyl group, - Rh represents a hydrogen atom or a (Ci-C5)alkyl group, and - R9 represents a hydrogen atom, a hydroxy group or a -OCORh group, in particular a hydrogen atom, as well as its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures.
[0226] Among the compounds of the invention falling within this general formula (Ibiii), mention may in particular be made of compounds (23), (26), (27) and (28).
[0227] According to a particular embodiment of this aspect of the invention, the compound of formula (Ib) as defined above, has the formula (Ibiv)
[0228] [Chem.72] R" R? :: .0, .-k .R; T 'ï......]i.....T „ . R . X' ..... / \41 il i T .........T
[0229] (Ibiv)
[0230] in which
[0231] [Chem.73]
[0232] , R1, R2 R4 R6 R8 and R9 are as defined above and in which R2 re has a (C2-C5)alkenyl group, such as an allyl group, and in particular,
[0233] [Chem.74]
[0234] represents a double bond, - R1 represents a hydroxy group or a methoxy group, - R4 and R6 represent hydroxy group, - R8 and R9 independently represent a hydrogen atom, a hydroxy group, or a group -OCORh, in which Rh represents a hydrogen atom or a (Ci-C5)alkyl group, as well as its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures.
[0235] Among the compounds of the invention falling within this general formula (Ibiv), we may notably cite compound (24).
[0236] According to a particular embodiment of this aspect of the invention, the compound of formula (Ib) as defined above, has the formula (Ibv)
[0237] [Chem.75]
[0239] [Chem.76]
[0240] , R1, R3 R4 R6 R7, R8 and R9 are as defined above and in which at at least one of R3 and R7 is a halogen atom, and in particular
[0241] [Chem.77]
[0242] represents a double bond, - R1 represents a hydroxy group or a methoxy group, - R4 and R6 represent hydroxy group, - R8 and R9 independently represent a hydrogen atom, a hydroxy group, or a group -OCORh, in which Rh represents a hydrogen atom or a (Ci-C5)alkyl group, and in particular a hydroxy group, as well as its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures.
[0243] Among the compounds of the invention falling within this general formula (Ibv), mention may in particular be made of compounds (29) and (30).
[0244] Certain compounds included in the general formula (I) as defined above turn out to be active metabolites with respect to the therapeutic target, of compounds themselves included in the general formula (I). This will appear more explicitly upon reading the experimental part. For example, compound (10) is a metabolite of compound (9), compound (2) is a metabolite of compound (1). This is equivalent to stating that compound (9) is a prodrug of compound (10) and compound (1) is a prodrug of compound (2). This specific case is also observed with respect to compounds (3) and (4), (5) and (6), (7) and (8), (11) and (12), (24) and (26), (25) and (27).
[0245] According to a preferred embodiment of the present invention, the compound of formula (I) is chosen from: - (1): (2 / ?,4a / ?,9a / ?)-5-hydroxy-7-((E )-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexah ydro-l / / -xanthen-2-yl formate, - (2): (2 / ?,4a / ?,9a / ?)-7-((E )-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexah ydro- l / / -xanthene-2,5-diol, - (3): (7a / ?,9 / ?,lla / ?)-5-((E )-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-8,8,l la-trimethyl-2,7,7a,8,9,10,l 1,11 a-octahydropyrano[3,2-c]xanthen-9-yl formate, - (4): (7aR,9Æ,llaR)-5-((E )-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-8,8,l la-trimethyl-2,7,7a,8,9,10,l 1,11 a-octahydropyrano [3,2-c]xanthen-9-ol, - (5): (2 / ?,4a / ?,9a / ?)-7-((E )-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a, 9,9a-hexahydro-17 / -xanthen-2-y 1 formate, - (6): (2 / ?,4a / ?,9a / ?)-7-((E )-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a, 9,9a-hexahydro- l / / -xanthen-2-ol, - (7): (2S,3 / ?,4a / ?,9a / ?)-7-((E )-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a, 9,9a-hexahydro-17 / -xanthene-2,3-diy 1 diformate, - (8): (2S,3 / ?,4a / ?,9a / ?)-7-((E )-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a, 9,9a-hexahydro-l / / -xanthene-2,3-diol, - (9): (2R,4a / ?,9aR )-5-hydroxy-7-(2-(5-hydroxy-2,2-dimethylchroman-7-yl)ethyl)-l,l,4a-trimethyl-2,3,4, 4a,9,9a-hexahydro- l / / -xanthen-2-yl formate, - (10): (2R,4a / ?,9aR )-7-(2-(5-hydroxy-2,2-dimethylchroman-7-yl)ethyl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hex ahydro- l / / -xanthene-2,5-diol, - (11): (2 / ?,4a / ?,9a / ? )-7-(2-(5-hydroxy-2,2-dimethylchroman-7-yl)ethyl)-5-methoxy-l,l,4a-trimethyl-2,3,4, 4a,9,9a-hexahydro- l / / -xanthen-2-yl formate, - (12): (2 / ?,4a / ?,9a / ? )-7-(2-(5-hydroxy-2,2-diméthylchroman-7-yl)éthyl)-5-méthoxy-l,l,4a-triméthyl-2,3,4, 4a,9,9a-hexahydro-l / / -xanthèn-2-ol, - (13) : (2R,4aR,9aR)-7-((E )-2-(5-(((2-chloroacetyl)carbamoyl)oxy)-2,2-diméthylchroman-7-yl)vinyl)-5-méthoxy-1,1,4a-triméthyl-2,3,4,4a,9,9a-hexahydro- l / / -xanthèn-2-yl formate, - (14) : Ethyl 6-(((((2R,4aR,9aR)-7-((E )-2-(5-(((6-éthoxy-6-oxohexyl)carbamoyl)oxy)-2,2-diméthylchroman-7-yl)vinyl)-2-(fo rmyloxy)-l,l,4a-triméthyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthèn-5-yl)oxy)carbonyl)am ino)hexanoate, - (15) : Ethyl 4-(((((2R,4aR,9aR)-7-((E )-2-(5-(((4-éthoxy-4-oxobutyl)carbamoyl)oxy)-2,2-diméthylchroman-7-yl)vinyl)-2-(for myloxy)-l,l,4a-triméthyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthèn-5-yl)oxy)carbonyl)ami no)butanoate, - (16) : (2R,4aR,9aR)-7-((E )-2-(5-(((2-chloroacetyl)carbamoyl)oxy)-2,2-diméthylchroman-7-yl)vinyl)-5-hydroxy- 1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydro- l / / -xanthene-2-yl formate, - (17) : (2R,4aR,9aR)-l,l,4a-trimethyl-7-((£' )-4-(3-methylbut-2-en-l-yl)-3,5-bis(prop-2-yn-l-yloxy)styryl)-2,3,4,4a,9,9a-hexahydro - l / / -xanthene-2,5-diol, - (18) : (2R,4aR,9aR)-7-((E )-3-hydroxy-4-(3-methylbut-2-en-l-yl)-5-(prop-2-yn-l-yloxy)styryl)-l,l,4a-trimethyl-5-(prop-2-yn-l-yloxy)-2,3,4,4a,9,9a- / 2,hydroxanoth,l - (19) : (2R,4aR,9aR)-7-((E )-3-hydroxy-4-(3-methylbut-2-en-l-yl)-5-(prop-2-yn-l-yloxy)styryl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthene-2,5-diol, - (20) : 5-((E)-2-((2R,4aR,9aR )-2-hydroxy-l,l,4a-trimethyl-5-(prop-2-yn-l-yloxy)-2,3,4,4a,9,9a-hexahydro-l / / -xant hen-7-yl)vinyl)-2-(3-methylbut-2-en-l-yl,)3-benzene- - (21) : (2R,4aR,9aR)-l,l,4a-trimethyl-7-((£' )-4-(3-methylbut-2-en-l-yl)-3,5-bis(prop-2-yn-l-yloxy)styryl)-5-(prop-2-yn-l-yloxy)-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-2-ol, - (22): 5-((E)-2-((7aR,9R,llaR )-9-hydroxy-8,8,l la-trimethyl-2,7,7a,8,9,10,l 1,1 la-octahydropyrano[3,2-c]xanthen-5-yl)vinyl)-2-(3-methylbut-2-en-l-yl)benzene-l,3-diol, - (23): 5-((E)-2-((2R,4aR,9aR )-2-acetoxy-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-7-yl)vin yl)-2-(3-methylbut-2-en-l-yl)-l,3-phenylene diacetate, -(24): (2R,4aR,9aR)-6-allyl-7-((E)-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-l,l,4a-tri methyl-2,3,4,4a,9,9a-hexahydro-lH-xanthene-2,5-diol, -(25): 5-((E)-2-((2R,4aR,9aR)-5-(allyloxy)-2-hydroxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahy dro-lH-xanthen-7-yl)vinyl)-2-(3-methylbut-2-en-l-yl)benzene-l,3-diol, -(26): (2R,4aR,9aR)-6-allyl-7-((E)-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-hydrox yl,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-2-yl acetate, - (27): (2R,4aR,9aR)-5-(allyloxy)-7-((E )-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexah ydro-l / / -xanthen-2-yl acetate, - (28): (2R,4aR,9aR)-7-((E )-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-hydroxy-l,l,4a-trimethyl-2,3,4,4a, 9,9a-hexahydro-17 / -xanthen-2-y 1 formate, - (29): (2S,3R,4aR,9aR)-7-((E )-2,6-dibromo-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-methoxy-l,l,4a-trimé thyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthene-2,3-diol, - (30): (2S,3R,4aR,9aR)-7-((E )-2-bromo-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-methoxy-l,l,4a-trimethyl -2,3,4,4a,9,9a-hexahydro-l / / -xanthene-2,3-diol, - (31): (2R,4aR,9aR)-7-((E )-3-Hydroxy-4-(3-methylbut-2-en-l-yl)-5-(prop-2-yn-l-yloxy)styryl)-5-methoxy-l,l,4 a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-2-ol, - (32): (2S,3R,4aR,9aR )-7-((E)-3-Hydroxy-4-(3-methylbut-2-en-l-yl)-5-(prop-2-yn-l-yloxy)styryl)-5-methox yl,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthene-2,3-diol, - (33): Methyl 2-(4,5-dimethoxy-2-nitrophenyl)-2-(5-((£')-2-((2R,4aR )-2-hydroxy-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-7-yl)vin yl)-2-(3-methylbut-2-en-l-yl)-3-(prop-2-yn-l-yloxy)phenoxy)acetate, - (34): Methyl 2-(5-((E)-2-((2S,3R,4aR )-2,3-dihydroxy-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-7-yl )vinyl)-2-(3-methylbut-2-en-l-yl)-3-(prop-2-yn-l-yloxy)phenoxy)-2-(4,5-dimethoxy-2 -nitrophenyl)acetate, - (35): Acid 2-(5-((E)-2-((2S,3R,4aR )-2,3-Dihydroxy-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-7-yl)vinyl)-2-(3-methylbut-2-en-l-yl)-3-(prop-2-yn-l-yloxy)phenoxy)-2-(4,5-dimethoxy-2-nitrophenyl)acetic acid, - (36): (2R,4aR,9aR)-5-methoxy-l,l,4a-trimethyl-7-((£' )-4-(3-methylbut-2-en-l-yl)-3,5-bis(prop-2-yn-l-yloxy)styryl)-2,3,4,4a,9,9a-hexahydro - l / / -xanthen-2-ol, -(37): (2,S\3 / ?,4aA\9aA')-5-Mcthoxy-1,1 ^a-trimcthyl^-GÆ? )-4-(3-methylbut-2-en-l-yl)-3,5-bis(prop-2-yn-l-yloxy)styryl)-2,3,4,4a,9,9a-hexahydro - l / / -xanthene-2,3-diol, - (38): (2RAaR,9aRy?-((E )-3-Hydroxy-4-(3-methylbut-2-en-l-yl)-5-(pent-4-yn-l-yloxy)styryl)-5-methoxy-l,l,4 a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-2-ol, - (39): (27?,4a7?,9a7?)-5-Methoxy-1,1,4a-trimethyl-7-((£' )-4-(3-methylbut-2-en-l-yl)-3,5-bis(pent-4-yn-l-yloxy)styryl)-2,3,4,4a,9,9a-hexahydro - l / / -xanthen-2-ol, - (40) : (2RAaR,9aR)-7-((E )-3-Hydroxy-4-(3-methylbut-2-en-l-yl)-5-(2-(prop-2-yn-l-yloxy)ethoxy)styryl)-5-met hoxy-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydrothè- l / / 2 - (41) : (27?,4a7?,9a7?)-5-Methoxy-l,l,4a-trimethyl-7-((£' )-4-(3-methylbut-2-en-l-yl)-3,5-bis(2-(prop-2-yn-l-yloxy)ethoxy)styryl)-2,3,4,4a,9,9a-hexahydro- l / / -xanthen-2-ol, - (42) : (2RAaR,9aR)-7-((E )-3-hydroxy-4-(3-methylbut-2-en-l-yl)-5-(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)styr yl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,-9,9,9a-hexa - (43) : (27?,4a7?,9a7?)-5-Methoxy-l,l,4a-trimethyl-7-((£' )-4-(3-methylbut-2-en-l-yl)-3,5-bis(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)styryl)-2,3 ,4,4a,9,9a-hexahydro-l / / -xanthen-2-ol, - (44) : Methyl 2-(5-((E)-2-((2S,3Æ,4aR )-2,3-dihydroxy-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-7-yl )vinyl)-3-hydroxy-2-(3-methylbut-2-en-l-yl)phenoxy)-2-(4,5-dimethoxy-2-nitrophenyl )acetate, - (45): Acid 2-(5-((E)-2-((2S,3Æ,4aR )-2,3-Dihydroxy-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-7-yl)vinyl)-3-hydroxy-2-(3-methylbut-2-en-l-yl)phenoxy)-2-(4,5-dimethoxy-2-nitropheny l)acetic acid, - (46): (25,37î,4aÆ)-7-((E )-3-((4,5-Dimethoxy-2-nitrobenzyl)oxy)-5-hydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5 -methoxy-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthene-2,3-diol, - (47): Dimethyl 2,2'-((5-((E)-2-((25,3Æ,4aR,9aR )-2,3-dihydroxy-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-7-yl )vinyl)-2-(3-methylbut-2-en-l-yl)-l,3-phenylene)bis(oxy))bis(2-(4,5-dimethoxy-2-nitr opheny 1) acetate), - (48): Acid 2,2'-((5-((E)-2-((25,3Æ,4aR,9aR )-2,3-Dihydroxy-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-177-xanthen-7-yl)vinyl)-2-(3-methylbut-2-en-l-yl)-l,3-phenylene)bis(oxy))bis(2-(4,5-dimethoxy-2-nitr ophenyl)acetic acid, - (49): 2-(3-((l-(2-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethoxy)ethyl)-\H acid - l,2,3-triazol-4-yl)methoxy)-5-((£')-2-((2S,37?,4a7?)-2,3-dihydroxy-5-methoxy-l,l,4a-tri methyl-2,3,4,4a,9,9a-hexahydro-177-xanthen-7-yl)vinyl)-2-(3-methylbut-2-en-l-yl)phenoxy)-2-(4,5-dimethoxy-2-nitrophenyl)acetic acid, - (50): (25,37î,4a7î)-7-((E)-3-(( l-(2-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethoxy)ethyl)-l 77-l,2,3-triazol-4-yl)methoxy)-5-hydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-methoxy-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydro- 177-xanthene-2,3-diol, - (51): (2Æ,4aÆ,9aÆ)-7-((7T)-3-(3-(l-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethyl 1)-177- l,2,3-triazol-4-yl)propoxy)-5-hydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-methoxy-l,l ,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-177-xanthen-2-ol, - (52): (2Æ,4aÆ,9aR)-7-((E )-3-(2-(( l-(2-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethoxy)ethyl)-177-1,2,3-triazol-4-yl)m ethoxy)ethoxy)-5-hydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-methoxy-l,l,4a-trimeth yl-2,3,4,4a,9,9a-hexahydro-177-xanthen-2-ol, - (53): (27?,4a7?,9a7?)-7-((£')-3-(2-((l-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethyl)-177 -l,2,3-triazol-4-yl)methoxy)ethoxy)-5-hydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-meth hoxy-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydro- 177-xanthen-2-ol, - (54): (27?,4a7?,9a7?)-7-((£')-3-(2-(2-((l-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-177 -l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-5-hydroxy-4-(3-methylbut-2-en-l-yl)styryl) -5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-177-xanthen-2-ol, - (55): (2Æ,4aS,9aS)-7-((E )-3-(( l-(2-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethoxy)ethyl)-177-1,2,3-triazol-4-yl)meth oxy)-5-hydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-methoxy-l,l,4a-trimethyl-l,2,3,4,4 a,9,9a,10-octahydroanthracen-2-ol, - (56): (27?,4a7?,9a7?)-7-((£')-3-((l-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethyl)-177 -l,2,3-triazol-4-yl)methoxy)-5-hydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-methoxy-l, l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-177-xanthen-2-ol, and its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures.
[0246] According to a particular embodiment, the invention relates to compounds (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (16), (24), (26), (29), (30), (50), (55) and (56).
[0247] The compounds of the invention may exist in the form of free bases or addition salts with pharmaceutically acceptable acids.
[0248] The compounds of formula (I) and or their salts can form solvates or hydrates also included in the present invention.
[0249] The terms "hydrates" and "solvated" mean that the compounds (I) according to the invention can exist in hydrate or solvate form, that is to say that the compounds of formula (I) can be combined or associated with one or more molecules of water or solvent.
[0250] The compounds of formula (I) and any of compounds (1) to (56) may comprise one or more asymmetric carbon atoms. They may thus exist in the form of enantiomers or diastereoisomers. These enantiomers, diastereoisomers and their mixtures, including racemic mixtures, are part of the present invention.
[0251] The compounds of formula (I) and any of compounds (1) to (56) may be in amorphous or crystalline forms and these forms are also within the scope of the present invention.
[0252] The present invention also encompasses any of the metabolites or prodrugs of the compound of formula (I).
[0253] Preparation of compounds of formula (I)
[0254] The compounds of the present invention may be prepared by conventional methods of organic synthesis known to those skilled in the art. The general reaction sequences described below represent a general method useful for preparing the compounds of the present invention and are not intended to limit their scope.
[0255] In particular, the compounds of the invention can be prepared from four molecules of formula II in which R1 represents a hydroxy group or a (Ci-C5)alkoxy group, in particular a methoxy group and R9 represents a hydrogen atom or a hydroxy group. These molecules are natural compounds of the swcheinfurthine family, namely vedelianine, schweinfurthine G (SW-G), schweinfurthine E (SW-E) or schweinfurthine F (SW-F). They can be obtained by isolation from plants of the genus Macaranga or by total synthesis (general review: Harmalkar et al. RSCAdv., 2018, 8, 21191).
[0256] [Chem.78] OH R1, R9 = OH: vedelianine R1 = OMe, R9 = OH : SW-E R1 = OMe, R9 = H : SW-F R' = OH, R9 ~ H : SW-G
[0257] The first reaction scheme entitled Scheme 1 comprises steps (A), (B), (C), (D), (E) to lead to the compounds of formula (Ia) and to the new intermediate (III).
[0258] The second scheme entitled scheme 2 comprises steps (H), (D), (E), (F), (J), (K), (A) and (C) to lead to the compounds of formulas (Ibi), (Ibii), (Ibiv), (Ibv) and (Ia”) as defined previously.
[0259] The third scheme entitled scheme 3 comprises steps (F), (G), (I) to lead to the compounds of formula (Ibiii) as defined previously.
[0260] Scheme 1: general scheme for the synthesis of compounds of formula (Ia)
[0261] [Chem.79]
[0262] Scheme 2: general scheme for the synthesis of compounds of formula (Ibi), (Ibii), (Ibiv), (Ibv) and (la”)
[0264] Scheme 3: general scheme for the synthesis of compounds of formula (Ibii) (steps (J) and (K)) and (Ibiii)
[0265] [Chem.81]
[0266] In the description which follows, the hexahydroxanthene or HHX motif corresponds to the motif
[0267] [Chem. 82] Step (A)
[0268] Step (A) corresponds, from compounds of general formula (II), to the intramolecular cyclization of the geranyl chain into pyran, accompanied by the esterification of the secondary alcohol of the hexahydroxanthene unit and in certain conditions for the reduction of the double bond of the stilbene unit, making it possible to lead to compounds of formula (Ia”), in which at least one of R8 and R9 represents a -OCORh group as defined above and in particular an -OCHO group or an -OCOCH3 group. They are obtained from compounds of general formula (II), when R2 is a hydrogen atom or from compounds of general formula (Ibiv), when R2 is a (C2-C5)alkenyl group, such as an allyl group.
[0269] The cyclization reaction can be carried out by any conventional method known to those skilled in the art.
[0270] According to a particular embodiment, this reaction can be carried out in formic acid.
[0271] According to a particular embodiment, this reaction can be carried out in the presence of a palladium catalyst chosen from palladium(II) acetate (Pd(OAc)2), palladium-tetrakis(triphenylphosphine) (Pd(PPh3)4), or tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) and mixtures thereof, preferably tris(dibenzylideneacetone)dipalladium(0).
[0272] According to a particular embodiment, this reaction can be carried out in the presence of a base serving as an additive, chosen from sodium acetate (NaOAc), sodium formate (HCOONa) or sodium tetraborate (Na2B4O7) and their mixtures, preferably sodium acetate.
[0273] According to another particular embodiment, the mixture of the compound of formula (II), formic acid, palladium, and the base can be carried out at a temperature between 0°C and 100°C, preferably at room temperature, for a period between 6h and 48h, preferably 18h or 24h if it is desired to obtain a compound whose double bond is reduced (as according to JM Brunei in Synlett, 2007, no. 2, p. 330).
[0274] Advantageously, this reaction can be carried out under argon.
[0275] Advantageously, the product obtained of formula (la”) according to the invention can be purified using any conventional method known to those skilled in the art, for example by column chromatography on silica gel using a heptane / ethyl acetate mixture in proportions that those skilled in the art will know how to adapt.
[0276] According to an alternative method, the compounds of formula (Ia”) in which R6 is different from OH can also be obtained starting from a compound of formula (II) in which one of the OH groups of the ring D has been functionalized to lead to R6 groups, as defined previously. Such functionalization steps can be carried out according to conventional methods. Step (B)
[0277] Step (B) corresponds to the functionalization of the phenol functions of the compounds of formula (Ia”), namely in which at least one of the groups R1 or R6 is a hydroxy group, making it possible to lead to compounds of formula (la”), namely in which R6 is a (Ci-C6)alkoxy group, a (C2-C5)alkynyloxy group, an -OCORc group, an -OCONH(CO)pRd group or an -OP(=O)-(ORf)(ORg) group, as defined previously.
[0278] The functionalization reaction can be carried out by any conventional method known to those skilled in the art.
[0279] According to a particular embodiment, this reaction can be carried out in the presence of a commercial isocyanate or prepared by any conventional method known to those skilled in the art.
[0280] According to another particular embodiment, this reaction can be carried out in the presence of a solvent chosen from tetrahydrofuran (THF), acetonitrile (ACN), diethyl ether, DMF (N,N-dimethylformamide), toluene, dichloromethane (DCM) and mixtures thereof, preferably dichloromethane.
[0281] Advantageously, the solvent or mixture of solvents can be degassed and anhydrous.
[0282] According to another particular embodiment, the mixture of the starting compound (la”), solvent and isocyanate can be carried out at a temperature between 0°C and 60°C, preferably at room temperature for a period between 1h and 24h, preferably 5h or 8h.
[0283] Advantageously, this reaction can be carried out under argon.
[0284] Advantageously, the product obtained of formula (la'”) according to the invention can be purified using any conventional method known to those skilled in the art, for example by column chromatography on silica gel using a heptane / ethyl acetate mixture in proportions that those skilled in the art will be able to adapt. Step (C)
[0285] Step (C) corresponds to the saponification of the ester function of the hexahydroxynthene unit of the compounds of general formula (Ia”) to lead to the compounds of general formula (Ia”), in which at least one of the groups R1, R6, R8 or R9 is a hydroxy group.
[0286] The saponification reaction can be carried out by any conventional method known to those skilled in the art.
[0287] According to a particular embodiment, this reaction can be carried out in the presence of a base chosen from potassium carbonate (K2CO3), sodium carbonate (Na2CO3), sodium hydrogen carbonate (NaHCO3), potassium hydroxide (KOH), sodium hydroxide (NaOH), lithium hydroxide (LiOH), cesium carbonate (Cs2CO3), potassium tert-butoxide, pyridine, ammonia, sodium ethylate (EtONa), sodium methylate (MeONa) and mixtures thereof, preferably lithium hydroxide.
[0288] According to another particular embodiment, this reaction can be carried out in presence of a solvent chosen from tetrahydrofuran (THF), water, a THF / water mixture, acetonitrile, diethyl ether, DMSO (dimethyl sulfoxide), acetone, dichloromethane, methanol, ethanol and mixtures thereof, preferably a THF / water mixture.
[0289] According to another particular embodiment, the mixing of the starting compound (la”), the base and the solvent can be carried out at a temperature between 0°C and 60°C, preferably at room temperature for a period between 10 min and 3 h, preferably 1 h.
[0290] Advantageously, the product obtained of formula (la”), in which at least one of the groups R1, R6, R8 or R9 is a hydroxy group, according to the invention can be purified using any conventional method known to those skilled in the art, for example by column chromatography on silica gel using a heptane / ethyl acetate mixture in proportions that those skilled in the art will know how to adapt. Step (D)
[0291] Step (D) corresponds to the alkylation of phenol function(s) of the compounds of formula (Ia”), in which at least R1 is a hydroxy group, to lead to the intermediate of general formula (Ia”), in which at least R1 is a (C2-C5)alkenyloxy group or a (C2-C5)alkynyloxy group, or of formula (III) as defined below.
[0292] This step (D) can also be carried out in the context of obtaining compounds of formula (Ibii), in which at least R1 is a (C2-C5)alkenyloxy group or a (C2-C5)alkynyloxy group, from a compound of formula (II), as indicated in scheme 2 above.
[0293] The alkylation reaction can be carried out by any conventional method known to those skilled in the art.
[0294] According to a particular embodiment, this reaction can be carried out in the presence of a base chosen from potassium carbonate (K2CO3), sodium hydride (NaH), potassium hydroxide (KOH), sodium hydroxide (NaOH), cesium carbonate (Cs2CO3), N,N-diisopropylethylamine (DIPEA), pyridine and mixtures thereof, preferably sodium hydride or potassium carbonate.
[0295] According to another particular embodiment, this reaction can be carried out in the presence of a solvent chosen from acetonitrile, THF (tetrahydrofuran), DMF (N,N-dimethylformamide), DMM (dimethoxymethane), DCM (dichloromethane), dioxane, MTBE (methyl tert-butyl ether), diethyl ether, toluene, and mixtures thereof, preferably DMF.
[0296] According to another particular embodiment, the electrophile allowing this alkylation reaction may be an alkyl halide, an alkenyl halide, an alkynyl halide, the tosylate or the mesylate of the corresponding alcohols, alkenols or alkynols.
[0297] Advantageously, the solvent or mixture of solvents can be degassed and anhydrous.
[0298] According to another particular embodiment, the base can be added dropwise to drop into a solution of the starting compound.
[0299] Advantageously, the mixture formed from the base, the solvent and the starting compound can be carried out at a temperature between -40°C and 10°C, preferably at -15°C, for a period ranging from 5 min to 45 min, preferably for 15 min.
[0300] According to another particular embodiment, the addition of the electrophile can be carried out at a temperature between -15°C and 25°C, preferably at 0°C for a duration between 30 min and 2 h, preferably 1 h.
[0301] Advantageously, this reaction can be carried out under argon.
[0302] Advantageously, the product obtained of formula (Ibii) or (III) according to the invention can be purified using any conventional method known to those skilled in the art, for example by column chromatography on silica gel using a heptane / ethyl acetate mixture in proportions that those skilled in the art will be able to adapt. Step (E)
[0303] Step (E) corresponds to the formation of the chromene unit from the intermediate of general formula (III) to give the compounds of formula (Ia').
[0304] This step (E) can also be implemented in the context of obtaining the compounds of formula (Ibi), from a compound of formula (Ibii), as indicated in scheme 2 above.
[0305] The cyclization reaction can be carried out by any conventional method known to those skilled in the art.
[0306] According to a particular embodiment, this reaction can be carried out in the presence of a catalyst chosen from gold(I)(acetonitrile)[(2-biphenyl)di-tert-butylphosphine]hexafluoroantimonate, ror(I)-[bis(trifluoromethanesulfonyl)imidate](triphenylphosphine), palladium(II) trifluoroacetate, platinum(II) chloride, palladium(II) diacetate, copper(I) iodide, gold(I) chloride (triphenylphosphine), silver trifluoromethanesulfonate, copper(II) bis(trifluoromethanesulfonate), gold(III) chloride, silver hexafluoroantimonate and mixtures thereof, preferably ror(I)-[bis(trifluoromethanesulfonyl)imidate](triphenylphosphine).
[0307] According to another particular embodiment, this reaction can be carried out in the presence of a solvent chosen from 1,2 dichloroethane, dichloromethane, acetonitrile, toluene, DMF (N, N dimethylformamide), 1,4 dioxane and their mixture, preferably dichloromethane.
[0308] Advantageously, the solvent or mixture of solvents can be degassed and anhydrous.
[0309] According to another particular embodiment, the mixture of the starting compound (III), of the catalyst and solvent can be carried out at a temperature between 0 °C and 60°C, preferably at room temperature for a period of between 1h and 8h, preferably 4h.
[0310] Advantageously, this reaction can be carried out under argon.
[0311] Advantageously, the product obtained of formula (la') according to the invention can be purified using any conventional method known to those skilled in the art, for example by column chromatography on silica gel using a heptane / ethyl acetate mixture in proportions that those skilled in the art will know how to adapt.
[0312] This step (E) can be followed by a saponification step (C) as described previously, to obtain a compound of formula (la'), in which R8 or R9 is a hydroxy group. Step (F)
[0313] Step (F) corresponds to a Claisen rearrangement from the compounds of general formula (Ibii), in which R1 is a (C2-C5)alkenyloxy group allowing the introduction of the R2 group comprising an allylic function.
[0314] The Claisen rearrangement can be carried out by any conventional method known to those skilled in the art.
[0315] According to a particular embodiment, this reaction can be carried out in the presence of a solvent chosen from tetrahydrofuran, HFIP, toluene, O-xylene, dichloromethane, DMF (N, N dimethylformamide), preferably DMF.
[0316] Advantageously, the solvent or mixture of solvents can be degassed and anhydrous.
[0317] According to another particular embodiment, the mixture of the starting compound (Ibii) and the solvent can be carried out at a temperature between 60°C and 200°C, preferably at 150°C for a period between 1h and 24h, preferably 10h.
[0318] Advantageously, this reaction can be carried out in the presence of activated molecular sieves.
[0319] Advantageously, the product obtained of formula (Ibiii) or (Ibiv) according to the invention can be purified using any conventional method known to those skilled in the art, for example by column chromatography on silica gel using a heptane / ethyl acetate mixture in proportions that those skilled in the art will be able to adapt. Step (G)
[0320] Step (G) corresponds to the esterification of a compound of formula (II) or of formula (Ibii), in which at least one of R8 and R9 represents a hydroxy group, in order to obtain a compound of formula (Ibiii), in which at least one of R8 and R9 represents a -OCORh group as defined previously and in particular an -OCHO group or an -OCOCH3 group.
[0321] The esterification reaction can be carried out by any conventional method known to those skilled in the art. Many esterification methods are described in the literature and in reference chemistry books, such as in March's advanced organic chemistry reactions, mechanisms and structure, sixth edition, Michael B. Smith and Jerry March, Wiley-Interscience, a John Wiley & Sons, Inc., publication, 2007).
[0322] According to another particular embodiment, this reaction can be carried out in the presence of an acid halide chosen from an acid chloride or an acid bromide, preferably an acid chloride.
[0323] According to another particular embodiment, this reaction can be carried out in the presence of a base chosen from sodium hydride (NaH), potassium tert-butoxide (tBuOK), pyridine, dimethylaminopyridine (dmap), triethylamine, potassium carbonate, N, N, diisopropylethylamine, preferably sodium hydride.
[0324] According to another particular embodiment, this reaction can be carried out in the presence of a solvent chosen from 1,2 dichloroethane, dichloromethane, acetonitrile, toluene, DMF (N,N dimethylformamide), 1,4 dioxane, tetrahydrofuran (THF) and their mixture, preferably a THF / DMF mixture.
[0325] Advantageously, the solvent or mixture of solvents may be anhydrous.
[0326] According to another particular embodiment, the mixture of solvents, of the compound starting material (II) or (Ibii), of the base can be carried out at a temperature between 0°C and 60°C, preferably at room temperature for a period of between 5 min and 30 min, preferably 15 min. According to another particular embodiment, the acid halide can then be added and the mixture can be stirred at a temperature between 0°C and 60°C, preferably at room temperature for a period of between 5h and 30h, preferably 16h.
[0327] Advantageously, this reaction can be carried out under argon.
[0328] Advantageously, the product obtained of formula (Ibiii) according to the invention can be purified using any conventional method known to those skilled in the art, for example by column chromatography on silica gel using a heptane / ethyl acetate mixture in proportions that those skilled in the art will be able to adapt. Step (H)
[0329] Step (H) corresponds to the halogenation of a compound of formula (II) in order to obtain a compound of formula (Ibv), in which at least one of the groups R3 and R7 is a halogen atom.
[0330] The halogenation reaction can be carried out by any conventional method known to those skilled in the art.
[0331] According to a variant, this step is an iodization.
[0332] According to another variant, this step is a chlorination.
[0333] According to another variant, this step is a bromination.
[0334] According to another variant, this step is a fluorination.
[0335] According to another particular embodiment, this reaction can be carried out in the presence of a reagent providing the halogen atom chosen from benzyltrimethylammonium dichloroiodate (BTMA.IC12), A-iodosuccinimide (NIS), N-bromosuccinimide (NBS), A-chlorosuccinimide (NCS), diodine (I2), dibromine (Br 2), dichlorine (Cl2), potassium iodide (Kl) and their mixtures, preferably A-bromosuccinimide (NBS).
[0336] According to a particular embodiment, this reaction can be carried out in the presence of a solvent chosen from a mixture of dichloromethane / methanol (DCM / MeOH), acetone, acetonitrile (ACN), dioxane, MTBE (methyl tert-butyl ether), diethyl ether, THF (tetrahydrofuran), DMF (N,N-dimethylformamide), DMM (dimethoxymethane), ethanol (EtOH), propanol, butanol, toluene, DMSO (dimethylsulfoxide) and mixtures thereof, preferably DMSO.
[0337] According to another particular embodiment, the mixture of the compound of formula (II), the solvent and the compound (or reagent) providing the halogen atom as defined in the invention can be carried out at a temperature of between 10°C and 70°C; preferably at 50°C, for a period of between 30 min and 24 h, preferably 3 h, 3 h or 8 h.
[0338] Advantageously, the product obtained of formula (Ibv) according to the invention can be purified using any conventional method known to those skilled in the art, for example by column chromatography on silica gel using a heptane / ethyl acetate mixture in proportions that those skilled in the art will be able to adapt. Step (I)
[0339] Step (I) corresponds to the esterification by a formate group of a compound of formula (II) in order to obtain a compound of formula (Ibiii), in which at least one of R8 and R9 represents a -OCORh group as defined previously and in particular an -OCHO group or an -OCOCH3 group.
[0340] The esterification reaction can be carried out by any conventional method known to those skilled in the art.
[0341] According to a particular embodiment, this reaction can be carried out in formic acid.
[0342] According to a particular embodiment, this reaction can be carried out in the presence of a palladium catalyst chosen from palladium(II) acetate (Pd(OAc)2), palladium-tetrakis(triphenylphosphine) (Pd(PPh3)4), or tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) and mixtures thereof, preferably tris(dibenzylideneacetone)dipalladium(0).
[0343] According to a particular embodiment, this reaction can be carried out in the presence of a base serving as an additive, chosen from sodium acetate (NaOAc), sodium formate sodium (HCOONa) or sodium tetraborate (Na2B4O7) and mixtures thereof, preferably sodium acetate.
[0344] According to another particular embodiment, the mixture of the compound of formula (II), formic acid, palladium, and the base can be carried out at a temperature between -20°C and 20°C, preferably at 0°C, for a period between 6h and 48h, preferably 18h.
[0345] Advantageously, this reaction can be carried out under argon.
[0346] Advantageously, the product obtained of formula (Ia”) according to the invention can be purified using any conventional method known to those skilled in the art, for example by column chromatography on silica gel using a heptane / ethyl acetate mixture in proportions that those skilled in the art will be able to adapt. Step (J)
[0347] Step (J) corresponds to the saponification of the methyl ester function of the dimethoxy nitrophenyl methoxy acetate unit of the compounds of general formula (Ibii) to lead to the compounds of general formula (Ibii), in which at least one of the groups R4 or R6 is a dimethoxy nitrophenyl methoxy acid group, like compounds (45) and (48) for example.
[0348] The saponification reaction can be carried out by any conventional method known to those skilled in the art.
[0349] According to a particular embodiment, this reaction can be carried out in the presence of a base chosen from potassium carbonate (K2CO3), sodium carbonate (Na2CO3), sodium hydrogen carbonate (NaHCO3), potassium hydroxide (KOH), sodium hydroxide (NaOH), lithium hydroxide (LiOH), trimethyltin hydroxide (Me3SnOH), cesium carbonate (Cs2CO3), potassium tert-butoxide, pyridine, ammonia, sodium ethylate (EtONa), sodium methylate (MeONa) and mixtures thereof, preferably trimethyltin hydroxide.
[0350] According to another particular embodiment, this reaction can be carried out in the presence of a solvent chosen from tetrahydrofuran (THF), water, a THF / water mixture, acetonitrile, diethyl ether, DMSO (dimethylsulfoxide), acetone, dichloromethane, methanol, ethanol and mixtures thereof, 1,2-dichloroethane, preferably 1,2-dichloroethane.
[0351] According to another particular embodiment, the mixing of the starting compound (Ibii), the base and the solvent can be carried out at a temperature between 0°C and 120°C, preferably at 60°C for a duration between 1h and 36h, preferably 16h.
[0352] Advantageously, the product obtained of formula (Ibii), in which at least one of the groups R4 or R6 is a dimethoxy nitrophenyl methoxy acid group, according to the invention can be purified using any conventional method known to a person skilled in the art, for example by column chromatography on silica gel using a heptane / ethyl acetate mixture in proportions that a person skilled in the art will be able to adapt. Step (K)
[0353] Step (K) corresponds to a 1,3-dipolar Huisgen cycloaddition reaction of the CuAAC type of an azide on the alkyne unit of the compounds of general formula (Ibii) to lead to the compounds of general formula (Ibii), in which at least one of the R4 or R6 groups comprises a 177-1,2,3-triazole unit, like compounds (49) to (56).
[0354] The CuAAC (Copper-catalyzed-azide-alkyne cycloaddition) type cycloaddition reaction can be carried out by any conventional method known to those skilled in the art.
[0355] According to a particular embodiment, this reaction can be carried out in the presence of a copper (I) salt such as copper iodide or copper bromide, or a copper (II) salt, for example copper sulfate or copper acetate, and sodium ascorbate which allows its reduction to copper (I), preferably a mixture of copper sulfate and sodium ascorbate.
[0356] According to another particular embodiment, this reaction can be carried out in the presence of a large number of solvents including water, acetonitrile, methanol, ethanol, t-butanol and their mixtures, DMSO (dimethylsulfoxide), dichloromethane, DMF and their mixtures, preferably a ternary mixture water / acetonitrile / t-butanol.
[0357] Advantageously, it has been shown in the literature that the addition of a mixture of 1,4-diazabicyclo[2,2,2]octane (DABCO) and acetic acid to the reaction medium makes it possible to reduce the formation of secondary products.
[0358] According to another particular embodiment, the mixture of the starting compound (Ibii), the copper (II) salt, sodium ascorbate, DABCO, acetic acid and the solvent can be carried out at a temperature between 0°C and 60°C, preferably at room temperature for a period between 1h and 36h, preferably 18h.
[0359] Advantageously, the product obtained of formula (Ibii), in which at least one of the groups R4 or R6 comprises a 1 / / -1,2,3-triazole unit, according to the invention can be purified using any conventional method known to those skilled in the art, for example by column chromatography on silica gel using a heptane / ethyl acetate mixture in proportions that those skilled in the art will be able to adapt.
[0360] Thus, according to one embodiment, the present invention relates to a synthetic process for preparing a compound of formula (Ia”)
[0361] [Chem. 83] R;
[0362] (the”),
[0363] in which R1 and R6 are as defined above and at least one of R8 and R9 represents a -OCORh group as defined above and in particular an -OCHO group or an -OCOCH3 group, and in which R2 is a hydrogen atom or a (C2-C5)alkenyl group, such as an allyl group or any of its pharmaceutically acceptable salts, comprising at least one step of intramolecular cyclization of the geranyl chain into pyran, of a compound of general formula (II), accompanied by the esterification of the secondary alcohol of the hexahydroxanthene unit
[0364] [Chem. 84]
[0366] , in which R1, R6 and R8 are as defined above, or a compound of formula (Ibiv)
[0367] [Chem. 85]
[0368] (Ibiv)
[0369] in which R1, R2, R4, R6, R8 and R9 are as defined above, in particular in the presence of a catalyst, in particular in the presence of a palladium catalyst and in particular in the presence of a base which can be chosen from sodium acetate (NaOAc), sodium formate (HCOONa) or sodium tetraborate (Na 2B4O7) and mixtures thereof, preferably sodium acetate, optionally followed of a step of saponification of the ester function of the hexahydroxanthene unit, to lead to compounds of general formula (la”), in which at least one of the groups R1, R6, R8 or R9 is a hydroxy group.
[0370] According to a particular embodiment, the present invention relates to an intermediate compound of formula (III)
[0371] [Chem. 86] Z O Rs
[0372] in which Rh, R9 and R6 are as defined previously.
[0373] The chemical structures and spectroscopic data of certain compounds of formula (I) of the invention are illustrated respectively in the following Tables 1 and 2.
[0374] [Tables 1] Compound number Chemical structure (la) (1) OH AO f XX Ji. À .L, .4 ..Js ... 0 ! ... h " o' xi- x." wr / \ H :i : 1 OH (2) HO'' OH ' ' ] (Z 7 Ah ' ' ' [i (3) çrX q ^YV .•A. -A -k H' '0' HO', <s .0.. zs : r\ y 0 o x v v a | x-a-x^- oh (8) _____v, a. , , w a '' ~ ît ï ' h a;:x,.,,,--j (9) x xïa... -x.0.a h xl y s t (10) aka. à 1 x. ...x o i,- hû- lv- -sx '-- -y 1; ■ ; (h) "0 aa . â..q 1.a ,0a- 0’ xi x -j- (12) ''o ,.- • 'ba..a. ho*' 'xb " ' a"" y°y tl kî s >(13) ''O -5.0 , A ? r ¥ A A K >'O- T G, ,Q '■'Cl (14) O >X ,-x^ .Œt o r-XAiH 6 „>.o- Ôx .0 $z' H» BO X (15) ... . ' o. 1.....L T J H ' '0' yr-'' / \H 9 A<xlxx zx ,œt ■X H 0 'A ■ ç® O. .O T' r 0 (16) ï l r R / \ H 'Ax-'" Ckx:f.O HXjsO < 'Cl (Ib) (17) OH YxkA -A . k X NO X '-if 'Y / \H ;| ; (18) A AA ......k NokX4^^ / \ n : j : ÔH (19) C ,,-x \O, J r T ¥ H0'AXP-^ / x ri 5H Àx^y^oh xv' ' 'A’ ...à (20) 'vo ^■k X ÂA.A .oh «' / g ¥ T . Av-' ÔH (21) A$a .--À- / \H il j X.-''" (22) 9'A ..A-Gx Z,. J rr YX ...A .-■■ >o' vr^-x^ -x.- ■•• ■'Y- z * l A Ox .... 1 cell (24) OH XX|VQ^ x XA X- A .Yx ,.^x ,-OH OH (25) 0' ' : ,-xi ,QA II XI .x HO ■'A'- '•■x-- ' AA OH J (26) OH .--xi , 0x - A • •• ., ^ 0 ■■ y Y" p -k ,YV .- Yx. ,Z OH Z x H :; s OH (27) aa . 0. À O p 'y YYAA À AA .--x .oh z vh HJ ÔH ' (28) OH o ZSAA A .À A -OH " Al ' ' ' OH * (29) 0 na, ,..-. / ,.0, ...À. | : i _..v.^ z''is-.x HO' X, p "' x' ï: 80" ^A OH, rï : .0 : 0 , HO. A?: Br yt H. X>K z-',x ■■■-■ ÔH S (31) ,,œ Ah OH (32) TTQP (p ( Q % (33) „A k HV / oy oAyO ArY 0^ (34) HEX, OX I 0^ The 1 ? X Af Q (35) 0^ XyS Cl o X^NOs àx (36) X HO'* I ï G r' xn ï ox 1 (37) HO„. „ HQ' "'O ?Ch
[0375] [Tables2] Ex Caractérisation (RMN et Masse) (1) 'H NMR (CDC13, 500 MHz): ô (ppm) = 0,96 (s, 3H) ; 1,01 (s, 3H) ; 1,24 (s, 3H) ; 1,32 (s, 6H) ; 1,66 (m, 1H) ; 1,79 (m, 3H; 1,84 (m, 1H) ; 1,96 (m, 1H) ; 2,03 (m, 1H) ; 2,64 (t, H, J = 6,8 Hz) ; 2,71 (m, 2H) ; 4,76 (dd, 1H, J = 4,6 and 11,1 Hz) ; 6,45 (s, 1H) ; 6,54 (s, 1H) ; 6,71 (s, 1H) ; 6,75 (d, 1H, J = 16,3 Hz) ; 6,84 (d, 1H, J = 16,3 Hz) ; 6,90 (s, 1H) ; 8,14 (s, 1H);13C NMR (CDC13, 125 MHz) : ô (ppm) = 15,7 ; 17,1 ; 20,5 ; 23,1 ; 25,0 ; 27,0 (2 C) ; 27,5 ; 32,31 ; 37,6 ; 37,7 ; 47,5 ; 74,2 ; 77,6 ; 79,6 ; 104,3 ; 108,1 (2 C) ; 109,9 ; 119,6 ; 121,7 ; 126,8 ; 128,7 ; 130,3 ; 139,3 ; 140,1 ; 145,6 ; 154,2; 155,4; 160,7 ; HRMS (ESI): m / z calculée pour C30H37O6+ [M+H]+: 493,2590; trouvé : 493,2567 (2) 'H NMR (CDC13, 500 MHz): ô (ppm) = 0,86 (s, 3H) ; 1,09 (s, 3H) ; 1,21 (s, 3H) ; 1,32 (s, 9H) ; 1,60 (m, 1H) ; 1,69 (dd, 1H, J = 5,7 and 12,3 Hz) ; 1,76 (m, 1H) ; 1,79 (t, 2H, J = 6,6 Hz) ; 1,85 (m, 1H) ; 2,00 (s, 1H) ; 2,64 (t, 2H, J = 6,6 Hz) ;2,69 (m, 2H) ; 3,41 (dd, 1H, J = 4,2 and 11,2 Hz) ; 6,45 (s, 1H) ; 6,54 (s, 1H) ; 6,70 (s, 1H) ; 6,73 (d, H, J = 16,6 Hz) ; 6,85 (d, 1H, J = 16,6 Hz) ; 6,89 (s, 1H); 13C NMR (CDC13, 125 MHz) : ô (ppm) = 14,6 ; 17,1 ; 20,2 ; 23,1 ; 26,9 (2 C) ; 27,4 ; 28,3 ; 32,3 ; 37,8 ; 38,9 ; 47,5 ; 74,2 ; 78,0 ; 78,1 ; 104,2 ; 107,9 ; 108,1 ; 109,9 ; 119,7 ; 122,3 ; 126,9 ; 128,5 ; 130,0 ; 137,3 ; 140,3 ; 145,7 ; 154,3 ; 155,3 ; HRMS (ESI): m / z calculé pour C29H37 O5+ [M+H]+: 465,2641; trouvé : 465,2620 (3) 'H NMR (CDC13, 500 MHz): ô (ppm) = 0,97 (s, 3H) ; 1,02 (s, 3H) ; 1,27 (s, 3H) ; 1,35 (s, 6H) ; 1,63 (m, 1H) ; 1,75 (m, 1H) ; 1,78 (m, 2H) ; 1,87 (m, 1H) ; 1,95 (m, 1H) ; 2,13 (m, 1H) ; 2,65 (t, 2H, J = 6,4 Hz) ; 2,71 (m, 2H) ; 4,74 (m, 3H) ; 5,81 (m, 1H) ; 6,45 (s, 1) ; 6,56 (s, 1H) ; 6,67 (d, 1H, J = 16,1 Hz) ; 6,73 (d, 1H, J = 10,3 Hz) ; 6,87 (s, 1H) ; 7,12 (d, 1H, J = 16,1 Hz) ; 8,12 (s, 1H); ; 13C NMR (CDC13, 125 MHz) : ô (ppm) = 15,4 ; 17,1 ; 19,9 ; 23,4 ; 25,2 ; 27,0 (2C) ; 27,4 ; 32,4 ;37,4 ; 37,7 ; 47,2 ; 66,3 ; 74,4 ; 76,7 ; 79,6 ; 104,6 ; 108,0 (2C) ; 119,4 ; 119,5 ; 121,3 ; 122,3 ; 122,9 ; 124,8 ; 125,9 ; 129,4 ; 137,1 ; 141,4 ; 142,9 ; 154,2 ; 155,3 ; 161,2 ; HRMS (ESI): m / z calculé pour C33H39O6+ [M+H]+: 531,2747; trouvé : 531,2738 (4) 'H NMR (CDC13, 500 MHz): ô (ppm) = 0,86 (s, 3H) ; 1,08 (s, 3H) ; 1,24 (s, 3H) ; 1,33 (s, 6H) ; 1,59 (m, 1H) ; 1,68 (m, 1H) ; 1,79 (m, 1H) ; 1,81 (m, 2H) ; 1,85 (m, 1H) ; 2,10 (m, 1H) ; 2,64 (m, 2H) ; 2,70 (m, 1H) ; 3,41 (dd, ; 1H, J = 3,9, 11,2 Hz) ; 4,74 (m, 2H) ; 5,81 (dt, 1H, J = 3,3, 10,4 Hz) ; 6,45 (s, 1H) ; 6,57 (s, 1H) ; 6,68 (d, 1H, J = 16,0 Hz) ; 6,74 (d, 1H, J = 10,4 Hz) ; 6,88 (s, 1H) ; 7,13 (d, 1H, J = 16,0 Hz) ; 13C NMR (CDC13, 125 MHz) : ô (ppm) = 14,6 ; 17,2 ; 20,2 ; 23,6 ; 26,9 (2C) ; 27,6 ; 28,5 ; 32,3 ; 38,0 (2C) ; 47,1 ; 65,0 ; 73,9 ; 77,0 ; 78,5 ; 121,0 ; 104,6 ; 107,8 ; 107,9 ; 119,1 ; 119,6 ; 122,3 ; 124,6 ; 124,8 ; 125,7 ; 129,3 ; 137,5 ; 141,4 ; 147,0 ; 154,1 ; 155,1 ; HRMS (ESI): m / z calculé pour C32H39O5+ [M+H]+: 503,2797; trouvé : 503,2796 (5) 'H NMR (CD3CN, 500 MHz): ô (ppm) = 0,96 (s, 3H) ; 1,00 (s, 3H) ; 1,21 (s, 3H) ; l,29(s, 6H) ; 1,72 (m, 1H, H3) ; 1,78 (m, 4H) ; 1,86 (m, 1H) ; 2,02 (m, 1H) ; 2,60 (t, H, J = 6,8 Hz) ; 2,72 (m, 2H) ; 3,80 (s, 3H) ; 4,74 (dd, 1H, J = 3,6, 10,8 Hz) ; 6,46 (s, 1H) ; 6,51 (s, 1H) ; 6,85 (s, 1H) ; 6,87 (d, 1H, J = 16,3 Hz) ; 6,95 (d, 1H, J = 16,3 Hz) ; 6,97 (s, 1H); 13C NMR (CD3CN, 125 MHz) : ô (ppm) : 15,7 ; 18,0 ; 20,4 ; 23, 9 ; 26,1 ;27,1 (2 C) ; 27,5 ; 33,0 ; 38,2 ; 38,3 ; 47,9 ; 56,4 ; 74,9 ; 77,5 ; 80,4 ; 104,8 ; 107,7 ; 108,0 ; 109,4 ; 121,9 ; 123,7 ; 127,3 ; 128,9 ; 130,3 ; 137,9 ; 143,5 ; 150,2 ; 156,2 ; 156,4 ; 162,3 ; HRMS (ESI): m / z calculé pour C3iH39O6+ [M+H]+: 507,2747; trouvé : 507,2736 (6) 'H NMR (CD3CN, 500 MHz): ô (ppm): 0,83 (s, 3H) ; 1,04 (s, 3H) ; 1,18 (s, 3H) ; 1,29 (s, 6H) ; 1,58b (m, 1H) ; 1,64 (t, 1H, J = 9,7 Hz) ; 1,70 (m, 1H) ; 1,74 (m, 1H) ; 1,78 (t, 1H, J = 7,0 Hz) ; 1,96 (m, 1H) ; 2,60 (t, 2H, J = 7,0 Hz) ; 2,71 (m, 2H) ; 3,32 (d, 1H) ; 3,80 (s, 3H) ; 6,44 (s, 1H) ; 6,51 (s, 1H) ; 6,84 (s, 1H) ; 6,86 (d, 1H, J = 16,7 Hz) ; 6,95 (d, 1H, J = 16,7 Hz) ; 6,95 (s, 1H) ; 13C NMR (CD3CN, 125 MHz): ô (ppm) : 15,0 ; 18,3 ; 20,5 ; 23,8 ; 27,0 (2 C) ; 27,8 ; 29,0 ; 33,0 ; 38,9 ; 39,3; 48,0 ; 56,5 ; 75,1 ; 77,87 ; 78,2 ; 105,1 ; 107,7 ; 108,1 ; 109,6 ; 121,9 ; 124,3 ; 127,2 ; 129,8 ; 130,3 ; 138,0 ; 143,7 ; 150,1 ; 156,2 ; 156,4 ; HRMS (ESI): m / z calculé pour C30H39O5+ [M+H]+: 479,2797 ;trouvé : 479,2778 (7) 'H NMR (CD3CN, 500 MHz): ô (ppm) = 1,03 (s, 3H) ; 1,16 (s, 3H) ; 1,28 (s, 6H) ; 1,37 (s, 3H) ; 1,77 (t, 2H, J = 6,8 Hz) ; l,97(m, 1H) ; 2,18 (m, 1H) ; 2,32 (m, 1H) ; 2,60 (t, 2H, J = 6,8 Hz) ; 2,80 (m, 2H) ; 3,81 (s, 3H) ; 4,93 (s, 1H) ; 5,53 (m, 1H) ; 6,45 (s, 1H) ; 6,52 (s, 1H) ; 6,87 (s, 1H) ; 6,89 (d, 1H, J = 16 Hz) ; 6,97 (d, 1H, J = 16 Hz) ; 6,99 (s, 1H) ; 8,11 (s, 1H) ; 8,14 (s, 1H); 13C NMR (CD3CN, 125 MHz): ô (ppm) = 17,0 ; 18,1; 21,7 ; 23,5 ; 27,2 (2C); 28,6 ; 33,0 ; 38,4 ; 42,0 ; 47,7 ; 56,4 ; 70,0 ; 75,0 ; 76,8 ; 77,6 ; 105,2 ; 108,4 ; 108,7 ; 109,1 ; 121,7 ; 123,9 ; 127,5 ; 129,0 ; 130,1 ; 137,9 ; 142,7 ; 150,3 ; 156,1 (2C) ; 161,75 ; 161,88 ; HRMS (ESI): m / z calculé pour C32H39 ; O8+ [M+H]+: 551,2645; trouvé : 551,2624 (8) 'H NMR (CD3CN, 500 MHz): ô (ppm) = 1,02 (s, 3H) ; 1,05 (s, 3H) ; 1,29 (s, 6H) ; 1,35 (s, 3H) ; 1,72 (m, 1H) ; 1,77 (t, 2H, J = 6,8 Hz) ; 1,88 (dd, 1H, J = 3,2, 14,0 Hz) ; 2,26 (dd, 1H, J = 2,8, 14,0 Hz) ; 2,60 (t, 2H, J = 6,8 Hz) ; 2,75 (m, 2H) ; 2,97 (m, OH) ; 3,28 (m, 1H) ; 3,80 (s, 3H) ; 4,10 (m, 1H) ; 6,44 (s, 1H) ; 6,51 (s, 1H) ; 6,86 (s, 1H) ; 6,87 (d, 1H, J = 6,8 Hz) ; 6,97 (s, 1H) 6,97, (d, 1H, J = 16 Hz); 13C NMR (CD3CN, 125 MHz) : ô (ppm) : 16,5 ; 17,85 ; 22,1; 23,9 ; 27,1 (2C) ; 29,1; 33,1 ; 38,8 ; 44,4; 47,8 ; 56,6 ; 71,5 ; 74,9 ; 77,7 ; 77,9 ; 104,9 ; 108,3 ; 108,2 ; 109,4 ; 121,7 ; 124,2 ; 127,1 ; 129,1 ; 130,3 ; 138,4 ; 143,4 ; 150,12 ; 156,11 ; 156,5 ; HRMS (ESI): m / z calculé pour C30H39O6+ [M+H]+: 495,2747; trouvé : 495,2727 (9) 'H NMR (CDC13, 500 MHz): ô (ppm) = 0,95 (s, 3H) ; 0,99 (s, 3H) ; 1,23 (s, 3H) ; 1,31 (s, 6H) ; 1,67 (m, 1H) ; 1,70 (m, 1H) ; 1,78 (t, 2H, J = 6,8 Hz) ; 1,85 (m, 1H) ; 1,94 (m, 1) ; 2,02 (m, 1H) ;2,61 (t, 2H, J = 6,8 Hz) ; 2,66 (m, 2H) ; 2,67 (s, 4H) ; 4,76 (dd, 1H, J = 4,2 and 11,7 Hz) ; 6,19 (s, 1H) ; 6,28 (s, 1H) ; 6,44 (s, 1H) ; 6,61 (s, 1H) ; 8,12 (s, 1H) ; 13C NMR (CDC13, 125 MHz): ô (ppm) = 15,5 ; 17,0 ; 20,3 ; 22,8 ; 25,0 ; 27,0 (2C) ; 27,5 ; 32,3 ; 37,2 ; 37,6 ; 37,7 ; 38,0 ; 47,6 ; 74,1 ; 77,2 ; 79,7 ; 106,1 ; 106,5 ; 109,7 ; 112,4 ; 120,2 ; 121,6 ; 134,3 ; 138,2 ; 141,8 ; 145,4 ; 155,0 ; 155,4 ; 161,0 ; HRMS (ESI): m / z calculé pour C30H39O6+ [M+H]+: 495,6360; trouvé : 495,2743 (10) 'H NMR (CDC13, 500 MHz) : ô (ppm) = 0,87 (s, 3H) ; 1,1 (s, 3H) ; 1,20 (s, 3H) ; 1,31 (s, 6H) ; 1,60 (m, 1H) ; 1,67 (dd, 1H, J = 5,5, 11,6 Hz) ; 1,75 (m, 1H) ; 1,78 (t, 2H, J = 7,0 Hz) ; 1,85 (m, 1H) ; 2,00 (m, 1H) ; 2,61 (t, 2H, J = 6,8 Hz) ; 2,66 (m, 2H) ; 2,70 (s, 4H) ; 3,41 (dd, 1H, J = 4,2 and 11,9 Hz) ; 6,19 (s, 1H) ; 6,29 (s, 1H) ; 6,44 (s, 1H) ; 6,59 (s, 1H); 13C NMR (CDC13, 125 MHz): ô (ppm) = 14,4 ; 17,0 ; 20,4 ; 22,9 ; 27,5 ; 26,9 (2 C) ; 28,3 ; 32,6 ; 38,1 ; 38,3 (2 C) ; 38,7 ;47,7 ; 74,4 ; 77,6 ; 78,6 ; 106,3 ; 106,9 ; 109,7 ; 112,6 ; 119,9 ; 122,0 ; 134,4 ; 138,6 ; 141,7 ; 145,4 ; 154,1 ; 155,1 ; HRMS (ESI): m / z calculé pour C29H39O5+ [M+H]+: 467,2797; trouvé : 467,2716 (H) 'H NMR (CDC13, 500 MHz): ô (ppm) = 0,94 (s, 3H) ; 0,98 (s, 3H) ; 1,24 (s, 3H) ; 1,31 (s, 6H) ; 1,67 (m, 1H) ; 1,70 (m, 1H) ; 1,78 (t, 2H, J = 6,8 Hz) ; 1,85 (m, 1H) ; 1,94 (m, 1H) ; 2,02 (m, 1H) ; 2,61 (t, 2H, J = 6,8 Hz) ; 2,66 (d, 2H, J = 8,9 Hz) ; 2,73 (m, 4H) ; 3,78 (s, 3H) ; 4,76 (dd, 1H, J = 4,3 and 11,5 Hz) ; 6,18 (s, 1H) ; 6,28 (s, 1H) ; 6,49 (s, 1H) ; 6,51 (s, 1H) ; 8,11 (s, 1H); 13C NMR (CDC13, 125 MHz): ô (ppm) = 15,5 ; 16,9 ; 19,9 ; 23,1 ; 24,9 ; 26,8 (2 C) ; 27,5 ; 32,3 ; 37,4 ; 37,6 ; 38,1 ; 38,7 ; 47,3 ; 56,2 ; 74,2 ; 76,3 ; ; 79,8 ; 106,1 ; 106,6 ; 109,7 ; 110,2 ; 121,2 ; 122,2 ; 133,6 ; 140,8 ; 141,8 ; 148,5 ; 154,2 ; 155,0 ; 161,2 ; HRMS (ESI): m / z calculé pour C3iH4iO6+ [M+H]+: 509,2903; trouvé : 509,2904 (12) 'H NMR (CDC13, 500 MHz) : ô (ppm) = 0,85 (s, 3H) ; 1,07 (s, 3H) ; 1,21 (s, 3H) ; 1,31 (s, 6H) ; 1,59 (m, 1H) ; 1,67 (t, 1H, J = 8,9 Hz) ; 1,78 (t, 2H, J = 6,6 Hz) ; 1,80 (m, 1H) ; 1,83 (m, 1H) ; 2,09 (m, 1H) ; 2,61 (t, 2H, J = 6,6 Hz) ; 2,66 (d, 2H, J = 8,9 Hz) ; 2,71 (m, 4H) ; 2,74 (m, 2H) ; 3,41 (dd, 1H, J = 3,8 and 11,5 Hz) ; 3,78 (s, 3H) ; 6,17 (s, 1H) ; 6,29 (s, 1H) ; 6,49 (s, 1H) ; 6,51 (s, 1H) ; 13C NMR (CDC13, 125 MHz) : ô (ppm) = 14,5 ; 17,0 ; 20,1 ; 23,3 ; 24,9 ; 26,8 (2 C) ; 27,8 ; 32,5 ; 37,5 ; 38,0 ; 38,1 ; 38,7 ; 47,0 ; 56,1 ; 74,1 ; 76,8 ; 78,6 ; 106,1 ; 106,6 ; 109,7 ; 109,9 ; 121,3 ; 122,7 ; 133,3 ; 141,8 ; 141,9 ; 148,7 ; 154,1 ; 155,1 ;HRMS (ESI): m / z calculé pour C30H4i O5+ [M+H]+: 481,2954; trouvé : 481,2879; (13) 'H NMR (CDC13, 500 MHz) : ô (ppm) = 0,96 (s, 3H) ; 1,01 (s, 3H) ;1,26 (s, 3H) ; 1,33 (s, 6H) ; 1,65 (m, 1H) ; 1,78 (m, 3H) ; 1,91 (m, 1H) ; 1,93 (m, 1H) ; 2,1 (m, 1H) ; 2,60 (t, H, J = 6,8 Hz) ; 2,72 (m, 2H) ; 3,80 (s, 3H) ; 4,45 (s, 2H) ; 4,76 (dd, 1H, J = 3,6, 10,8 Hz) ; 6,77 (d, 1H, J = 16.3 Hz); 6,79 (s, 1H), 6,80 (s, 1H), 6,83 (s, 1H), 6,86 (s, 1H), 6,89 (d, 1H, J = 16.3 Hz) ; 13C NMR (CDC13, 125 MHz) : ô (ppm) = 15,7 ; 17,6 ; 20,1 ; 23, 4 ; 25,1 ; 26,9 (2 C) ; 27,5 ; 33,0 ; 37,7 ; 38,3 ; 43,9 ; 47,0 ; 56,3 ; 74,4 ; 76,0 ; 79,3 ; 107,5 ; 110,6 ; 112,9 ; 113,5 ; 120,7 ; 122,2 ; 125,7 ; 128,3 ; 129,7 ; 137,7 ; 142,5 ; 148,1 ; 148,6 ; 148,9 ; 155,0 ; 161,2 ; 166,5 ; HRMS (ESI): m / z calculé pour C34H42C1NO8+ [M+H]+: 626,2521; trouvé : 626,2513 (14) 'H NMR (CDC13, 500 MHz): ô (ppm) = 0, 95 (s, 3H) ; 0, 99 (s, 3H) ; 1, 23 (s, 3H) ; 1, 24 (t, 6H, J = 7, 0 Hz) ; 1, 32 (s, 6H); 1, 40 (m, 4H) ; 1, 60 (m, 4H) ; 1, 67 (m, 4H) ; 1, 69 (m, 1H) ; 1, 79 (m, 3H) ; 1, 81 (m, 1H) ; 1, 92 (m, 1H) ; 1, 96 (m, 1H) ; 2, 31 (m, 4H) ; 2, 59 (t, 2H, J = 6, 9 Hz) ;2, 71 (m, 2H) ; 3, 25 (m, 4H) ; 4, 11 (q, 4H, J = 7,0 Hz) ; 4, 75 (dd, 1H, J = 4, 2 and 11, 4 Hz) ; 5, 04 (si, 2H, NH) ; 6, 74 (s, 1H) ; 6, 75 (d, 1H, J = 16, 0 Hz) ; 6, 76 (s, 1H) ; 6, 87 (d, 1H, J = 16, 0 Hz) ; 7, 00 (s, 1H) ; 7, 03 (s, 1H) ; 8, 12 (s, 1H) ; 13C NMR (CDC13, 125 MHz): ô (ppm) = 14,5 (2 C) ; 15,6 ; 17,6 ; 20,1 ; 23,2 ; 24,8 (2 C) ; 25,0 ; 26,5 (2 C) ; 27,0 (2 C) ; 27,4 ; 29,8 (2 C) ; 32,4 ; 34,4 (2 C) ; 37,5 ; 37,6 ; 41,3 (2 C) ; 47,4 ; 60,8 (2 C) ; 74,6 ; 76,9 ; 79,7 ; 111,6; 112,6; 114,4; 119,3; 123,3 ; 125,5 ; 126,7; 128,3; 129,5 ; 137,3; 139,8 ; 145,2 ; 149,8 ; 154,2 (2 C) ; 154,9 ; 160,9 ; 173,7 (2 C) ; HRMS (ESI): m / z calculé pour C48H67N2Oi2+ [M+H]+: 863, 4694; trouvé : 863, 4697 (15) 'H NMR (CDC13, 500 MHz): ô (ppm) = 0,95 (s, 3H) ; 1,00 (s, 3H) ; 1,23 (s, ; 3H) ; 1,24 (dt, 6H, J = 2,4, 7,1 Hz) ; 1,32 (s, 6H) ; 1,65 (m, 1H) ; 1,77 (m, 2H) ; 1,79 (m, 1H) ; 1,80 (m, 1H) ; 1,92 (q, 4H, J = 7,0 Hz) ; 1,95 (m, 1H) ; 1,96 (m, 1H) ; 2,40 (m, 4H) ; 2,59 (t, 2H, J = 6,9 Hz) ; 2,72 (m, 2H) ; 3,31 (m, 4H) ; 4,14 (dq, 4H, J = 3,4, 7,1 Hz) ; 4,75 (dd, 1H, J = 4,2 and 11,0 Hz) ; 5,15 (m, 2H, NH) ; 6,74 (s, 1H) ; 6,76 (d, 1H, J = 16,0 Hz) ; 6,78 (s, 1H) ; 6,87 (d, 1H, J = 16,0 Hz) ; 7,00 (s, 1H) ; 7,03 (s, 1H) ; 8,11 (s, 1H) ; 13C NMR (CDC13, 125 MHz): ô (ppm) = 14,4 (2 C) ; 15,7 ; 17,7 ; 20,0 ; 23,2 ; 24,6 ; 26,0 (2 C) ; 26,4 (2 C) ; 27,3 ; 32,3 ; 34,5 (2 C) ; 37,4 ; 37,7 ; 41,5 (2 C) ; 47,2 ; 60,3 (2 C) ; 74,6 ; 76,9 ; 79,5 ; 111,4 ; 112,6 ; 114,4 ; 118,9 ; 123,5 ; 125,6 ; 126,7 ; 128,1 ; 129,7 ; 137,4 ; 140,3 ; 145,9 ; 150,0 ; 154,5 (2 C) ; 151,1 ; 161,0 ; 173,9 (2 C) ; HRMS (ESI): m / z calculé pour C44H59N2 O12+ [M+H]+: 807,4068; trouvé : 807,4108 (16) 'H NMR (CDC13, 500 MHz): ô (ppm) = 0,96 (s, 3H) ; 1,02 (s, 3H) ; 1,25 (s, 3H) ; 1,33 (s, 6H) ;1,66 (m, 1H) ; 1,78 (m, 3H) ;1,82 (m, 1H) ;1,94 (m, 1H) ; 2,03 (m, 1H) ; 2,59 (t, H, J = 6,8 Hz) ; 2,72 (m, 2H) ; 4,53 (m, 2H) ; 4,76 (m, 1H) ; 6,71 (s, 1H) ; 6,76 (d, 1H, J = 16,3 Hz) ; 6,77 (s, 1H) ; 6,84 (s, 1H) ; 6,88 (d, 1H, J = 16,3 Hz) ; 6,91 (s, 1H) ; 8,14 (s, 1H) ; 13C NMR (CDC13, 125 MHz): ô (ppm) = 15,7 ; 17,6 ; 20,1 ; 22, 8 ; 25,0 ; 26,9 (2C) ; 27,5 ; 32,1 ; 37,4 ; 37,5 ; 43,8 ; 47,2 ; 74,7 ; 77,5 ; 79,7 ; 109,9 ; 110,2 ; 110,7 ; 113,7 ; 120,9 ; 122,0 ; 125,8 ; 129,7 ; 129,8 ; 137,8 ; 140,2 ; 145,3 ; 148,5 ; 155,7 ; 160,6 ; 166,1 (CCONH n’apparaît pas, 146 ppm théoriques) ; HRMS (ESI): m / z calculé pour C33H39C1NO8+ [M+H]+: 612,2364 ; trouvé : 612,2374 (17) 'H NMR (CD3CN, 500MHz) : ô (ppm) = 0,83 (s, 3H) ; 1,06 (s, 3H) ; 1,21 (s, 3H) ; 1,60 (m, 1H) ; 1,65 (s, 3H) ; 1,70 (m, 1H) ; 1,75 (m, 1H) ; 1,77 (s, 3H) ; 1,77 (m, 1H) ; 2,02 (m, 1H) ; 2,72 (m, 1H-0H) ; 2,74 (m, 2H) ; 2,81 (t, 2H, J = 2,3 Hz) ; 3,34 (s, 1H) ; 3,30 (d, 2H, J = 7,4 Hz) ; 4,78 (d, 4H, H17, J = 2,3 Hz) ;5,14 (t, 1H, J = 7,4 Hz) ; 6,36 (s, 1H-OH) ; 6,85 (s, 2H) ; 6,79 (d, 1H, J = 1,8 Hz) ; 6,87 (d, 1H, J = 1,8 Hz) ; 6,92 (d, 1H, J = 16,3 Hz) ; 7,03 (d, 1H, J = 16,3 Hz); 13C NMR (CD3CN, 125 MHz): ô (ppm) = 15,2; 18,5; 20,7; 23,6; 23,9; 26,3; 28,2; 29,5; 38,9; 39,6; 48,5; 57,6 (2 C) ; 77,1 (2 C) ; 78,4; 78,6; 80,4 (2 C) ; 105,6 (2 C) ; 111,0; 119,8 ; 121,1; 123,8; 124,4; 127,4; 130,3; 130,6; 132,7; 138,3; 142,3; 147,2; 157,6 (2 C) ; HRMS (ESI): m / z calculé pour C^H^CV [M+H]+: 541,2949; trouvé : 541,2957 (18) 'H NMR (CD3CN, 500MHz) : ô (ppm) = 0,83 (s, 3H) ; 1,05 (s, 3H) ; 1,20 (s, 3H) ; 1,59 (m, 1H) ; 1,66 (s, 3H) ; 1,67 (m, 1H) ; 1,72 (m, 1H) ; 1,74 (m, 1H) ; 1,76 (s, 3H) ; 1,98 (m, 1H) ; 2,74 (m, 2H) ; 2,80 (m, 2H) ; 3,33 (m, 1H) ; 3,28 (d, 2H, J = 7,6 Hz) ; 4,75 (d, 2H, J = 2,2 Hz) ; 4,77 (d, 2H, J = 2,0 ; Hz) ; 5,15 (t, 1H, J = 7,6 Hz) ; 6,64 (s, 1H) ; 6,74 (s, 1H,) ; 6,90 (d, 1H, J = 16,6 Hz) ; 6,94 (d, 1H, J = 1,5 Hz) ; 6,99 (d, 1H, J = 16,6 Hz) ; 7,03 (d, 1H, J = 1,5 Hz) ; 13C NMR (CD3CN, 125 MHz) : ô (ppm) = 14,9 ; 18,1 ; 20,5 ; 23,3 ; 24,1 ; 26,4 ; 27,9 ; 29,1 ; 38,7 ; 39,3 ; 47,9 ; 57,3 (2 C) ; 76,8 (2 C) ; 77,9 ; 78,8 ; 80,5 (2 C) ; 103,2 ; 108,2 ; 111,3 ; 118,8 ; 123,2 ; 123,7 ; 125,1 ; 127,3 ; 129,1 ; 128,5 ; 132,5 ; 137,8 ; 144,8 ; 148,2 ; 156,7 ; 157,8 ; HRMS (ESI): m / z calculé pour C35H40CV [M+H]+: 541,2949; trouvé : 541,2943 (19) 'H NMR (CD3CN, 500MHz) : ô (ppm) = 0,83 (s, 3H) ; 1,05 (s, 3H) ; 1,21 (s, 3H) ; 1,60 (m, 1H) ; 1,66 (s, 3H) ; 1,70 (m, 1H) ; 1,76 (m, 1H) ; 1,76 (s, 3H) ; 1,77 (m, 1H) ; 2,02 (m, 1H) ; 2,71 (m, 2H) ; 2,79 (d, 1H-0H, J = 5,3 Hz) ; 2,80 (t, 1H, J = 2,3 Hz) ; 3,28 (d, 2H, J = 7,0 Hz) ; 3,30 (m, 1H, H2) ; 4,75 (d, 2H, J = 2,3 Hz) ; 5,15 (t, 1H, J = 7,0 Hz) ; 6,38 (s, 1H-OH) ; 6,65 (s, 1H) ; 6,72 (s, 1H) ; 6,78 (d, 1H, J = 1,5 Hz) ;6,86 (d, 1H, J = 16,4 Hz) ; 6,87 (d, 1H, J = 1,5 Hz) ; 6,93 (s, 1H-OH) ; 6,95 (d, 1H, J = 16,4 Hz);13C NMR (CD3 CN, 125 MHz) : ô (ppm) = 14,9 ; 18,1 ; 20,5 ; 23,2 ; 23,7 ; 25,9 ; 27,8 ; 29,1 ; 38,6 ; 39,3 ; 48,2 ; 57,2 ; 76,6 ; 78,0 ; 78,7 ; 80,2 ; 103,2 ; 108,1 ; 110,6 ; 117,5 ; 120,6 ; 123,7 ; 124,; 126,; 129,; 129,; 132,; 137,; 141,9; 146,8 ; 156,5 ; 157,6 ; HRMS (ESI): m / z calculé pour C32H39O5+ [M+H]+: 503,2792; trouvé : 503,2806 (20) 'H NMR (CD3CN, 500MHz) : ô (ppm) = 0,83 (s, 3H) ; 1,05 (s, 3H) ; 1,19 (s, 3H) ; 1,59 (m, 1H) ; 1,66 (s, 3H) ; 1,66 (m, 1H) ; 1,72 (m, 1H) ; 1,74 (s, 3H) ; 1,75 (m, 1H) ; 1,98 (m, 1H) ; 2,73 (m, 2H) ; 2,77 (d, 1H-OH, J = 5,3 Hz) ; 2,79 (t, 1H, J = 2,2 Hz) ; 3,33 (s, 1H,) ; 3,25 (d, 2H, J = 7,1 Hz) ; 4,74 (d, 2H, J = 2,2 Hz) ; 5,17 (t, 1H, J = 7,1 Hz) ; 6,52 (s, 2H) ; 6,84 (d, 1H, J = 16,6 Hz) ; 6,91 (d, 1H, J = 16,6 Hz) ; 6,93 (d, 1H, J = 1,5 Hz) ; 7,02 (d, 1H, J = 1,5 Hz); 13C NMR (CD3CN, 125 MHz) :ô (ppm) = 15,3 ; 18,3 ; 20,7 ; 23,8 ; 24,2 ; 26,3 ;28,1 ; 29,3 ; 39,0 ; 39,5 ; 48,2 ; 57,8 ; 77,2 ; 78,2 ; 78,6 ; 80,4 ; 106,4 (2 C) ; 111,6 ; 115,6 ; 123,4 ; 124,2 ; 125,1 ; 127,6 ; 128,9 ; 130,2 ; 132,6 ; 137,8 ; 144,7 ; 148,0 ; 157,2 (2 C) ; HRMS (ESI): m / z calculé pour C 32H39O5+ [M+H]+: 503,2792; trouvé : 503,2798 (21) 'H NMR (CD3CN, 500MHz) : ô (ppm) = 0,83 (s, 3H) ; 1,05 (s, 3H) ; 1,20 (s, 3H) ; 1,59 (m, 1H) ; 1,65 (s, 3H) ; 1,66 (m, 1H) ; 1,73 (m, 1H) ; 1,74 (m, 1H) ; 1,77 (s, 3H) ; 1,98 (m, 1H) ; 2,74 (m, 2H) ; 2,81 (m, 3H) ; 3,33 (s, 1H) ; 3,30 (d, 2H, J = 7,4 Hz) ; 4,76 (d, 2H, J = 2,5Hz) ; 4,79 (d, 4H, J = 2,3Hz) ; 5,14 (t, 1H, J = 7,4 Hz) ; 6,87 (s, 2H) ; 6,95 (d, 1H, J = 2,0 Hz) ; 6,97 (d, 1H, J = 16,4 Hz) ; 7,04 (d, 1H, J = 2,0 Hz) ; 7,07 (d, 1H, J = 16,4 Hz) ; 13C NMR 1 (CD3CN, 125 MHz) :ô (ppm) = 15,2 ; 18,4 ; 20,8; 23,7; 24,3; 26,4; 28,2; ; 29,3; 39,1; 39,6 ; 48,0 ; 57,5 (2 C) ; 76,8; 77,0 (3 C) ; 78,3; 78,7; 80,3 (3 C) ; 105,7 (2 C) ; 111,5; 119,8; 123,5; 123,8; 125,3 ; 127,6; 129,9; 130,0; 132,7 ; 138,2; 144,8 ; 147,8; 157,6 (2 C); HRMS (ESI): m / z calculé pour C38H43O5+ [M+H]+: 579,3105; trouvé : 579,3104 (22) 'H NMR (CDC13, 500 MHz) : ô (ppm) = 0,86 (s, 3H) ; 1,09 (s, 3H) ; 1,22 (s, 3H) ; 1,59 (m, 1H) ; 1,69 (dd, 1H, J = 6,7, 11,5 Hz) ; 1,74 (s, 3H) ; 1,80 (m, 1H) ; 1,81 (s, 3H) ; 1,84 (m, 1H) ; 2,10 (m, 1H) ; 2,71 (m, 1H) ; 3,40 (m, 1H) ; 3,42 (m, 1H) ; 4,76 (ddd, 2H, J = 3,1, 14,6, 27,6 Hz) ; 5,25 (t, 1H, J = 6,6 Hz) ; 5,82 (m, 1H) ; 6,52 (s, 2H) ; 6,67 (d, 1H, J = 16,0 Hz) ; 6,73 (d, 1H, J = 10,3 Hz) ; 6,89 (s, 1H) ; 7,13 (d, 1H, J = 16,0 Hz) ; 13C NMR (CDC13 , 125 MHz) : ô (ppm) = 14,5 ; 18,1 ; 20,4 ; 22,8 ; 23,7 ; 26,0 ; 27,6 ; 28,6 ; 38,0; 38,7; 47,1 ; 65,1 ; 74,4 ; 78,2 ; 78,4 ; 106,5 (2 C) ; 113,3; 119,2; 119,7 ; 121,2 ; 121,6 ; 122,3 ; 123,6 ; 125,1 ; 125,7 ; 129,1 ; 137,5 ; 141,6 ; 143,0 ; 155,4 (2 C) ;HRMS (ESI): m / z calculé pour C32H39O5+ [M+H]+: 503,2797; trouvé : 503,2781 (23) 'H NMR (CDC13, 500 MHz) : ô (ppm) = 0,94 (s, 3H) ; 0,98 (s, 3H) ; 1,25 (s, 3H) ; 1,60 (m, 1H) ; 1,66 (s, 1H) ; 1,70 (s, 3H) ; 1,77 (m, 1H) ; 1,89 (m, 1H) ; 1,90 (m, 1H) ; 2,06 (s, 3H) ; 2,13 (m, 1H) ; 2,29 (s, 6H) ; 2,70 (d, 2H, J = 9Hz) ; 3,15 (d, 2H, J = 6Hz) ; 3,86 (S, 3H) ; 4,63 (dd, 1H, J = 4,0 and 11,6 Hz) ; 5,04 (dd, 1H, J = 6,1 Hz) ; 6,79 (s, 1H) ; 6,81 (d, 1H, J = 15,8 Hz) ; 6,82 (s, 1H) ; 6,93 (d, 1H, J = 15,8 Hz) ; 7,05 (s, 2H); 13C NMR (CDC13, 125 MHz) : ô (ppm) = 15,7 ; 17,9 ; 20,1 ; 21,1 (2 C) ; 21,2 ; 23,3 ; 24,3 ; 24,9 ; 25,8 ; 27,5 ; 37,6 ; 37,7 ; 47,0 ; 56,4 ; 76,8 ; 79,7 ; 107,6 ; 118,2 (2 C) ; 121,3 ; 121, 5 ; 122,7 ; 124,9 ; 125,3 ; 128,8 ; 130,4 ; 132,2 ; 137,4 ; 143,2 ; 149,3 ; 150,2 (2 C) ; 169, 4 (2 C) ; 171,1 ; HRMS (ESI): m / z calculé pour C 36H45O8+ [M+H]+: 605,3114; trouvé : 605,3141 (24) 'H NMR (CDC13, 500 MHz) : ô (ppm): 0,87 (s, 3H) ; 1,09 (s, 3H) ; 1,23 (s, 3H) ;1,62 (m, 1H) ; 1,71 (m, 1H) ; 1,75 (s, 3H) ; 1,77 (m, 1H) ; 1,85 (m, 1H) 1,82 (s, 3H) ; 1,87 (m, 1H) ; 2,01 (m, 1H) ; 2,70 (m, 2H) ; 3,40 (m, 2H) ; 3,44 (m, 1H) ; 3,50 (m, 2H) ; 4,98 (m, 2H) ; 5,17 (s large, 1H, OH) ; 5,25 (t, 1H, J = 6,6 Hz) ; 5,52 (s, 1H, OH) ; 5,96 (m, 1H) ; 6,5 l(s, 2H) ; 6,76 (d, 1H, J = 16 Hz) ; 6,92 (s, 1H) ; 7,21 (d, 1H, J = 16 Hz); 13C NMR (CDC13, 125 MHz) : ô =14,3 ; 17,7 ; 20,3 ; 22,6 ; 22,7 ; 26,0 ; 27,4 ; 28,2 ; 29,2 ; 37,8 ; 38,7 ; 47,5 ; 77,8 ; 78,2 ; 106,4 (2 C) ; 112,8 ; 115,1 ; 117,4 ; 121,4 ; 121,7 ; 126,6 ; 127,8 ; 128,9 (2 C) ; 135,5 ; 136,6 ; 137,9 ; 139,8; 143,2 ; 155,2 (2 C) ; HRMS (ESI): m / z calculé pour C32H41O5+ [M+H]+: 505,2954; trouvé : 505,3015 ; (25) RMN 'H (CDC13, 500 MHz) : ô (ppm) = 0,86 (s, 3H); 1,08 (s, 3H); 1,24 (s, 3H); 1,59 (m, 1H); 1,69 (m, 1H); 1,75 (s, 3H); 1,81 (s, 3H); 1,82 (m, 1H, H4); 1,84 (m, 1H); 2,07 (m, 1H); 2,70 (m, 2H); 3,40 (m, 3H); 4,61 (d, 2H, J = 4,9 Hz); 5,08 (s large, 1H, OH); 5,25 (m, 2H); 5,38 (d, 1H, J = 18,0 Hz); 6,07 (ddd, 1H, J = 5,5, 10,6, 18,0 Hz); 6,52 (s, 2H); 6,72 (d, 2H, J = 17.7 Hz); 6,85 (m, 3H);RMN 13C (CDC13, 125 MHz) : ô = 14,4 ; 18,3 ; 20,2 ; 22,9 ; 23,5 ; 26,0 ; 27,5 ; 28,6 ; 38,1 ; 38,9 ; 47,1 ; 78,4 ; 70,7 ; 77,2 ; 106,4 (2 C) ; 110,7 ; 112,7 ; 117,6 ; 121,4 ; 121,7 (2 C) ; 123,2 ; 125,9 ; 128,9 ; 134,2 ; 135,6 ; 137,8 ; 144,3 ; 148,2 ; 155,6 (2 C) ; HRMS (ESI): m / z calculé pour C32H4iO5+ [M+H]+: 505.2954; trouvé : 505.2948 (26) 'H NMR (CDC13, 500 MHz) : ô (ppm) = 0,94 (s, 3H) ; 0,98 (s, 3H) ; 1,24 (s, 3H) ; 1,61 (m, 1H) ; 1,74 (s, 1H) ; 1,79 (m, 1H) ; 1,80 (s, 3H) ; 1,84 (m, 1H) ; 2,03 (m, 1H) ; 2,09 (s, 3H) ; 2,70 (m, 2H) ; 3,42 (d, 2H, J = 6,7 Hz) ; 3,50 (m, 2H) ;4,63 (dd, 1H, J = 3,8 and 12,0 Hz) ; 4,98 (m, 2H) ; 5,00 (si, 1H, OH) ; 5,25 (m, 1H) ; 5,53 (s, 1H, OH) ; 5,96 (m, 1H) ; 6,51 (s, 2H) ; 6,68 (d, 1H, J = 16,0 Hz) ; 6,90 (s, 1H) ; 7,14 (d, 1H, J = 16,0 Hz) ; 13C NMR (CDC13 , 125 MHz) : ô (ppm) = 15,3 ; 18,3 ; 20,1 ; 21,6 ; 22,7 ; 22,8 ; 24,9 ; 26,2 ; 27,2 ;; 30,1 ; 37,6 ; 37,7 ; 47,7 ; 77,7 ; 79,7 ; 106,4 (2 C) ; 113,1 ; 115,2 ; 117,40 ; 119,8 ; 121,6 ; 121,9 ; 126,7 ; 128,2 ; 129,3 ; 137,0 ; 135,7 ; 137,7 ; 139,8 ; 143,2 ; 155,4 (2 C) ; 171,0 ; HRMS (ESI): m / z calculé pour C34H43O6 + [M+H]+: 547,3060; trouvé : 547,3055 (27) 'H NMR (CDC13, 500 MHz): ô (ppm) = 0,93 (s, 3H) ; 0,97 (s, 3H) ; 1,23 (s, 3H) ; 1,60 (m, 1H) ; 1,74 (s, 3H) ; 1,77 (m, 1H) ; 1,81 (s, 3H) ; 1,88 (m, 2H) ; 2,05 (m, 1H) ; 2,07 (s, 3H) ; 2,68 (d, 2H, J = 9,0 Hz) ; 3,39 (d, 2H, J = 7,6 Hz) ; 4,59 (d, 2H, J = 5,2 Hz) ; 4,63 (dd, 1H, J = 4,1, 10,4 Hz) ; 5,22 (m, 2H) ; 5,37 (d, 1H, J = 16,8 Hz) ; 6,05 (m, 1H) ; 6,50 (s, 2H) ; 6,69 (d, 1H, J = 17,6 Hz) ; 6,79 (s, 1H) ;6,81 (d, 1H, J = 17,6 Hz) ; 6,86 (s, 1H) ; 13C NMR (CDC13, 125 MHz) : ô (ppm) = 15,3 ; 17,8 ; 19,7 ; 21,4 ; 22,4 ; 22,7 ; 24,8 ; 25,7 ; 27,5 ; 37,2 ; 37,7 ; 46,8 ; 70,5 ; 76,6 ; 79,5 ; 106,2 (2 C) ; 110,6 ; 113,2 ; 117,4 ; 121,2 ; 121,7 ; 122,7 ; 126,1 ; 126,2 ; 128,7 ; 133,6 ; 135,2 ; 137,0 ; 143,5 ; 147,8 ; 155,2 (2 C) ; 170,9 ; HRMS (ESI): m / z calculé pour C 34H43O6+ [M+H]+: 547,3060; trouvé : 547,3070 (28) 'H NMR (CDC13, 500 MHz): ô (ppm) = 0.97 (s, 3H); 1.01 (s, 3H) ; 1.25 (s, 3H) ; 1.74 (s, 3H) ; 1.81 (s, 3H) ; 1.81 (m, 1H) ; 1.82 (m, 1H) ; 1.83 (m, 1H) ; 1.96 (m, 1H) ; 2.04 (m, 1H) ; 3.39 (d, 2H, J = 6.9 Hz) ; 4.78 (dd, 1H, J = 4.2 et 11.2 Hz) ; 5.09 (s, 1H, OH) ; 5.24 (t, 1H, J = 7.6 Hz) ; 5.44 (s, 1H, OH) ; 6.51 (s, 2H) ; 6.73 (s, 1 H) ; 6.74 (d, 1H, J = 15.8 Hz) ; 6.85 (d, 1H, J ; = 15.8 Hz) ; 6.92 (s, 1H) ; 8.13 (s, 1H) ; 13C NMR (CDC13, 125 MHz): ô (ppm) = 15.4 ; 17.9 ; 20.2 ; 22.6 (2C) ; 24.7 ; 25.9 ; 27.5 ; 37.3 ; 37.5 ; 47.3 ; 77.4 ; 79.5 ; 106.4 (2 C) ; 109.7 ; 112.7 ; 119.5 ; 121.7 ; 128.6 ; 126.1 ; 128.5 ; 129.9 ; 135.3 ; 137.1 ; 139.9 ; 145.2 ; 155.2 (2 C) ; 160.7 ; HRMS (ESI): m / z calculé pour C30H57CV [M+H]+: 493,2590; trouvé : 493,2578 (29) 'H-NMR (300 MHz, CD3CN) : ô (ppm) = 1,01 (s, 3 H) ; 1,05 (s, 3 H) ; 1,36 (s, 3 H) ; 1,68 (s, 3 H) ; 1,73 (m, 1 H) ; 1,77 (s, 3 H) ; 1,89 (dd, 1 H, J = 13,9, 3,4 Hz) ; 2,27 (dd, 1 H, J = 13,9, 3,3 Hz) ; 2,76 (m, 2 H) ; 3,28 (d, 1 H, J = 2,8 Hz) ; 3,42 (d, 2 H, J = 7,2 Hz) ; 3,80 (s, 3 H) ; 4,07 (m, 1 H) ; 5,17 (t, 1 H, J = 7,3 Hz) ; 6,58 (s, 2 OH) ; 6,70 (m, 1 H) ; 6,83 (m, 1 H) ; 6,89 (d, 1 H, J = 1,8 Hz) ; 6,95 (d, 1 H, J = 1,8 Hz); 13C-NMR (75 MHz, CD3CN) : ô (ppm) = 16,5 ; 18,0 ; 22,1 ; 23,7 ; 25,2 ; 25,8 ; 29,2 ; 38,8 ; 44,3 ; 47,8 ; 56,4 ; 71,4 ; 77,8 ; 77,9 ; 104,2 (2 C) ; 108,3 ; 116,7 ;121,7 ; 122,3 ;124,5 ; 125,9 ; 128,7 ; 133,7 ; 137,0 ; 137,6 ; 144,0 ; 150,2 ; 152,0 (2 C) ; HRMS (ESI): m / z calculé pour C3oH37Br206+ [M+H]+: 651,0957; trouvé : 651,0977 (30) 'H-NMR (300 MHz, CDC13): ô (ppm) =1,06 (s, 3 H) ; 1,10 (s, 3 H) ; 1,44 (s, 3 H) ; 1,74 (s, 3 H) ; 1,76 (m, 1 H) ; 1,81 (s, 3 H) ; 1,99 (m, 1 H) ; 2,49 (dd, 1 H, J = 3,2 Hz, 14,4) ; 2,77 (m, 2 H) ; 3,36 (d, 1 H, J = 3,5 Hz) ; 3,46 (d, 2 H, J = 7,6 Hz) ; 3,88 (s, 3 H) ; 4,24 (dd, 1 H, J = 2,9, 6,4 Hz) ; 5,25 (t, 1 H, J = 7,3 Hz) ; 5,34 (1H, OH) ; 5,77 (1H, OH) ; 6,74 (s, 1H) ; 6,84 (d, 1 H, J = 15,4 Hz) ; 6,87 (s, 2H) ; 7,11 (d, 1 H, J = 15,4 Hz) ; 13C-NMR (75 MHz, CDC13): ô (ppm) = 16,0 ; 17,8 ; 21,6 ; 22,9 ; 23,7 ; 25,8 ; 29,1 ; 38,1 ; 43,6 ; 47,81 ; 56,3 ; 70,9 ; 76,8 ; 77,8 (; 104,0 ; 105,6 ; 107,9 ; 113,5 ; 120,8 ; 121,2 ; 123,1 ; 125,7 ; 128,8 ; 131,5 ; 131,8 ; 135,7 ; 142,9 ; 149,2 ; 151,3 ; 154,8 ; HRMS (ESI): m / z calculé pour C30H38BrO6+ [M+H]+: 573,1852;trouvé : 573,1843 (31) 'H NMR (500 MHz, CDC13): <5 (ppm) = 0,89 (s, 3H) ; 1,11 (s, 3H) ; 1,26 (s, 3H) ; 1,66 - 1,52 (m, 1H) ; 1,74 (s, 3H) ; 1,82 (s, 3H) ; 1,91 - 1,81 (m, 3H) ; 2,18 - 2,10 (m, 1H) ; 2,53 (t, 1H, J= 2,4 Hz) ; 2,75 - 2,70 (m, 2H) ; 3,47 -3,40 (m, 3H) ; 3,90 (s, 3H) ; 4,74 (d, 2H, J= 2,4 Hz) ; 5,27-5,22 (m, 1H) ; 6,67 (s, 1H) ; 6,69 (s, 1H) ; 6,83 (d, 1H, J= 16,2 Hz) ; 6,87 (s, 2H) ; 6,92 (d, 2H, J= 16,2 Hz) ; 13C NMR (125 MHz, CDC13): <5 (ppm) = 14,3 ; 17,9 ; 19,9 ; 22,5 ; 23,2 ; 25,8 ; 27,4 ; 28,3 ; 37,7 ; 38,4 ; 46,8 ; 56,1 ; 56,6; 75,3 ; 77,1 ; 78,1 ; 78,9 ; 103,2 ; 107,1 ; 107,6 ; 115,4 ; 120,7 ; 121,8 ; 122,7 ; 126,1 ; 128,7 ; 128,8 ; 134,6 ; 137,0 ; 142,8 ; 149,0 ; 155,7 ; 156,2 ; HRMS (ESI): m / z calculé pour C33H4iO5+[M+H]+ 517,2949; trouvé : 517,2975 (32) 'H NMR (500 MHz, CDC13): <5 (ppm) = 1,06 (s, 3H) ; 1,09 (s, 3H) ; ; 1,43 ; (s, 3H) ; 1,72 (s, 3H) ; 1,76 (dd, 1H, J= 12,4,5,2 Hz) ; 1,80 (s, 3H) ; 2,00 (dd, 1H, J= 14,3, 3,0 Hz) ; 2,48 (dd, J= 14,3, 3,0 Hz, 1H) ; 2,51 (t, 1H, J = 2,1 Hz) ; 2,82-2,71 (m, 2H) ; 3,36 (d, 1H, J= 3,0 Hz) ; 3,40 (d, 1H, J= 7,0 Hz) ; 3,87 (s, 3H) ; 4,71 (s, 2H) ; 5,22 (t, 1H, J = 7 Hz) ; 6,67 (s, 1H) ; 6,82 (d, 1H, J= 16,5 Hz) ; 6,85 (s, 1H) 6,83 (s, 1H) ; 6,91 (d, 1H, J= 16,5 Hz) ;13 C NMR (125 MHz, CDC13): <5 (ppm) = 15,9 ; 17,8 ; 21,5 ; 22,5 ; 23,0 ; 25,7 ; 28,9 ; 38,0; 43,3 ; 46,9 ; 56,0 ; 56,5 ; 70,8 ; 75,3 ; 76,6 ; 77,5 ; 78,8 ; 103,1 ; 107,1 ; 107,5 ; 115,3 ; ; 120,5; 121,7; 122,8; 126,0; 128,6 ; 128,8 ; 134,4 ; 136,9 ; 142,3 ; 149,0 ; 155,6 ; 156,1 ; HRMS (ESI) : m / z cale, pour C33H41O6+ [M+H]+ 532.2898; trouvé : 533.2903.(33) 'H NMR (500 MHz, CDC13): <5 (ppm) = 0,86 (s, 3H) ; 1,08 (s, 3H) ; 1,23 (s, 3H) ; 1,63-1,57 (m, 1H) ; 1,64 (s, 3H) ; 1,72-1,65 (m, 1H) ; 1,76 (s, 3H) ; 1,85-1,80 (m, 2H) ; 2,14-2,10 (s, 1H) ; 2,50 (s, 1H) ; 2,73-2,65 (m, 2H) ; 3,43-3,38 (m, 1H) ; 3,53 (dd, 1H, J = 13,6 Hz, 7,1 Hz) ; 3,76 (s, 3H) ; 3,87 (s, 3H) ; 3,94 (s, 3H) ; 4,73 (s, 2H) ; 5,25 (t, 1H, J = 6,9 Hz) ; 6,53 (s, 1H) ; 6,67 (s, 1H) ; 6,75 (d, 1 H, J = 16,0 Hz) ; 6,78 (s, 1H) ; 6,80 (s, 1H) ; 6,81 (s, 1H) ; 6,81 (d, 1H, J = 16,0 Hz) ; 7,26 (s, 1H) ; 7,70 (s, 1H) ; 13C NMR (125 MHz, CDC13): <5 (ppm) =14,2; 17,8 ; 19,8; 22,8 ; 23,1; 25,8 ; 27,3 ; 28,3 ; 37,6; 38,3 ; 46,7 ; 52,8 ; 56,1 (2C) ; 56,3 ; 56,4 ; 75,1 ; 75,4; 77,1 ; 78,0 ; 78,7 ; 104,3 ; 104,7 ; 107,0 ; 108,1 ; 109,4 ; 119,1 ; 120,7 ; 122,4; 122,6 ; 125,9 ; 126,7 ; 128,5 ; 128,8 ; 131,5 ; 136,8 ; 140,2 ; 142,8 ; 148,7 ; 148,9 ; 153,8 ; 155,7 ; 156,5 ; 168,6; HRMS (ESI): m / zealcd. pour C44H51NOiiNa [M+Na] 792,3360; trouvé 792,3360.(34) 'H NMR (500 MHz, CDC13): <5 (ppm) =1,05 (s, 3H) ; 1,09 (s, 3H) ; 1,42 (s, 3H) ; 1,64 (s, 3H) ; 1,73 (dd, 1H, J= 13,3, 5,4 Hz) ; 1,76 (s, 3H) ; 1,99 (dd, 1H, J= 14,8, 2,2 Hz) ; 2,48 (dd, 1H, J= 14,8, 2,2 Hz) ; 2,51 (s, 1H) ;2,81-2,69 (m, 2H) ; 3,35 (d, J= 2,5 Hz) ; 3,41 (dd, 1H, J= 13,8,6,5 Hz) ; 3,52 (dd, 1H, J= 13,8, 6,5 Hz) ; 3,76 (s, 3H) ; 3,87 (s, 3H) ; 3,94 (s, 3H) ; 4,23 (d, 1H, J= 2,2 Hz) ; 4,73 (s, 2H) ; 5,25 (t, 1H, J= 6,5 Hz) ; 6,53 (s, 1H) ; 6,67 (s, 1H) ; 6,75 (d, 1H, J= 16,3 Hz) ; 6,78 (s, 1H) ; 6,82 (s, 1H) ; 6,82 (d, 1H, J= 16,3 Hz) ; 6,83 (s, 1H) ; 7,25 (s, 1H) ; 7,70 (s, 1H) ; 13C NMR (125 MHz, CDC13): <5 (ppm) = 15,9 ; 17,8 ; 21,5; 22,7 ; 23,0; 25,8 ; 28,9; 38,0 ; 43,4; 46,9 ; 52,8 ; 56,1 (2C) ; 56,3 11 ; 56,4 ; 70,8 ; 75,1 ; 75,4; 77,5 ; 76,6 ; 78,8 ; 104,4; 104,7 ; 107,1 ; 108,1 ; 109,6 ; 119,1 ; 120,6 ; 122,4; 122,8 ; 125,9 ; 126,7 ; 128,5 ; 128,9 ; 131,5; 136,8 ; 140,2 ; 142,4 ; 148,8 ; 149,0 ; 153,9 ; 155,7 ; 156,5 ; 168,7 ; HRMS (ESI): m / z calcd.for C44H52 NOi2+ [M+H]+785.3484; found 786.3491. (35) 'H NMR (500 MHz, CDC13): <5 (ppm) = 1,06 (s, 3H) ; 1,09 (s, 3H) ; 1,42 (s, 3H) ; 1,64 (s, 3H) ; 1,76 (s, 3H) ; 1,99 (dd, 1H, J= 15,2, 3,0 Hz) ; 2,47 (dd, 1H, J= 15,2, 3,0 Hz) ; 2,51 (s, 1H) ; 2,81-2,68 (m, 2H) ; 3,41 (dd, 1H, J = 14,0, 6,8 Hz) ; 3,55 (dd, 1H,, J= 14,0, 6,8 Hz) ; 3,87 (s, 3H) ; 3,94 (s, 3H) ; 4,21 (d, 1H, J= 3,0) ; 4,73 (d, 2H, J= 1,6 Hz) ; 5,24 (t, 1H, J= 6,8 Hz) ; 6,57 (s, 1H) ; 6,72 (s, 1H) ; 6,75 (d, 1H, J= 16,3 Hz) ; 6,78 (s, 1H) ; 6,78 (s, 1H) ; 6,81 (s, 1H) ; 6,82 (s, 1H) ; 6,82 (d, 1H, J= 16,3 Hz) ; 7,23 (s, 1H) ; 7,68 (s, 1H) ; 13C NMR (125 MHz, CDC13): <5 (ppm) = 15,9 ; 17,9 ; 21,5 ; 22,8 ; 23,0 ; 25,8 ; 28,9 ; 38,0 ; 43,3 ; 46,9 ; 56,1 (2C) ; 56,3 ; 56,4 ; 70,7 ; 74,7 ; 75,4 ; 76,6 ; 77,6 ; 78,7 ; 104,6 (2C) ; 107,1 ; 108,2 ; 109,5 ; 119,0 ; 120,7 ; 122,5 ; 122,9 ; 125,9 ; 126,2 ; 128,5 ; 128,9 ; 131,8 ; 136,9 ; 140,4 ; 142,5 ; 148,8 ; 149,0 ; 153,7 ; 155,6 ; 156,5 ; 170,8 ; HRMS (ESI): m / z cale, pour C43H50NO12+[M+H]+772.3328 ; trouvé 772.3387.(36) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 0,88 (s, 3H) ; 1,11 (s, 3H) ; 1,26 (s, 3H) ; 1,64 (s, 3H) ; 1,66 - 1,52 (m, 1H) ; 1,79 (s, 3H) ; 1,91 - 1,77 (m, 2H) ; 2,04 (s, 3H) ; 2,17 - 2,11 (m, 2H) ; 2,52 (t, 2H, J = 2,6 Hz) ; 2,81 - 2,70 (m, 2H) ; 3,37 (d, 2H, J = 6,6 Hz) ; 3,44 (m, 1H) ; 3,90 (s, 3H) ; 4,74 (d, 4H, J = 2,6 Hz) ; 5,25-5,19 (m, 1H) ; 6,79 (s, 2H) ; 6,90 (d, 1 H, J= 16,0 Hz) ; 6,87 (s, 1H) ; 6,88 (s, 1H ) ; 6,95 (d, 2H, J= 16,0 Hz) ; 13C NMR (125 MHz, CDC13): <5 (ppm) = 14,6 ; 18,1 ; 20,2 ; 22,7 ; 23,5 ; 26,0 ; 27,7 ; 28,6 ; 38,0 ; 38,7 ; 47,1 ; 56,2 ; 56,7 (2C) ; 75,5 (2C) ; 77,3 ; 78,3 ; 79,2 (2C) ; 104,7 (2C) ; 107,2 ; 119,7 ; 120,6 ; 122,7 ; 123,1 ; 126,7 ; 128,8 ; 129,1 ; 131,1 ; 136,8 ; 142,9 ; 149,1 ; 156,6 (2C) ; HRMS (ESI) : m / z cale, pour C36H43O5+ [M+H]+555,3066 ; trouvé 555,3107.(37) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 1,07 (s, 3H) ; 1,09 (s, 3H) ; 1,44 (s, 3H) ; 1,75 (s, 3H) ; 1,76 (s, 1H) ; 2,03-1,98 (m, 1H) ; 2,50 (t, 2H, J= 2,0 Hz) ; 2,51-2,48 (m, 1H) ; 2,80-2,75 (m, 2H) ; 3,35 (d, 1H, J = 7,0 Hz) ; 3,36 (d, 1H, J= 3,0 Hz) ; 3,88 (s, 3H) ; 4,72 (s, 4H) ; 5,18 (t, 1H, J= 7 Hz) ; 6,77 (s, 2H) ; 6,86 (s, 1H) ; 6,87 (s, 1H) ; 6,87 (d, 1H, J= 15 Hz) ; 6,92 (d, 1H, J = 15 Hz) ; 13C NMR (125 MHz, CDC13): <5 (ppm) = 16,0 ; 17,8 ; 21,5 ; 22,5 ; 23,0 ; 25,8 ; 28,9 ; 38,0 ; 43,4 ; 46,9 ; 56,0 ; 56,4 (2 C) ; 70,8 ; 75,2 (2 C) ; 76,6 ; 77,5 ; 78,9 (2 C) ; 104,3 (2 C) ; 107,1 ; 119,4 ; 120,5 ; 122,3 ; 122,8 ; 126,4 ; 128,6 ; 128,8 ; 131,4 ; 136,5 ; 142,3 ; 149,0 ; 155,6 ; 156,4 ; HRMS (ESI) : m / z cale, pour C36H42O6 [M+H]+ 571.3054 ; trouvé 571.3060.(38) 'H NMR (500 MHz, CDC13): <5 (ppm) = 0,89 (s, 3H) ; 1,11 (s, 3H) ; 1,26 (s, 3H) ; 1,67 - 1,60 (m, 1H) ; 1,74 (s, 3H) ; 1,82 (s, 3H) ; 1,91 - 1,83 (m, 4H) ; 1,98 (t, 1H, J = 2,6 Hz) ; 2,04 (quint,, 2H, J = 6,5 Hz) ; 2,43 (td, 2H, J = 6,5, . 2,6 Hz) ; 2,75 - 2,70 (m, 2H) ; 3,41 (d, 2H, J = 7,5 Hz) ; 3,47 - 3,39 (m, 1H) ; 3,90 (s, 3H) ; 4,11 (t, 2H, J= 6,5 Hz) ; 5,24 (t, 1H, J= 7,5 Hz) ; 6,61 (s, 1H) ; 6,62 (s, 1H) ; 6,83 (d, 1H, J= 16,0 Hz) ; 6,87 (s, 2H) ; 6,93 (d, 1H, J = 16,0 Hz) ; 13C NMR (125 MHz, CDC13): <5 (ppm) = 14,3 ; 15,3 ; 17,9 ; 19,9 ; 22,5 ; 106,8 ; 23,2 ; 25,8 ; 27,4 ; 28,3 ; 28,4 ; 37,7 ; 38,4 ; 46,8; 56,1 ; 66,7 ; 68,9 ; 77,1 ; 78,1 ; 83,6 ; 102,3 ; 107,0 ; 114,8 ; 120,6 ; 122,0 ; 122,7 ; 126,3 ; 128,4 ; 128,9 ; 134,2 ; 137,0 ; 142,7 ; 149,0 ; 155,5 ; 157,3 ; HRMS (ESI): m / z calcd.pour [M+H]+545,3262; trouvé 545,3250, (39) 'H NMR (500 MHz, CDC13): <5 (ppm) = 0,89 (s, 3H) ; 1,11 (s, 3H) ; 1,26 (s, 3H) ; 1,67 (s, 3H) ; 1,75 - 1,69 (m, 1H) ; 1,77 (s, 3H) ; 1,91 -1,80 (m, 3H) ; 1,98 (t, 2H, J= 2,6 Hz) ; 2,18 - 2,10 (m, 1H) ; 2,04 (quint,, 4H, J= 6,3 Hz) ; 2,44 (td, 4H, J = 6,3 Hz, 2,6 Hz) ; 2,75 - 2,69 (m, 2H) ; 3,35 (d, 2H, J = 6,8 Hz) ; 3,44 (dd, 1H, J= 11,6 et 3,7 Hz) ; 3,90 (s, 3H) ; 4,12 (t, 4H, J= 6,3 Hz) ; 5,18 (t, 1H, J= 6,8 Hz) ; 6,66 (s, 2H) ; 6,86 (s, 1H) ; 6,88 (s, 1H) ; 6,88 (d, 1H, J= 15,5 Hz) ; 6,94 (d, J= 15,5 Hz, 1H) ; 13C NMR (125 MHz, CDC13): <5 (ppm) = 14.3 ; 15.3 (2 C) ; 17.8 ; 19.9 ; 22.5 ; 23.2 ; 25.8 ; 27.4 ; 28.3 ; 28.5 (2 C) ; 37.7 ; 38.4 ; 46.8 ; 56.0 ; 66.6 (2 C) ; 68.9 (2 C) ; 77.1 ; 78.1 ; 83. 142.7 ; 7 (2 C) ; 102.9 (2 C) ; 107.0 ; 118.1 ; 120.6 ; 122.7 ; 123.1 ; 126.9 ; 128.1 ; 129.0 ; 130.8 ; 136.6 ; 149.0 ; 157.5 (2 C) ; HRMS (ESI): m / z calcd. pour C4oH5i05+ [M+H]+611.3731; trouvé 611.3722.(40) 'H NMR (500 MHz, CDC13): <5 (ppm) = 0,89 (s, 3H) ; 1,11 (s, 3H) ; 1,26 (s, 3H) ; 1,72 - 1,58 (m, 1H) ; 1,74 (s, 3H) ; 1,82 (s, 3H) ; 1,91 - 1,81 (m, 3H) ; 2,18 - 2,11 (m, 1H) ; 2,46 (t, 1H, J= 2,3 Hz) 3,92 (t, 2H, J= 4,9 Hz); 2,75 -2,70 (m, 2H) ; 3,70 - 3,40 (m, 3H) ; 3,89 (s, 3H) ; 4,20 (t, 2H, J= 4,6 Hz) ; 4,28 (d, 2H, J= 2,3 Hz) ; 5,31 - 5,23 (m, 1H) ; 6,60 (s, 1H) ; 6,63 (s, 1H) ; 6,82 (d, 1H, J= 16,8 Hz) ; 6,87 (s, 2H) ; 6,93 (d, J= 16,8 Hz, 2H) ; 13C NMR (125 MHz, CDC13): <5 (ppm) = 14,3 ; 17,9 ; 19,9 ; 22,5 ; 23,2 ; 25,8 ; 27,4 ; 28,3 ; 37,7 ; 38,4 ; 46,8 ; 56,1 ; 58,6 ; 68,0 ; 68,4 ; 74,7 ; 77,1 ; 77,8 ; 78,1 ; 102,8 ; 107,1 ; 107,14 ; 115,1 ; 120,6 ; 122,0 ; 122,7 ; 126,2 ; 128,5 ; 128,9 ; 134,3 ; 137,0 ; 142,7 ; 149,0 ; 155,6 ; 157,2 ; HRMS (ESI): m / z calcd. pour C55H45CV [M+H]+561,3216; trouvé 561,3218.(41) 'H NMR (500 MHz, CDC13): <5 (ppm) = 0,89 (s, 3H) ; 1,11 (s, 3H) ; 1,26 (s, 3H) ; 1,74- 1,68 (m, 1H) ; 1,66 (s, 3H) ; 1,78 (s, 3H) ; 1,91 - 1,82 (m, 3H) ; 2,18 - 2,11 (m, 1H) ; 2,46 (t, 2H, J= 2,3 Hz) ; 2,75-2,70 (m, 2H) ; 3,46-3,41 (m, 3H) ; 3,90 (s, 3H) ; 3,92 (t, 2H, J= 4,8 Hz) ; 4,20 (t, 4H, J = 4,8 Hz) ; 4,28 (d, 4H, J= 2,3 Hz) ; 5,27-5,22 (m, 1H) ; 6,66 (s, 2H) ; 6,86 (d, 1H, J = 16,8 Hz) ; 6,88 (s, 2H) ; 6,93 (d, 2H, J= 16,0 Hz) ; 13C NMR (125 MHz, . CDC13): <5 (ppm) = 14.3; 18.0; 19.9; 22.5; 23.2; 26.0; 27.6; 28.3; 37.8; 38.6; 46.9; 56.1; 58.8 (2C); 67.8 (2C); 68.5 (2C); 74.9 (2C); 77.1; 78.1; 79.7 (2C); 103.0 (2C); 106.9; 118.7; 120.6; 122.7; 123.0; 126.7; 128.5; 129.1; 131.0; 137.6; 142.7; 149.0; 157.7 (2C); HRMS (ESI): m / z calcd. for C40H51CM [M+H]+ 643.3624; found 643.3633.(42) 'H NMR (500 MHz, CDC13): <5 (ppm) = 0,89 (s, 3H) ; 1,11 (s, 3H) ; 1,25 (s, 3H) ; 1,68-1,53 (m, 2H) ; 1,72-1,68 (m, 1H) ; 1,74 (s, 3H) ; 1,81 (s, 3H) ; 2,20-2,10 (m, 2H) ; 2,45 (t, 1H, J= 2,2 Hz) ; 2,76-2,70 (m, 2H) ; 3,41 (d, 2H, J= 5,8 Hz) ; 3,47-3,44 (m, 1H) ; 3,75-3,71 (m, 2H) ; 3,79-3,75 (m, 2H) ; 3,85 (t, 2H, J= 5,0 Hz) ; 3,89 (m, 5H) ; 4,18 (t, 2H, J= 5,0 Hz) ; 4,22 (d, 2H, J= 2,2 Hz) ; 5,25 (t, 1H, J= 5,8 Hz) ; 6,60 (s, 1H) ; 6,62 (s, 1H) ; 6,82 (d, 1H, J = 16,0 Hz) ; 6,84 (s, 1H) ; 6,87 (s, 1H) ; 6,92 (d, 1H, J = 16,0 Hz) ; 13C NMR (125 MHz, CDC13): <5 (ppm) = 14,3 ; 17,8 ; 19,9 ; 22,5 ; 23,2 ; 25,8 ; 27,4 ; 28,3 ; 29,0 ; 37,7 ; 38,4 ; 46,8 ; 56,0 ; 58,5 ; 68,2 ; 69,2 ; 69,9 ; 70,7 ; 74,6 ; 77,1 ; 78,1 ; 79,8 ; 107,0 ; 107,1 ; 102,7 ; 115,1 ; 120,6 ; 122,1 ; 122,7 ; 126,2 ; 128,4 ; 128,9 ; 134,0 ; 136,9 ; 142,7 ; 149,0 ; 155,5 ; 157,3 (C7’) ; HRMS (ESI): m / z cale, pour C37H49O7+ [M+H]+605,3434; trouvé 605,3475.(43) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 0,89 (s, 3H) ; 1,11 (s, 3H) ; 1,26 (s, 3H) ; 1,68-1,50 (m, 3H) ; 1,66 (s, 3H) ; 1,77 (s, 3H) ; 2,19-2,08 (m, 2H) ; 2,42 (t, 2H, J= 2,2 Hz) ; 2,81-2,71 (m, 2H) ; 3,36 (d, 2H, J= 6,9 Hz) ; 3,48-3,40 (m, 1H) ; 3,75-3,70 (m, 4H) ; 3,80-3,75 (m, 4H) ; 3,90 (m, 7H) ; 4,19 (t, 4H, J= 5,1 Hz) ; 4,22 (d, 4H, J= 2,2 Hz) ; 5,22 (t, 1H, J= 6,9 Hz) ; 6,66 (s, 2H) ; 6,85 (d, 1H, J= 16,5 Hz) ; 6,86 (s, 2H) ; 6,93 (d, 1H J= 16,5 Hz) ; 13C NMR (125 MHz, CDC13) : <5 (ppm) = 14,3 ; 17,8 ; 19,9 ; 22,6 ; 23,2 ; 25,8 ; 27,4 ; 28,3 ; 37,7 ; 38,4 ; 46,8 ; 56,1 ; 58,5 (2 C) ; 68,0 (2 C) ; 69,21 (2 C) ; 69,9 (2 C) ; 70,7 (2 C) ; 74,5 (2 C) ; 77,1 ; 78,0 ; 103,4 (2 C) ; 107,1 ; 119,8 ; 120,6 ; 120,5 ; 122,7 ; 123,0 ; 128,1 ; 128,9 ; 130,7 ; 136,5 ; 142,7 ; 149,0 ; 157,4 (2 C) ; HRMS (ESI): m / z cale, pour C44H59O9+ [M+H]+ 731,4114; trouvé 731,4167.(44) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 1,06 (s, 3H) ; 1,08 (s, 3H) ; 1,42 (s, 3H) ; 1,71 (s, 3H) ; 1,74 (dd, 1H, J= 14,0, 5,0 Hz) ; 1,80 (s, 3H) ; 1,99 (dd, 1H, J= 14,3 Hz, 2,9 Hz) ; 2,47 (dd, J= 2,9 Hz, 1H, J= 14,3 Hz) ; 2,70 (dd, 1H, J= 14,0 Hz, 5,0 Hz) ; 2,81-2,72 (m, 1H) ; 3,36 (d, 1H, J= 2,8 Hz) ; 3,46 (dd, 1H, J= 15,0, 6,5 Hz) ; 3,55 (dd, 1H, J= 15,0, 6,5 Hz) ; 3,76 (, 3H) ; 3,86 (s, 3H) ; 3,89 (s, 3H) ; 3,95 (s, 3H) ; 4,22 (d, 1H, J= 2,8 Hz) ; 5,26 (d, 1H, J= 6,5 Hz) ; 6,46 (s, 1H) ; 6,65 (s, 2H) ; 6,69 (d, 1H, J= 15,5 Hz) ; 6,79 . (s, 1H) ; 6,80 (d, 1H, J= 15,5 Hz) ; 6,81 (s, 1H) ; 7,25 (s, 1H) ; 7,70 (s, 1H) ; 13C NMR (125 MHz, CDC13) : <5 (ppm) = 15,9 ; 17,8 ; 21,5 ; 22,7 ; 23,0 ; 25,8 ; 28,9 ; 38,0 ; 43,3 ; 46,9 ; 52,9 ; 56,1 ; 56,3 ; 56,4 ; 70,8 ; 75,5 ; 76,6 ; 77,6 ; 104,1 ; 107,1 ; 107,7 ; 109,6 ; 115,7 ; 120,7 ; 121,7 ; 122,8 ; 125,6 ; 126,7 ; 128,6 ; 128,9 ; 134,2 ; 137,3 ; 140,2 ; 142,4 ; 148,7 ; 149,0 ; 153,8 ; 155,6 ; 155,8 ; 168,8 ; HRMS (ESI): m / z cale, pour C4iH50NOi2+ [M+H]+ 748,3328; trouvé 748,3305. (45) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 1,06 (s, 3H) ; 1,08 (s, 3H) ; 1,42 (s, 3H) ; 1,70 (s, 3H) ; 1,80 (s, 3H) ; 1,98 (dd, 1H, J= 14,0, 3,4 Hz) ; 2,47 (dd, 1H, J= 14,0, 3,4 Hz) ; 2,71 (dd, 2H, J= 14,0, 5,0 Hz) ; 2,75 (dd, 1H, J = 14,0, 5,0 Hz) ; 3,36 (d, 1H, J= 3,4 Hz) ; 3,46 (dd, 1H, J= 15,3, 6,8 Hz) ; 3,55 (dd, 1H, J= 15,3, 6,8 Hz) ; 3,87 (s, 3H) ; 3,90 (s, 3H) ; 3,95 (s, 3H) ; 4,22 (d, 1H, J= 3,4 Hz) ; 5,24 (t, 1H, J= 7,5 Hz) ; 6,48 (s, 1H) ; 6,65 (s, 1H) ; 6,69 (d, 1H, J= 15,7 Hz) ;6,71 (s, 1H) ; 6,79 (s, 1H) ; 6,80 (d, 1H, J= 15,7 Hz) ; 6,81 (s, 1H) ; 7,22 (s, 1H) ; 7,70 (s, 1H) ; 13C NMR (125 MHz, CDC13) : <5 (ppm) = 169,6 ; 155,5 ; 155,4 ; 153,9 ; 149,0 (2 C) ; 142,4 ; 140,4 ; 137,4 ; 134,7 ; 129,2 ; 128,5 ; 125,9 ; 125,4 ; 122,9; 121,7 ; 120,7 ; 115,6 ; 09,5 ; 108,3 ; 107,9 ; 107,0 ; 103,9 ; 77,6 ; 76,6 ; 74,8 ; 70,8 ; 56,4 (2 C) ; 56,1 ; 46,9 ; 43,3 ; 38,0 ; 28,9 ; 25,8 ; 23,0 ; 22,7 ; 21,5 ; 17,9 ; 16,0 ; HRMS (ESI): m / z cale, pour C43H48NOi2+ [M+H]+734,3177; trouvé 734,3193. (46) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 1,06 (s, 3H) ; 1,09 (s, 3H) ; 1,43 (s, 3H) ; 1,70 (s, 3H) ; 1,77-1,65 (m, 1H) ; 1,78 (s, 3H) ; 1,99 (dd, J= 14,1, 3,0 Hz, 1H) ; 2,48 (dd, J= 14,1, 3,0 Hz, 1H) ; 2,77-2,69 (m, 2H) ; 3,36 (d, J = 3,2 Hz, 1H) ; 3,50 (d, J= 6,3 Hz, 2H) ; 3,87 (s, 3H) ; 3,92 (s, 3H) ; 3,96 (s, 3H) ; 4,22 (d, J= 3,2 Hz, 1H) ; 5,29 (t, J= 6,8 Hz, 1H) ; 5,52 (s, 1H) ; 6,62 (s, 1H) ; 6,90-6,80 (m, 1H) ; 6,90-6,75 (m, 1H) ; 6,94-6,85 (m, 1H) ; 7,40 (s, 1H) ;7,77 (s, 1H) ;13C NMR (125 MHz, CDC13) : <5 (ppm) = 16,0 ; 18,0 ; 21,6 ; 22,7 ; 23,1 ; 25,8 ; 29,0 ; 38,1 ; 43,4 ; 47,0 ; 56,1 ; 56,3 ; 56,4 ; 67,4 ; 70,8 ; 76,7 ; 77,6 ; 103,2 ; 107,1 (2 C) ; 108,0 ; 109,4 ; 115,1 ; 120,7 ; 122,0 ; 122,9 ; 125,9 ; 128,7 ; 128,8 ; 129,8 ; 134,0 ; 137,3 ; 139,0 ; 142,4 ; 147,8 ; 149,1 ; 154,0 ; 155,3 ; 156,7 (C7’) ; HRMS (ESI): m / z cale, pour C39H48NOi0 + [M+H]+ 690.3273; trouvé 690.3278. (47) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 1,10 (s, 3H) ; 1,13 (s, 3H) ; 1,46 (s, 3H) ; 1,67 (s, 3H) ; 1,77 (m, 1H) ; 1,80 (s, 3H) ; 2,03 (d, 1H, J = 14,2 Hz) ; 2,52 (d, 1H, J = 14,2 Hz) ; 2,78 (m, 2H) ; 3,40 (s, 1H) ; 3,60 (d, 2H, J = 6,80 Hz) ; 3,80 (s, 6H) ; 3,92 (s, 9H) ; 3,99 (s, 6H) ; 4,27 (m, 1H) ; 5,31 (t, 1H, J = 6,5 Hz) ; 6,53 (s, 1H) ; 6,57 (s, 1H) ; 6,66 (m, 1H) ; 6,70 (m, 1H) ; 6,72 (s, ; 2H) ; 6,84 (m, 2H) ; 7,26 (s, 2H) ; 7,69 (s, 2H) ; 13C NMR (125 MHz, CDC13 ) : <5 (ppm) = 16,1 ; 17,8 ; 21,5 ; 23,1 (2 C) ; 25,8 ; 29,0 ; 38,2 ; 43,4 ; 46,9 ; 53,2 (2 C) ; 56,4 (5C) ; 70,8 ; 76,1 ; 75,2 (2 C) ; 77,6 ; 104,9 ; 105,2 ; 107,1 ; 108,2 (2 C) ; 109,7 (2 C) ; 119,2 ; 120,8 ; 122,8 ; 122,9 ; 125,5 ; 126,5 (2 C) ; 129,3 (2 C) ; 131,9 ; 137,2 ; 140,2 (2 C) ; 143,0 ; 149,1 (2 C) ; 149,2 ; 153,9 (2 C) ; 155,9 (2 C) ; 169,1 (2 C) ; HRMS (ESI): m / z cale, pour C52H61 N20i8+[M+H]+ 1001.3919; trouvé 1001.3937.(48) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 1,03 (s, 3H) ; 1,05 (s, 3H) ; 1,40 (s, 3H) ; 1,63 (s, 3H) ; 1,70 (m, 1H) ; 1,72 (s, 3H) ; 1,95 (d, 1H, J = 14,7 Hz) ; 2,43 (d, 1H, J = 14,7 Hz) ; 2,69 (m, 2H) ; 3,34 (s, 1H) ; 3,59 (d, 2H, J = 5,30 Hz) ; 3,85 (s, 3H) ; 3,88 (s, 6H) ; 3,94 (s, 6H) ; 4,18 (s, 1H) ; 5,31 (t, 1H, J = 6,2 Hz) ; 6,74-6,59 (m, 4H) ; 6,73 (s, 2H) ; 6,79 (m, 2H) ; 7,21 (s, 2H) ; 7,69 (s, 2H) ; 13C NMR (125 MHz, CDC13) : <5 (ppm) =15,7 ;21,9 ; 29,0 ; 18,1 ; 23,1 (2 C) ; 26,0 ; 38,3 ; 43,5 ; 47,0 ; 56,4 ; 56,8 (4C) ; 71,1 ; 76,6 ; 77,9 ; 105,6 (2 C) ; 74,9 (2 C) ; 121,2 ; 107,2 ; 109,7 (2 C) ; 108,5 (2 C) ; 119,3 ; 122,7 ; 122,9 ; 125,6 ; 125,8 (2 C) ; 129,8 (2 C) ; 131,8 ; 137,4 ; 140,4 (2 C) ; 142,5 ; 148,9 (3 C) ; 153,8 (2 C) ; 155,8 (2 C) ; 170,6 (2 C) ; HRMS (ESI): m / z cale, pour C5oH55N2Oi8 [M-H] 971.3463; trouvé 971.3444.(49) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 1,06 (s, 3H) ; 1,08 (s, 3H) 1,24 (m, 2H) ; 1,38 (m, 2H) ; 1,44 (s, 3H) ; 1,57 (m, 2H) ; 1,65 (s, 3H) ; 1,73 (m, 2H) ; 1,76 (s, 3H) ; 1,77 (m, 1H) ; 2,00 (m, 1H) ; 2,49 (m, 1H) ; 2,74 (m, 2H) ; 3,68-3,34 (m, 17H) ; 3,88 (s, 3H) ; 3,90 (s, 3H) ; 3,95 (s, 3H) ; 4,22 (m, 1H) ; 4,48 (m, 2H, J= 5,0 Hz) ; 5,24 (m, 1H) ; 5,32 (s, 2H) ; 6,57 (s, 1H) ; 6,62 (s, 1H) ; 6,88-6,68 (m, 5H) ; 7,20 (s, 1H) ; 7,30 (s, 1H) ; 7,70 (s, 1H) ; (HRMS (ESI): m / z cale, pour C55H74NO12+ [M+H]+ 1065.4839 ; trouvé 1065.4839.(50) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 1,06 (s, 3H) ; 1,10 (s, 3H) ; 1,31 (m, 2H) ; 1,40 (m, 2H) ; 1,44 (1,77 (m, 1H) ; s, 3H) ; 1,56 (m, 2H) ; 1,70 (s, 3H) ; 1,73 (m, 2H) ; 1,76 (s, 3H) ; 2,00 (dd, J= 14,0, 2,5 Hz, 1H) ; 2,49 (dd, 1H, J= 14,0, 2,5 Hz) ; 2,73 (m, 2H) ; 3,38 (t, 2H, J= 5,0 Hz) ; 3,39 (s, 3H) ; 3,48 (t, 2H, J= 5,0 Hz) ; 3,61-3,50 (m, 8H) ; 3,84 (t, 2H, J= 5,0 Hz) ; 3,88 (s, 3H) ; 4,24 (m, 1H) ; 4,52 (t, 2H, J= 5,0 Hz) ; 5,21 (t, 1H, J = 7,0 Hz) ; 5,25 (s, 2H) ; 6,63 (s, 1H) ; 6,70 (s, 1H) ; 6,81 (d, 1H, J= 16,1 Hz) ; 6,84 (s, 1H) ; 6,87 (s, 1H) ; 6,91 (d, 1H, J= 16,1 Hz) ; 7,73 (s, 1H) ; 13C NMR (125 MHz, CDC13) : <5 (ppm) = 16,0 ; 17,9 ; 21,6 ; 22,6 ; 23,0 ; 25,4 ; 25,8 ; 26,6 ; 28,9 ; 29,4 ; 32,5 ; 38,0 ; 43,4 ; 45,0 ; 46,9 ; 50,4 ; 56,1 ; 62,8 ; 69,5 ; 70,1 ; 70,3 (2 C) ; 70,6 ; 70,8 ; 71,3 ; 76,5 ; 77,6 ; 107,1 (2 C) ; 115,1 ; 120,6 ; . 121,9 ; 122,8 ; 123,7 ; 126,0 ; 128,6 ; 128,8 ; 134,1 ; 137,0 ; 142,4 ; 144,3 ; 149,0 ; 155,6 ; 156,7 ; HRMS (ESI) : m / z cale, pour C45H64ClN3O9Na+ [M+Na]+ 848.4229; trouvé 848.4238. (51) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 0,89 (s, 3H) ; 1,11 (s, 3H) ; 1,26 (s, 3H) ; 1,39-1,31 (m, 2H) ; 1,48-1,40 (m, 2H) ; 1,68-1,53 (m, 4H) ; 1,74 (s, 3H) ; 1,76-1,68 (m, 3H) ; 1,82 (s, 3H) ; 2,18-2,11 (m, 2H) ; 2,23 (quint, 2H, J = 6,9 Hz) ; 2,76-2,70 (m, 2H) ; 2,95 (t, 2H, J= 6,9 Hz) ; 3,48-3,28 (m, 5H) ; 3,55-3,48 (m, 4H) ; 3,61-3,55 (m, 2H) ; 3,85 (t, 2H, J= 5,0 Hz) ; 3,89 (s, 3H) ; 4,06 (t, 2H, J= 6,9 Hz) ; 4,51 (t, 2H, J= 5,0 Hz) ; 5,25 (t, 1H, J= 7,0 Hz) ; 6,57 (s, 1H) ; 6,62 (s, 1H) ; 6,82 (d, 1H, J= 16,1 Hz) ; 6,85 (s, 1H) ; 6,87 (s, 1H) ; 6,92 (d, 1H, J= 16,1 Hz) ; 7,50 (s, 1H) ; 13C NMR (125 MHz, CDC13) : <5 (ppm) = 14,3 ; 17,9 ; 19,9 ; 22,1 ; 22,2 ; 22,5 ; 23,2 ; 25,4 ; 26,1 ; 26,7 ; 27,4 ; 28,3 ; 29,0 ; 29,5 ; 32,5 ; 37,7 ; 38,4 ; 45,0 ; 46,8 ; 50,3 ; 56,1 ; 67,3 ; 69,5 ; 70,0 ; 70,6 ;71,3 ; 77,1 ; 78,0 ; 103,0 ; 107,0 ; 102,3 ; 115,0 ; 120,6 ; 122,1 ; 122,3 ; 122,7 ; 126,4 ; 128,4 ; 128,9 ; 134,1 ; 137,0 ; 142,7 ; 146,9 ; 149,0 ; 155,5 ; 157,4 ; HRMS (APPI): m / z cale, pour C45H65C1N3O7+-[M+H]+-794,4506 ; trouvé 794,4501. (52) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 0,89 (s, 3H) ; 1,11 (s, 3H) ; 1,25 (s, 3H) ; 1,39-1,31 (m, 2H) ; 1,48-1,39 (m, 2H) ; 1,67-1,52 (m, 4H) ; 1,72 (s, 3H) ; 1,78-1,67 (m, 2H) ; 1,81 (s, 3H) ; 2,22-2,10 (m, 2H) ; 2,76-2,70 (m, 2H) ; 3,48-3,38 (m, 7H) ; 3,58-3,48 (m, 8H) ; 3,83 (t, 2H, J= 5,2 Hz) ; 3,89 (s, 3H) ; 3,96-3,91 (m, 2H) ; 4,25-4,18 (m, 2H) ; 4,50 (t, J= 5,2 Hz, 2H) ; 4,77 (s, 2H) ; 5,25 (t, J= 7,4 Hz, 1H) ; 6,58 (s, 1H) ; 6,63 (s, 1H) ; 6,80 (d, 1H, J= 15,5 Hz) ; 6,83 (s, 1H) ; 6,86 (s, 1H) ; 6,90 (d, 1H, J= 15,5 Hz) ; 7,69 (s, 1H) ; 13C NMR (125 MHz, CDC13) : <5 (ppm) = 14,3 ; 17,9 ; 19,9 ; 22,5 ; 22,7 ; 23,2 ; 25,4 ; 25,8 ; 26,7 ; 27,4 ; 29,4 ; 29,7 ; 32,5 ; 37,7 ; 38,4 ; 45,0 ; 46,8 ; 50,2 ; 56,1 ; 64,7 ; 68,0 ; 69,1 ; 69,4 ;70,1 (2 C) ; 70,6 (2 C) ; 77,1 ; 78,0 ; 107,1 (2 C) ; 102,7 ; 115,9 ; 120,6 ; 122,1 ; 122,3 ; 122,7 ; 126,2 ; 128,4 ; 128,5 ; 133,6 ; 136,6 ; 142,7 ; 146,1 ; 149,0 ; 156,5 ; 156,4 ;HRMS (APPI): m / z cale, pour C47H69C1N3O9+- [M+H]+‘ 854.4717; trouvé 854.4720 (53) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 0,90 (s, 3H) 1,11 (s, 3H) ; 1,26 (s, 3H) ; 1,40-1,33 (m, 2H) ; 1,45 (quint, J = 6,9 Hz, 2H) ; 1,66-1,51 (m, 4H) ; 1,74 (s, 3H) ; 1,80-1,68 (m, 3H) ; 1,81 (s, 3H) ; 2,20-2,11 (m, 2H) ; 2,76-2,71 (m, 2H, H9) ; 3,48-3,36 (m, 7H) ; 3,56-3,49 (m, 4H) ; 3,62-3,57 (m, 2H) ; 3,86 (t, 2H, J= 5,1 Hz) ; 3,90 (s, 3H) ; 3,93 (t, 2H, J= 5,1 Hz) ; 4,52 (t, 2H, J= 5,1 Hz) ; 4,75 (s, 2H) ; 5,25 (t, 1H, J = 7,2 Hz) ; 6,60 (s, 1H) ; ; 6,63 (s, 1H) ; 6,82 (d, 1H, J= 16,1 Hz) ; 6,85 (s, 1H) ; 6,87 (s, 1H) ; 6,92 (d, 1H, J= 16,1 Hz) ; 7,70 (s, 1H) ; 13C NMR (125 MHz, CDC13) : <5 (ppm) = 14,2 ; 17,9 ; 19,9 ; 22,6 ; 22,7 ; 23,2 ; 25,4 ; 25,8 ; 27,1 ; 27,4 ; 29,4 ; 29,7 ; 32,5 ; 37,7 ; 38,4 ; 45,1 ; 46,8 ; 50,2 ; 56,1 ; 64,9 ; 68,6 ; 69,5 ; 70,0 ; 70,6 ; 71,5 ; 77,1 ; 78,1 ; 107,1 (2 C) ; 102,8 ; 115,1 ; 120,6 ; 122,0 ; 122,7 ; 123,7 ; 126,1 ; 128,4 ; 128,9 ; 134,2 ; 137,0 ; 142,7 ; 145,4 ; 149,0 ; 155,6 ; 157,0 ; HRMS (APPI): m / z cale, pour C45H65C1N3O8+- [M+H]+' 810.4455; trouvé 810.4474. (54) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 0,89 (s, 3H) ; 1,11 (s, 3H) ; 1,25 (s, 3H) ; 1,40-1,32 (m, 2H) ; 1,48-1,41 (m, 2H) ; 1,68-1,54 (m, 4H) ; 1,71 (s, 3H) ; 1,73-1,68 (m, 1H) ; 1,80 (s, 3H) ; 1,82-1,73 (m, 2H) ; 1,93-1,82 (m, 1H) ; 2,19-2,09 (m, 1H) ; 2,75-2,70 (m, 2H) ; 3,48-3,37 (m, 5H) ; 3,56-3,49 (m, 6H) ; 3,62-3,56 (m, 2H) ; 3,77-3,73 (m, 2H) ; 3,84-3,80 (m, 2H) ; 3,89 (s, 3H) ; 3,92-3,85 (m, 2H) ; 4,18 (t, 2H, J= 4,4 Hz) ;4,69 (s, 2H) ; 5,24 (t, 1H, J= 7,1 Hz) ; 6,60 (s, 1H) ; 6,62 (s, 1H) ; 6,82 (d, 1H, J= 16,1 Hz) ; 6,84 (s, 1H) ; 6,86 (s, 1H) ; 6,92 (d, 1H, J= 16,1 Hz) ; 7,62 (s, 1H) ; 13C NMR (125 MHz, CDC13) : <5 (ppm) = 14,3 ; 17,9 ; 19,9 ; 22,5 ; 22,6 ; 23,0 ; 25,4 ; 25,8 ; 26,6 ; 27,4 ; 28,4 ; 29,4 ; 32,5 ; 37,4 ; 38,4 ; 45,0 ; 46,5 ; 50,1 ; 56,1 ; 64,7 ; 68,2 ; 69,4 ; 69,8 ; 69,9 ; 70,0 ; 70,6 ; 70,9 ; 77,1 ; 78,2 ; 102,5 ; 107,0 (2 C) ; 115,1 ; 120,5 ; 122,1 ; 122,7 ; 123,8 ; 126,4 ; 128,4 ; 128,8 ; 133,9 ; 136,9 ; 142,7 ; 144,9 ; 149,0 ; 155,5 ; 157,3 ; HRMS (ESI): m / z cale, pour C 47H69C1N3O9+ [M+H]+854.4678; trouvé 854.4752. (55) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 0,89 (s, 3H) ; 1,11 (s, 3H) ; 1,26 (s, 3H) 1,37-1,29 (m, 2H) ; 1,46-1,38 (m, 2H) ; 1,68-1,53 (m, 4H) ; 1,72 (s, 2H) ; 1,77 (s, 3H) ; 1,79-1,68 (m, 3H) ; 1,91-1,81 (m, 1H) ; 2,20-2,10 (m, 1H) ; 2,76-2,70 (m, 2H) ; 3,47-3,36 (m, 6H) ; 3,53-3,48 (m, 3H) ; 3,60-3,53 (m, 4H) ; 3,87 (t, 2H, J= 5,1 Hz) ; 3,90 (s, 3H) ;4,55 (t, 2H, J= 5,1 Hz) ; 5,22 (t, 1H J= 7,4 Hz,) ; 5,27 (s, 2H) ; 6,65 (s, 1H) ; 6,71 (s, 1H) ; 6,82 (d, 1H, J = 16,2 Hz) ; 6,85 (s, 1H) ; 6,87 (s, 1H) ; 6,92 (d, 1H, J= 16,2 Hz) ; 7,75 (s, 1H) ; 3C NMR (125 MHz, CDC13) : <5 (ppm) = 14,3 ; 17,8 ; 19,9 ; 22,6 ; 23,2 ; 25,4 ; 25,8 ; 26,7 ; 27,4 ; 29,4 (2 C) ; 32,5 ; 37,8 ; 38,4 ; 45,0 ; 46,8 ; 50,4 ; 56,1 ; 62,9 ; 69,5 ; 70,1 ; 70,6 ; 71,3 ; 77,1 ; 78,0 ; 103,1 ; 107,0 ; 107,2 ; 115,2 ; 120,7 ; 122,0 ; 122,7 ; 123,8 ; 126,1; 128,6 ; 128,8 ; 134,1 ; 137,1 ; 142,7 ; 144,4 ; 149,0 ; 155,6 ; 156,8 ; HRMS (APPI): m / z cale, pour C46H67 C1N3O7+ [M+H]+808,4667; trouvé 808,4670 (56) 'H NMR (500 MHz, CDC13) : <5 (ppm) = 0,90 (s, 3H) ; 1,11 (s, 3H) ; 1,26 (s, 3H) ; 1,37-1,29 (m, 2H) ; 1,45-1,37 (m, 2H) ; 1,60-1,52 (m, 2H) ; 1,68-1,58 ; (m, 1H) ; 1,73 (s, 2H) ; 1,76-1,68 (m, 3H) ; 1,78 (s, 3H) ; 1,91-1,81 (m, 2H) ; 2,15-2,11 (m, 1H) ; 2,75-2,70 (m, 2H) ; 3,42-3,37 (m, 2H) ; 3,44 (dd, 1H, J = 11,2,3,65 Hz) ; 3,47-3,42 (m, 2H) ; 3,51-3,47 (m, 2H) ; 3,59-3,56 (m, 2H) ; 3,88 (t, 2H, J= 5,0 Hz) ; 3,90 (s, 3H) ; 4,56 (t, 2H, J= 5,0 Hz) ; 5,23 (t, 1H, J= 7,2 Hz) ; 5,26 (s, 2H) ; 6,65 (s, 1H) ; 6,73 (s, 1H) ; 6,83 (d, 1H, J = 16,2 Hz) ; 6,86 (s, 1H) ; 6,87 (s, 1H) ; 6,93 (d, 1H, J= 16,2 Hz) ; 7,77 (s, 1H) ; 13C NMR (125 MHz, CDC13) : <5 (ppm) = 14,3 ; 17,9 ; 19,9 ; 22,6 ; 23,2 ; 25,4 ; 25,8 ; 26,7 ; 27,4 ; 28,3 ; 29,5 ; 32,5 ; 37,7 ; 38,4 ; 45,0 ; 46,8 ; 50,4 ; 56,1 ; 62,9 ; 69,5 ; 70,0 ; 70,7 ; 71,3 ; 77,1 ; 78,1 ; 103,0 ; 107,0 ; 107,1 ; 115,0 ; 120,6 ; 121,9 ; 122,7 ; 123,7 ; 126,0 ; 128,7 ; 128,8 ; 134,3 ; 137,1 ; 142,8 ; 144,4 ; 149,0 ; 155,6 ; 156,8 ; HRMS (ESI): m / z cale, pour C 43H61C1N3O7+[M+H]+ 766.4193; trouvé 766.4217. COMPOSITIONS PHARMACEUTIQUES
[0376] The present invention also relates to a pharmaceutical composition comprising at least one compound of formula (I) as defined according to the invention and at least one pharmaceutically acceptable excipient.
[0377] By way of example, it may comprise an amount of compounds of formula (I) as defined in the invention ranging from 0.05% to 10% by weight, in particular from 0.1% to 5% by weight, relative to the total weight of the composition.
[0378] The composition according to the invention further comprises at least one pharmaceutically acceptable excipient.
[0379] This excipient may be solid or liquid. It may be chosen, for example, from purified water, ethyl alcohol, propylene glycol, glycerin, vegetable oils, animal oils, hydrocarbons, silicones, sugars such as glucose, levulose, wheat starch, corn starch, potato starch, cyclodextrins, xanthan gum, pectins, alginates, magnesium stearate, gelatin, cellulose and its derivatives.
[0380] The composition of the invention may be administered by any suitable route, for example orally, rectally, locally (topically, for example), intraperitoneally, systemically, intravenously, intramuscularly, subcutaneously or mucosally, in particular sublingually, or by using a patch, or in the form encapsulated in, or immobilized on, liposomes, microparticles, microcapsules, associated with nanoparticles and the like.
[0381] The excipients suitable for the present invention may be any excipient conventionally used in the therapeutic field.
[0382] Non-limiting examples of excipients suitable for oral administration include talc, lactose, starch and its derivatives, cellulose and its derivatives, polyethylene glycols, acrylic acid polymers, gelatin, magnesium stearate, animal, vegetable or synthetic fats, paraffin derivatives, glycols, stabilizers, preservatives, antioxidants, wetting agents, anti-caking agents, dispersants, emulsifiers, taste modifying agents, penetration agents, solubilizing agents. For example, to prepare an aqueous solution for intravenous injection, a cosolvent such as an alcohol such as ethanol or a glycol such as polyethylene glycol or propylene glycol may be used. According to another example, to prepare an oily solution for intramuscular injection, at least one compound of formula (I) may be solubilized using a triglyceride or a glycerol ester.
[0383] The pharmaceutical composition may thus comprise one or more pharmaceutically acceptable diluents, carriers, excipients, fillers, binders, lubricants, glidants, disintegrants, absorbents and / or preservatives.
[0384] Techniques for formulating and administering drugs and pharmaceutical compositions are well known in the art herein to those skilled in the art.
[0385] According to the invention, the composition can advantageously be administered orally or by intravenous injection.
[0386] A therapeutically effective dose for the pharmaceutical compositions according to the invention is determined by standard clinical techniques according to the judgment of the physician.
[0387] Advantageously, the composition according to the invention is suitable for being administered orally or intravenously at a dose equal to or greater than 1 mg / kg / 24h and equal to or less than 200 mg / kg / 24h in one or more doses to a mammal having such a need.
[0388] Thus, the compounds of formula (I) of the invention may be used at doses of between 0.01 mg and 5,000 mg per day, given in a single dose once a day or administered in several doses throughout the day, for example twice a day in equal doses. The dose administered per day is advantageously between 5 mg and 2,500 mg, even more advantageously between 10 mg and 1,000 mg.
[0389] Suitable oral administration forms include tablets, capsules, powders, granules, syrups, and oral solutions or suspensions.
[0390] For parenteral administration, aqueous suspensions, isotonic saline solutions or sterile, injectable solutions which contain pharmaceutically acceptable and compatible dispersing agents and / or wetting agents may be used.
[0391] According to a particular embodiment, the pharmaceutical composition as defined in the present invention may further comprise another active ingredient, useful in particular in the treatment and / or prevention of neurodegenerative diseases, viral diseases, dyslipidemia, hypercholesterolemia and / or cancers.
[0392] Thus, the present invention also relates to a pharmaceutical preparation which comprises a pharmaceutical composition according to the invention, and, in addition, in admixture or packaged separately, at least one antiviral agent and / or an anticancer agent and / or an agent effective against neurodegenerative diseases, and / or an agent effective against dyslipidemia, and / or an agent effective against hypercholesterolemia for their use in treating and / or preventing and / or inhibiting infections caused by pathogenic agents such as viruses, cancers, neurodegenerative diseases, hypercholesterolemia and dyslipidemia, administered simultaneously, sequenced or spaced out in time. THERAPEUTIC APPLICATIONS
[0393] As mentioned above, the present invention relates to a compound of formula (I) according to the invention or a pharmaceutical composition according to the invention for use as a medicament, and in particular for its use for preventing and / or treating and / or inhibiting cancers, neurodegenerative diseases, dyslipidemia, hypercholesterolemia and / or viral diseases.
[0394] The compound of formula (I) as defined in the present invention makes it possible to inhibit OSBP (Oxysterol-binding protein), a protein responsible for the intracellular transfer of cholesterol.
[0395] According to a particular embodiment, the cancers are selected from breast cancer, including triple negative breast cancer, kidney cancer, head and neck cancer, prostate cancer, colorectal cancer, colon cancer, gallbladder cancer, bile duct cancer (cholangiocarcinoma), gastrointestinal cancer, gastric cancer, hepatocellular carcinoma, lymphoma, lung cancer, small cell lung cancer, non-small cell lung cancer, pancreatic cancer, pancreatic carcinoma, stomach cancer, brain cancer, metastases, leukemia, T-cell acute lymphoblastic leukemia, chronic myeloid leukemia, melanoma, and glioblastoma, in particular kidney cancer, triple negative breast cancer, melanoma, leukemia and glioblastoma.
[0396] Glioblastoma or glioblastoma multiforme (GBM), also known as grade 4 astrocytoma, is the most common and aggressive brain tumor.
[0397] According to another particular embodiment, the neurodegenerative diseases are chosen from amyotrophic lateral sclerosis (ALS or Charcot's disease), Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease (Huntington's chorea), and Niemann-Pick disease type C, especially Alzheimer's disease, Parkinson's disease, Huntington's disease (Huntington's chorea), and Niemann-Pick disease type C.
[0398] In the present invention, viral diseases are understood to mean any disease, benign or serious, caused by a virus.
[0399] According to one embodiment of the invention, the viral diseases targeted by the compounds of the invention are caused by RNA viruses.
[0400] According to an even more particular embodiment, a viral infection with an RNA virus is understood more particularly in the context of the present invention to mean a viral infection caused by a virus belonging to group III (double-stranded RNA virus (dsRNA)), group IV (positive-polarity single-stranded RNA virus: RNA with (+) polarity), group V (negative-polarity single-stranded RNA virus: RNA with (-) polarity) or group VI (single-stranded RNA retrovirus: RNA with (+) polarity with intermediate DNA in the life cycle).
[0401] According to this classification, viruses belonging to group VI are not, strictly speaking, RNA viruses. A well-studied example of a family of viruses belonging to group VI is the Retroviridae family (retroviruses) which includes HIV.
[0402] As representatives of viruses belonging to group III, we can cite Reoviridae and Birnaviridae.
[0403] As a representative of viruses belonging to group IV, we can cite Picor-naviridae (which is a family of viruses that includes well-known viruses such as hepatitis A virus, enteroviruses, rhinoviruses, poliovirus and foot-and-mouth disease virus), SARS virus, hepatitis C virus, yellow fever virus and rubella virus. The Togaviridae family also belongs to group IV and a known genus of it is alphavirus, encompassing the Chikungunya virus. Flaviridae is also a family belonging to group IV, encompassing a famous mosquito-borne virus, namely the Dengue virus or the Zika virus.An acute respiratory illness has recently been caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), also referred to herein as coronavirus disease 2019 (COVID-19), which belongs to the Coronaviridae and is part of group IV of the Baltimore classification.
[0404] Representatives of viruses belonging to group V include the Filoviridae family of viruses including the Ebola virus, the Paramyxoviridae family including the respiratory syncytial virus (RSV), the Rhabdoviridae family, the Ortho-myxoviridae family including influenza virus A, influenza virus B and influenza C. Measles is also caused by a group V virus of the paramyxovirus family.
[0405] According to another embodiment of the invention, the viral diseases targeted by the The compounds of the invention are infections caused by RNA viruses of classes IV and V of the Baltimore classification. Viral angina can be caused by different viruses such as rhinoviruses, coronaviruses, respiratory syncytial virus (RSV), influenza virus and parainfluenza virus.
[0406] According to yet another particular embodiment, the viral diseases targeted by the compounds of the invention are chosen from dengue fever, Zika virus infection, influenza, viral angina, measles, AIDS, Chikungunya, yellow fever, poliomyelitis, hepatitis A, hepatitis C, hepatitis E, SARS-CoV virus infection, SARS-CoV-2 virus infection, and rubella, in particular dengue fever, Zika virus infection, chikungunya, yellow fever, poliomyelitis, hepatitis A, hepatitis C, hepatitis E, SARS-CoV virus infection, SARS-CoV-2 virus infection and rubella.
[0407] Thus, according to a particularly preferred embodiment, the viral diseases are in particular those caused by a Baltimore Class IV (+)-stranded RNA virus such as dengue fever, Zika virus infection, chikungunya, yellow fever, poliomyelitis, hepatitis A, hepatitis C, hepatitis E, SARS-CoV virus infection, SARS-CoV-2 virus infection, and rubella.
[0408] Other viral infections, not caused by RNA viruses, may also be targeted within the scope of the present invention, such as chickenpox.
[0409] As already mentioned above, a compound of formula (I) as defined in the invention can be administered alone or in combination with other active ingredients which can act in synergy with the compound of formula (I).
[0410] Furthermore, other treatment techniques may be combined with the treatment carried out via the administration of a pharmaceutical composition according to the invention or of a medicament comprising at least one compound of formula (I).
[0411] For example, when the pathology concerned is cancer, it is possible to combine radiotherapy, possibly coupled with chemotherapy, with other active ingredients initially, then to continue the treatment as monotherapy by administering a pharmaceutical composition according to the invention or a medicament comprising at least one compound of formula (I).
[0412] The present invention also relates to a method for administering at least one compound of formula (I) as defined in the invention to a subject in need thereof, comprising: - Provide a pharmaceutical composition comprising at least one compound of formula (I) as defined in the invention, and at least one pharmaceutically acceptable excipient; and - Administer the pharmaceutical composition in an effective amount to a subject in need thereof.
[0413] According to other embodiments, the present invention relates to methods of administration, in particular by oral or intravenous route, of a pharmaceutical composition according to the invention comprising at least one compound of formula (I) as defined in the invention and an additional active ingredient.
[0414] A “subject” (including a patient) includes mammals (e.g., humans, domestic pets, farm animals, or laboratory animals).
[0415] According to another aspect, the present invention relates to the use of at least one compound of formula (I) as defined in the invention or of a pharmaceutical composition according to the invention for the preparation of a medicament.
[0416] According to another aspect, the present invention relates to the use of at least one compound of formula (I) as defined in the invention or of a pharmaceutical composition according to the invention for the preparation of a medicament for treating and / or preventing and / or inhibiting cancers, neurodegenerative diseases, dyslipidemia, hypercholesterolemia, and / or viral diseases.
[0417] According to yet another aspect, the present invention relates to a method of treating and / or preventing and / or inhibiting cancers, neurodegenerative diseases, dyslipidemia, hypercholesterolemia, and / or viral diseases, comprising administering to a subject in need thereof a pharmaceutical composition according to the invention comprising at least one compound of formula (I) as defined in the present invention.
[0418] According to yet another aspect, the present invention relates to a method of treating and / or preventing and / or inhibiting cancers, neurodegenerative diseases, dyslipidemia, hypercholesterolemia, and / or viral diseases, comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound of formula (I) as defined in the present invention.
[0419] Throughout the description, including the claims, the expression "comprising a" must be understood as being synonymous with "comprising at least one", unless otherwise specified. The expressions "between ... and ..." and "ranging from ... to ..." must be understood inclusively, unless otherwise specified.
[0420] In the description and examples, temperature is expressed in degrees Celsius unless otherwise indicated, and pressure is atmospheric pressure unless otherwise indicated. Example MATERIALS AND METHODS
[0421] Proton nuclear resonance spectra (1H NMR) are recorded in deuterated CDC13 or CD3CN on a Bruker Avance device (300 MHz or 500 MHz). Chemical shifts (δ) are expressed in parts per million (ppm) relative to the undeuterated solvent residue. Coupling constants (J) are in Hertz (Hz). For signal multiplicity, the following abbreviations are used: s (singlet), d (doublet), t (triplet), dd (doublet of doublet), dt (doublet of triplet), td (triplet of doublet), q (quadruplet), m (multiplet).
[0422] Carbon magnetic resonance spectra (13C NMR) are recorded on a Bruker Avance device (75 or 125 MHz), chemical shifts are expressed in ppm relative to the solvents used.
[0423] High resolution mass spectra (HRMS) are obtained on a Waters LCT Premier XE spectrometer in ESI (electrospray ionization) mode.
[0424] Flash chromatography purifications are performed on a Teledyne Isco Combiflash Rf 200i with GraceResolv pre-packaged silica cartridges.
[0425] When necessary, organic solvents are dried or distilled before use and stored on molecular sieves under argon.
[0426] Example 1: Preparation of (2R,4aR,9aR)-5-hydroxy-7-((E )-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexah ydro-l / / -xanthen-2-yl formate - compound (1)
[0427] Compound (1) is a prodrug of compound (2).
[0428] SW-G (150 mg, 0.32 mmol), di-palladium(O) tris(dibenzylideneacetone) (Pd2 dba3: 6 mg, 0.006 mmol, 0.02 eq), sodium acetate (NaOAc: 8 mg, 0.096 mmol, 0.3 eq) are dissolved in formic acid (1 ml) and placed under an argon atmosphere. The mixture is stirred at room temperature for 18 h and then poured into a separating funnel. Dichloromethane (DCM: 2 ml) is added and the organic phase is decanted, washed successively with water (2 times), a saturated solution of sodium hydrogen carbonate (NaHCO3) and then sodium chloride (NaCl). The organic phase is dried over magnesium sulfate (MgSO4) and concentrated under reduced pressure. The reaction crude is purified by flash chromatography on a silica column (solvent: heptane / ethyl acetate: 2 / 8) to give compound (1) in the form of a brown oil (80 mg, 55%).
[0429] Example 2: Preparation of (2R,4aR,9aR)-7-((E )-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexah ydro-177-xanthene-2,5-diol - compound (2)
[0430] To a solution of (2R,4aR,9aR)-5-hydroxy-7-((E )-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexah ydro-177-xanthen-2-yl formate (compound (1): 61 mg, 0.12 mmol) in tetrahydrofuran (THF: 1 ml), an aqueous solution (0.2 ml) of lithium hydroxide monohydrate (LiOH.H2O: 13 mg, 0.31 mmol, 2.5 eq) is added. The resulting brown solution is stirred at room temperature for 1 hour and then 1 ml of an IN solution of hydrochloric acid (HCl) is added. The reaction medium is extracted three times with ethyl acetate (AcOEt). The organic phases are combined, dried over MgSO4 and concentrated under reduced pressure. The reaction crude is purified by preparative silica plates using a heptane / AcOEt (4 / 6) eluent to give compound (2) in the form of a yellow oil (36 mg, 62%).
[0431] Example 3: Preparation of (2R,4aR,9aR )-5-hydroxy-7-(2-(5-hydroxy-2,2-dimethylchroman-7-yl)ethyl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-2-yl formate - compound (9)
[0432] Compound (9) is a prodrug of compound (10)
[0433] SW-G (500 mg, 1.08 mmol), di-palladium(O) tris(dibenzylideneacetone) (Pd2 dba3: 19 mg, 0.02 mmol, 0.02 eq), sodium acetate (NaOAc: 26 mg, 0.32 mmol, 0.3 eq) are dissolved in formic acid (3.3 ml) and placed under an argon atmosphere. The mixture is stirred at room temperature for 24 hours and then poured into a separating funnel. Dichloromethane (DCM: 2 ml) is added and the organic phase is decanted, washed successively with water (2 times), a saturated solution of sodium bicarbonate (NaHCO3) and then sodium chloride (NaCl). The organic phase is dried over magnesium sulfate (MgSO4) and concentrated under reduced pressure. The reaction crude is purified by flash chromatography on a silica column (solvent: heptane / ethyl acetate: 2 / 8) to give compound (1) in the form of a brown oil (204 mg, 38%) as well as compound (9) (73 mg, 13%).
[0434] Example 4: Preparation of (2R,4aR,9aR )-7-(2-(5-hydroxy-2,2-dimethylchroman-7-yl)ethyl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hex ahydro-l / / -xanthene-2,5-diol - compound (10)
[0435] To a solution of (2R,4aR,9aR)-5-hydroxy-7-(2-(5-hydroxy-2,2-dimethylchroman-7-yl)ethyl)-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-1H-xanthen-2-yl formate (compound (9): 25 mg, 0.051 mmol) in tetrahydrofuran (THF: 0.4 ml), an aqueous solution (0.1 ml) of lithium hydroxide monohydrate (LiOH.H2O: 5 mg, 0.13 mmol, 2.5 eq) is added. The resulting brown solution is stirred at room temperature for 1 hour and then 1 ml of a 1N hydrochloric acid (HCl) solution is added. The reaction medium is extracted three times with ethyl acetate (AcOEt). The organic phases are combined, dried over MgSO4 and concentrated under reduced pressure. The reaction crude is purified by preparative silica heptane / AcOEt (3 / 7) plates to give compound (10) as a yellow oil (12 mg, 49%).
[0436] Example 5: Preparation of 5-((£')-2-((7aR,9R,l laR )-9-hydroxy-8,8,l la-trimethyl-2,7,7a,8,9,10,l 1,1 la-octahydropyrano[3,2-c]xanthen-5-yl)vinyl)-2-(3-methylbut-2-en-l-yl)benzene-l,3-diol - compound (22)
[0437] To a solution of 5-((^)-2-((27^,4aR,9aR )-2-hydroxy-l,l,4a-trimethyl-5-(prop-2-yn-l-yloxy)-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-7-yl)vinyl)-2-(3-methylbut-2-en-l-yl)benzene-l,3-diol (compound (20): 97 mg, 0.19 mmol, 1 eq) in anhydrous dichloromethane (CH2Cl2: 5 mL), is added ror(I)-[bis(trifluoromethanesulfonyl)imidate](triphenylphosphme) (PPh3AuNtf2: 3 mg, 0.002 mmol, 0.01 eq). The resulting orange solution is stirred under argon at room temperature for 2 hours and then concentrated under reduced pressure. The reaction crude is purified by preparative silica heptane / acetone (1 / 1) plates to give compound (22) as a yellow oil (37 mg, 37%).
[0438] Example 6: Preparation of the (2R,4aR,9aR)-6-allyl-7-((E)-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-l,l,4a-tri methyl-2,3,4,4a,9,9a-hexahydro-lH-xanthene-2,5-diol - compound (24)
[0439] A solution of 5-((E)-2-((2R,4aR,9aR)-5-(allyloxy)-2-hydroxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahy dro-lH-xanthen-7-yl)vinyl)-2-(3-methylbut-2-en-l-yl)benzene-l,3-diol (compound (25): 35 mg, 0.07 mmol) in anhydrous dimethylformamide (DMF: 0.8 ml) is heated at 150 °C for 10 hours and then concentrated under reduced pressure. The reaction crude is purified directly by preparative silica heptane / AcOEt (3 / 7) plates to give compound (24) as a yellow oil (11 mg, 32%).
[0440] Example 7: Preparation of the (2R,4aR,9aR)-6-allyl-7-((E)-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-hydrox yl,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-2-yl acetate - compound (26)
[0441] Compound (26) is a prodrug of compound (24)
[0442] A solution of (2R,4aR,9aR)-5-(allyloxy)-7-((£' )-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexah ydro-l / / -xanthen-2-yl acetate (compound (27): 35 mg, 0.07 mmol) in anhydrous dimethylformamide (DMF: 0.8 ml) is heated at 150 °C for 10 hours and then concentrated under reduced pressure. The crude reaction product is purified directly by preparative silica heptane / AcOEt (3 / 7) plates to give compound (26) as a yellow oil (11 mg, 30%).
[0443] Example 8: Preparation of (25,3R,4aR,9aR)-7-((E )-2-bromo-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-methoxy-l,l,4a-trimethyl -2,3,4,4a,9,9a-hexahydro-l / / -xanthene-2,3-diol - compound (30)
[0444] SW-E (34 mg, 0.069 mmol) and N-bromosuccinimide (NBS: 12 mg, 0.65 mmol, 0.95 eq) in solution in dimethyl sulfoxide (DMSO: 1 ml) are stirred for 3 hours at 50 °C. The crude reaction product is cooled to room temperature and poured into a separating funnel. After adding a saturated solution of sodium hydrogen carbonate (NaHCO3), the mixture is extracted four times with ethyl acetate (AcOEt). The organic phases are combined, dried over MgSO4 and concentrated under reduced pressure. The reaction crude is purified by preparative silica heptane / AcOEt (3 / 7) plates to give compound (30) in the form of a yellow oil (8 mg, 21%).
[0445] Example 9: Preparation of (27?,4aR,9a7?)-7-((E )-3-Hydroxy-4-(3-methylbut-2-en-l-yl)-5-(prop-2-yn-l-yloxy)styryl)-5-methoxy-l,l,4 a-trimethyl-2,3,4,4a,9,9a-hexahydro- 17Exanthen-2-ol (31)
[0446] NaH (32 mg, 0.82 mmol) is added portionwise to a solution of SW-F (96 mg, 0.20 mmol) in anhydrous DMF (2 mL) at 0 °C. After stirring for 20 minutes, propargyl bromide (20 μL, 0.22 mmol) is added. The reaction mixture is stirred at room temperature for 18 h before adding an aqueous solution of NH4Cl (10 mL). The reaction mixture is extracted three times with ethyl acetate (AcOEt). The organic phases are combined, dried over MgSO4 and concentrated under reduced pressure. The crude reaction product is purified by reverse-phase silica chromatography (H2O / acetonitrile gradient 8 / 2 to 0 / 1) to give the desired compound 31 as a brown oil (28 mg, 26%).
[0447] Example 10: Preparation of (2E,4aE,9aE)-7-((E )-3-((l-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethyl)-l / / -l,2,3-triazol-4-yl)methoxy)-5-hyd roxy-4-(3-methylbut-2-en-l-yl)styryl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexah ydro-177-xanthen-2-ol (56)
[0448] To a solution of (2E,4aE,9aE)-7-((E )-3-Hydroxy-4-(3-methylbut-2-en-l-yl)-5-(prop-2-yn-l-yloxy)styryl)-5-methoxy-l,l,4 a-trimethyl-2,3,4,4a,9,9a-hexahydro-l / / -xanthen-2-ol (compound 31: 28 mg, 0.054 mmol) in acetonitrile (1 mL) at room temperature are successively added l-[2-(2-azidoethoxy)ethoxy]-6-chlorohexane (14 mg, 0.056 mmol), CuSO4.5 H2O (22 mg, 0.089 mmol), sodium ascorbate (47 mg, 0.24 mmol), DABCO (13 mg, 0.12 mmol) and acetic acid (6 pL, 0.11 mmol). The reaction medium is stirred at room temperature for 18 h before adding an aqueous solution of NH4Cl (10 mL). The reaction medium is extracted three times with ethyl acetate (AcOEt). The organic phases are combined, dried over MgSO4 and concentrated under reduced pressure. The crude reaction product is purified by flash chromatography on a silica column (heptane / AcOEt gradient 6 / 4 to 2 / 8) to give the desired compound 56 in the form of a pale yellow oil (21 mg, 51%).
[0449] Example 11: Biological activity
[0450] The inhibitory biological activities of oxysterol binding protein 1 (OSBP) as well as the cytotoxic activity on two cell lines, U87 and A549 were measured. MATERIAL AND METHOD
[0451] Measurement of OSBP inhibitory activity is performed by a robotic test on the purified ORD domain of the OSBP protein. The measurements are carried out according to a protocol using two liposome preparations: - Donor liposomes (A) contain a fluorescent sterol (DHE); - Acceptor liposomes (B) contain a fluorescent lipid (dansyl PE) whose excitation spectrum overlaps the emission spectrum of DHE.
[0452] The transport of DHE from liposomes A to liposomes B catalyzed by the ORD domain is accompanied by a FRET signal between DHE and Dansyl-PE. Thanks to this signal, the transport kinetics can be measured in real time. This fluorescence measurement is carried out in a microplate on a TECAN Infinité 1000 Pro device (temperature = 37 °C). Initially, each measuring well contains liposomes B (130 pM), the ORD domain (200 nM) and the compound to be tested. At time t = 5 min, liposomes A (130 pM) are added to start the exchange reaction. Each compound is tested in triplicate for final concentrations of 50 nM to 3 pM. The time constant (k) obtained for each kinetic is then represented as a function of the concentration of the analogue. From this representation, an inhibition constant is determined for each compound. The Ki affinity constants are classified as follows: - Very high affinity Ki < 1 nM - Good affinity Ki from 1 to 100 nM - Low affinity Ki from 100 to 2000 nM - Very low affinity Ki > 2000 nM
[0453] Compounds, other than prodrugs, having a Ki < 100 nM are considered active on OSBP.
[0454] U87-MG and A549 lines were obtained from the American Type Culture Collection (Rockville, MD, USA) and were cultured according to the supplier's instructions. U87-MG human glioblastoma cells were cultured in Dulbecco's minimal essential medium (DMEM) containing 10% FCS and 1% L-glutamine. A549 lung cancer cells were cultured in RPMH640 medium containing 10% FCS and 1% L-glutamine. Cell lines were maintained at 37°C in a humidified atmosphere containing 5% CO2. Products were tested at 10 concentrations in triplicate and cell viability was assessed after 72h of treatment using the CellTiter Glo assay (Promega) which measures the number of live cells by luminescence (ATP quantification).
[0455] Thus, the cells were seeded in 96-well plates (2.5 x 103 cells / well) each containing 90 pL of growth medium. After 24 hours of culture, the wells were supplemented with 10 pL of medium containing ten decreasing concentrations of the test compound dissolved in DMSO (less than 0.1% in each preparation). After 72 h of incubation, 100 pL of Cell Titer GLo reagent was added for 15 min before quantifying the emitted luminescence using a mi crop plates. The dose-response curve was analyzed using Graph Prism software and the activity of the molecules is expressed as IC50. RESULTS
[0456] The results are shown in the table below. The same measurements were carried out on Schweinfurthine G, indicated SW-G in the table below.
[0457] [Tables3] Ex OSBP Affinity (nM) IC50 (nM) U87 A549 SW-G Ki <l 15 391 (1) 100 < Ki < 2000 5 90 (2) Ki < 1 nM 14 900 (3) 100 < Ki < 2000 107 / (4) 1 < Ki < 100 425 / (5) 100<Ki< 2000 380 2421 (6) 1 < Ki < 100 478 2533 (7) 100<Ki< 2000 304 2147 (8) 1 < Ki < 100 47 1095 (9) Ki>2000 67 3040 (10) Ki < 1 nM 76 3910 (H) Ki>2000 1170 / (12) 1 < Ki < 100 2259 / (13) Ki>2000 122 / (14) Ki>2007 (10) 09 146,901 (16) Ki>2000 71,363 (17) 100 <Ki< 2000 / / (18) 1 < Ki < 100 107 2401 (19) 1 < Ki < 100 9 1684 (20) 1 < Ki < 100 286 3901 (21) 100<Ki< 2000 501 6223 (22) 1 < Ki < 100 482 10000 (23) Ki>2000 157 382 (24) 1 < Ki < 100 66 2855 (25) 1 < Ki < 100 420 5000 (26) 100 <Ki< 2000 742 4459 (27) 1 < Ki < 100 49 2783 (28) ND but 100 <Ki< 2000 théo 7 7142 (29) ND 71,5 363 (30) ND 50 313 (31) ND 214 1059 (32) ND 32 1111 (33) ND 1943 > 10,000 (34) ND 296 2902 (35) ND 44 618 (36) ND 96 335 (37) ND 34 178 (38) ND 358 850 (39) ND 933 > 10,000 (40) ND 641 2182 (41) ND 90 302 (42) ND 31 168 (43) ND 522 645 (44) ND 244 1296 (45) ND 55 572 (46) ND 49 429 (47) ND 2820 > 10,000 (48) ND 117 1186 (49) ND 26 267 (50) NA 7 171 (51) ND 174 645 (52) ND 356 2157 (53) ND 100 148 (54) ND 35 194 (55) ND 4 577 (56) ND 4 30
[0458] As these results show, the compounds according to the invention have a oxysterol-binding protein 1 (OSBP) inhibitory activity.
[0459] It appears that certain compounds included in the general formula (I) are metabolites of other compounds included in the same general formula (I) as defined according to the present invention. This situation is identifiable for the pair of compounds (1) and (2), for which compound (2) is the metabolite of compound (1), or for the pair of compounds (9) and (10), for which compound (10) is the metabolite of compound (9).
[0460] Evaluation of plasma stability and microsomal stability.
[0461] Plasma stability and hepatic microsome stability tests were carried out on SW-G, compounds (1), (2), (5), (6), (9) and (10) according to the invention. Protocols
[0462] The compounds are placed in mouse plasma and mouse microsomes, and their stability is assessed by UPLC-MS / MS monitoring.
[0463] For plasma stability, the concentration tested is 2.5 pM and the incubation volume is 50 pL. The incubation times are 0, 15, 30, 45, 60 and 120 minutes. Protein precipitation is then performed on the samples, and the latter are analyzed by UPLC-MS / MS. The remaining percentage of the compound and its elimination half-life are thus obtained.
[0464] For metabolic stability in microsomes, the concentration of the test compound is 2.5 pM, and the incubation volume is 400 pL. The concentration in mouse microsomes is 0.5 mg / mL. The incubation times are 0, 15, 30 and 45 minutes. The cofactor used is NADPH. Two negative controls are performed, one without microsomes and without cofactor at 0 and 45 minutes, and one without cofactor and with microsome at 0 and 45 minutes. A positive control is performed in the presence of diphenhydramine. The samples are analyzed by LC-MS / MS. The intrinsic clearance and half-life are thus obtained.
[0465] LC-MS / MS is performed on an AcquityTM UPLC coupled with a XEVO TQ-S (WATERS). Liquid chromatography is performed on an Acquity UPLC BEH 1.7 pm, 2.1x50 mm column with a 4-minute gradient of water + 0.1% formic acid / acetonitrile + 0.1% formic acid 90:10 to 0:100. The column temperature is + 50 °C and the injector temperature is + 4 °C. Mass spectrometry acquisition is performed by MRM (Multiple Reaction Monitoring), with positive electrospray ionization.
[0466] Intrinsic clearance is considered high if it is > 48 pL / min / mg of protein and low if it is < 8.8 pL / min / mg of protein. Results
[0467] Metabolic stability in mouse plasma at 120 minutes of SW-G is 100%, its metabolic stability in mouse microsomes is 100% and its clearance in microsomal medium is 90 pL / min / mg of protein.
[0468] The metabolic stability in mouse plasma at 120 minutes of compound 1 according to the invention is 20%, its metabolic stability in mouse microsomes is 16% and its clearance in microsomal medium is 120 pL / min / mg of protein. This compound is transformed into compound (2) according to the invention. Compound (1) is a prodrug of compound (2).
[0469] The metabolic stability in mouse plasma at 120 minutes of the compound (2) according to the invention is 100%, its metabolic stability in mouse microsomes is 100% and its clearance in microsomal medium is 32 pL / min / mg of protein.
[0470] The metabolic stability in mouse plasma at 120 minutes of compound (5) according to the invention is 1%, its metabolic stability in mouse microsomes is 30% and its clearance in microsomal medium is 74 pL / min / mg of protein. This compound is transformed into compound (6) according to the invention. Compound (5) is a prodrug of compound (6).
[0471] The metabolic stability in mouse plasma at 120 minutes of the compound (6) according to the invention is 100%, its metabolic stability in mouse microsomes is 100% and its clearance in microsomal medium is 40 pL / min / mg of protein.
[0472] The metabolic stability in mouse plasma at 120 minutes of the compound (9) according to the invention is 0%, its metabolic stability in mouse microsomes is 4% and its clearance in microsomal medium is 396 pL / min / mg of protein.
[0473] The metabolic stability in mouse plasma at 120 minutes of the compound (10) according to the invention is 90%, its metabolic stability in mouse microsomes is 99% and its clearance in microsomal medium is 98 pL / min / mg of protein.
[0474] It emerges from these results that certain compounds of formula (I) according to the invention are stable in plasma and for the most part exhibit good microsomal stability, more particularly for those whose clearance is less than 50. In particular, certain compounds of formula (I) according to the invention have a clearance better than that of SW G.
[0475] It is clear from all the biological tests set out above that the compounds of formula (I) according to the invention are useful as OSBP (Oxysterol-binding protein) inhibitors and can in particular be used as medicaments, in particular for the prevention, inhibition and / or treatment of cancers, neurodegenerative diseases, alcohol addiction, atherosclerosis, type 2 diabetes, dyslipidemia, hypercholesterolemia, autosomal dominant non-syndromic hearing loss, infertility, hypertension, and / or viral diseases.< / s>
Claims
Claims
1. Compound of formula (I), its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures: (I) in which: represents a single or double bond, - R1 represents a hydroxy group, a (Ci-C5)alkoxy group, a (C2-C5)alkenyloxy group, a (C2-C5)alkynyloxy group, or a group -OCONH(CH2)nCOORa, in which n represents an integer between 2 and 6, and Ra represents a (Ci-C4)alkyl group, - R2 represents a hydrogen atom or a (C2-C5)alkenyl group, or alternatively, R1 and R2 together form, with the cycle which carries them, a 6-membered cycle comprising an oxygen atom and optionally an unsaturation, - R3 and R7 independently represent a hydrogen atom or a halogen atom, for example a bromine atom, - R4 represents a hydroxy group, a group m being equal to 1, 2 or 3, a group , n being equal to 1, 2 or 3, preferably 1 or 2, a group GOLD" , in which R is a hydrogen atom or a methyl group and R' and R” are independently a (Ci-C3)alkyl group, a group , in which s is 0, 1 or 2, t is 1, 2 or 3, p is 2 or 3, q is 1, 2, 3, 4, 5 or 6, preferably 6, and X is a hydrogen atom, halogen, in particular a chlorine atom, or an amine group, or a group -OCORb, in which Rb represents a (Ci-C4)alkyl group, - R5 represents a group of formula or alternatively, R4 and R5 together form, with the ring which carries them, a 6-membered ring comprising an oxygen atom and optionally substituted by one or two (Ci-C4)alkyl groups, - R6 represents a hydroxy group, a (Ci-C6)alkoxy group, a group , m being equal to 1, 2 or 3, a group , n being equal to 1, 2 or 3, preferably 1 or 2, a group Or , in which R is a hydrogen atom or a methyl group and R' and R” are independently a (Ci-C3)alkyl group, a group , in which s is 0, 1 or 2, t is 1, 2 or 3, p is 2 or 3, q is 1, 2, 3, 4, 5 or 6, preferably 6, and X is a hydrogen atom, halogen atom, in particular a chlorine atom, or an amine group, a group -OCORc, in which Rc represents a (Ci-C4)alkyl group, or a group -OCONH(CO)pRd, in which p represents an integer chosen from 0 or 1, Rd represents a (Ci-C6)alkyl group optionally substituted by a halogen atom, such as a chlorine atom, by a sugar radical, by a group -COORe, in which Re represents a (Ci-C4)alkyl group or a hydrogen atom or by a group -OP(=O)-(ORf)(ORg), in which Rf and Rg independently represent a (Ci-C4)alkyl group, - R8 and R9 independently represent a hydrogen atom, a hydroxy group, or a group -OCORh, in which Rh represents a hydrogen atom or a (Ci-C5)alkyl group, and in which at least: a. R4 and R5 together form, with the ring which carries them, a 6-membered ring comprising an oxygen atom and optionally substituted by one or two (CrC4)alkyl groups, or b. R5 represents a group of formula and at least one of the following conditions is true: i. R1 and R2 together form, with the ring which carries them, a 6-membered ring comprising an oxygen atom and optionally an unsaturation, ii. at least one of R1, R4 and R6 is a (C2-C5)alkenyloxy group or a (C2-C5)alkynyloxy group, iii. R8 represents a group -OCORh, in which Rh represents a hydrogen atom or a (C1-C5)alkyl group, iv. R2 represents a (C2-C5)alkenyl group, or v. at least one of R3 and R7 is a halogen atom, excluding the following compound
2. Compound of formula (I) according to claim 1, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R1 represents a hydroxy group, a methoxy group, a -OCONH(CH2)nCOORa group, in which n is equal to 3, 4 or 5, in particular is equal to 3 or 5, and Ra represents a methyl or ethyl group, in particular ethyl, a propenyloxy group, or a propynyloxy group.
3. Compound of formula (I) according to claim 1 or 2, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R2 represents a hydrogen atom or a (C2-C5)alkenyl group, such as an allyl group.
4. Compound of formula (I) according to claim 1, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R1 and R2 together form, with the cycle which carries them, a 6-membered cycle comprising an oxygen atom and an unsaturation, in particular a group
5. Compound of formula (I) according to any one of claims 1 to 4, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, stereoisomers, mixtures of stereoisomers, pure enantiomers and racemic or non-racemic mixtures, in which R4 represents a hydroxy group, a group —O CH , m being equal to 1 or 3, a group —CH; CH , n being equal to 1 or 2, a group RO R'O GOLD Or HO GOLD , in which R is a hydrogen atom or a methyl group and R' and R” are methyl groups, a group ; in which s is equal to 0, 1 or 2, t is equal to 1 or 3, p is equal to 2 or 3, q is 6, and X is a halogen atom, specifically a chlorine atom, or a -OCOCH3 group. ^Claim 6] Compound of formula (I) according to any one of claims 1 to 5, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R5 represents a group of formula ^Claim 7] Compound of formula (I) according to any one of claims 1 to 4, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R4 and R5 together form, with the ring which carries them, a 6-membered ring comprising an oxygen atom, and optionally substituted by one or two methyl groups,in particular a group ^Claim 8] Compound of formula (I) according to any one of claims 1 to 7, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R6 represents a hydroxy group, a methoxy or ethoxy group, a group —DH C__-CH , m being equal to 1 or 3, a group, , n being equal to 1 or 2 a group AJ RO V -NO2 "v GOLD' Or , wherein R is a hydrogen atom or a methyl group and R' and R” are methyl groups, an -OCOCH3 group, an -OCONHCOCH2C1 group, or a group -OCONH(CH2)qCOORk, in which q represents an integer chosen from 3, 4 or 5, in particular 3 and 5, and Rk represents a methyl or ethyl group, in particular ethyl.
9. Compound of formula (I) according to any one of claims 1 to 8, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R8 and R9 independently represent a hydrogen atom, a hydroxy group, an -OCHO group, or an -OCOCH3 group.
10. A compound of formula (I) according to any one of the preceding claims, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, represented by the formula (Ia): in which: represents a single or double bond, - R3 and R7 are as defined in claim 1, and more particularly represent a hydrogen atom, - R1 represents a hydroxy group, a (Ci-C5)alkoxy group, a (C2-C5)alkenyloxy group, a (C2-C5)alkynyloxy group, or a group -OCONH(CH2)nCOORa, in which n represents an integer between 2 and 6, and Ra represents a (Ci-C4)alkyl group, - R2 represents a hydrogen atom or a (C2-C5)alkenyl group, or alternatively, R1 and R2 together form, with the cycle which carries them, a 6-membered cycle comprising an oxygen atom and optionally an unsaturation, - R6 represents a hydroxy group, a (Ci-C6)alkoxy group, a (C2-C5)alkynyloxy group, a group -OCORc, in which Rc represents a (Ci-C4)alkyl group, or a group -OCONH(CO)pRd, in which p represents a chosen integer among 0 or 1, Rd represents a (Ci-C6)alkyl group optionally by a halogen atom, such as a chlorine atom, by a sugar radical, by a -COORe group, in which Re represents a (CrC4)alkyl group or a hydrogen atom or by a -OP(=O)-(ORf)(ORg) group, in which Rf and Rg independently represent a (CrC4)alkyl group, and - R8 and R9 independently represent a hydrogen atom, a hydroxy group, or a -OCORh group, in which Rh represents a hydrogen atom or a (Ci-C5)alkyl group.
11. Compound of formula (Ia) according to the preceding claim, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which R1 and R2 are as defined respectively in claims 2 and 3 or R1 and R2 are as defined in claim 4, R6 is as defined in claim 8 and R8 and R9 are as defined in claim 9.
12. Compound of formula (I) as defined in any one of claims 1 to 9, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, represented by formula (Ib) (Ib) in which represents a single or double bond, in particular a double bond, - R1 represents a hydroxy group, a (Ci-C5)alkoxy group, a (C2-C5)alkenyloxy group, a (C2-C5)alkynyloxy group, or a group -OCONH(CH2)nCOORa, in which n represents an integer between 2 and 6, and Ra represents a (Ci-C4)alkyl group, - R2 represents a hydrogen atom or a (C2-C5)alkenyl group, such as an allyl group, or alternatively, R1 and R2 together form, with the cycle which carries them, a 6-membered cycle comprising an oxygen atom and optionally an unsaturation, - R3 and R7 independently represent a hydrogen atom or a halogen atom, for example a bromine atom, - R4 represents a hydroxy group, a group —O -^CH xcSEr.CH , m being equal to 1, 2 or 3, a group , n being equal to 1, 2 or 3, preferably 1 or 2, a group Or ,.0 CR' , in which R is a hydrogen atom or a methyl group and R' and R” are independently a (Ci-C3)alkyl group, a group , in which s is 0, 1 or 2, t is 1, 2 or 3, p is 2 or 3, q is 1, 2, 3, 4, 5 or 6, preferably 6, and X is a hydrogen atom, halogen, in particular a chlorine atom, or an amine group, or a group -OCORb, in which Rb represents a (Ci-C4)alkyl group, - R6 represents a hydroxy group, a (Ci-C6)alkoxy group, a (C2-C5)alkynyloxy group, a group —OHH , m being equal to 1, 2 or 3, a group , n being equal to 1, 2 or 3, preferably 1 or 2, a group CS' , in which R is a hydrogen atom or a methyl group and R' and R” are independently a (Ci-C3)alkyl group, a group , in which s is 0, 1 or 2, t is 1, 2 or 3, p is 2 or 3, q is 1, 2, 3, 4, 5 or 6, preferably 6, and X is a hydrogen or halogen atom, in particular a chlorine atom, or an amine group, Or a group -OCORc, in which Rc represents a (Ci-C4)alkyl group, or a group -OCONH(CO)pRd, in which p represents an integer chosen from 0 or 1, Rd represents a (Ci-C6)alkyl group optionally substituted by a halogen atom, such as a chlorine atom, by a sugar radical, by a group -COORe, in which Re represents a (Ci-C4)alkyl group or a hydrogen atom or by a group -OP(=O)-(ORf)(ORg), in which Rf and Rg independently represent a (Ci-C4)alkyl group, and - R8 and R9 independently represent a hydrogen atom, a hydroxy group, or a group -OCORh, in which Rh represents a hydrogen atom or a (Ci-C5)alkyl group, and in which at least one of the following conditions is satisfied: i. R1 and R2 together form, with the ring which carries them, a 6-membered ring comprising an oxygen atom and optionally unsaturation, ii. at least one of R1, R4 and R6 is a (C2-C5)alkenyloxy group or a (C2-C5)alkynyloxy group, iii. R8 represents a group -OCORh, in which Rh represents a hydrogen atom or a (Ci-C5)alkyl group, iv. R2 represents a (C2-C5)alkenyl group, or v. at least one of R3 and R7 is a halogen atom.
13. Compounds of formula (Ib) according to the preceding claim, their pharmaceutically acceptable salts, their hydrates, their solvates, as well as their tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, in which represents a double bond, - R1 and R2 are as defined respectively in claims 2 and 3 or R1 and R2 are as defined in claim 4, - R4 is as defined in claim 5, - R6 is as defined in claim 8, and represents in particular a hydroxy group, a methoxy or ethoxy group, a -OCOCH3 group, a group , m being equal to 1 or 3, a group , n being equal to 1 or 2, or a group Or , in which R is a hydrogen atom or a methyl group and R' and R” are methyl groups, - R8 and R9 are as defined in claim 9.
14. Compound of formula (I) according to any one of the preceding claims, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, the stereoisomers, the mixtures of stereoisomers, the pure enantiomers and the racemic or non-racemic mixtures, chosen from: -(1): (2R,4aR,9aR)-5-hydroxy-7-((E)-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-1H-xanthen-2-yl formate, -(2): (2R,4aR,9aR)-7-((E)-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-l, l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthene-2,5-diol, -(3): (7aR,9R,llaR)-5-((E)-2-(5-hydroxy-2,2-dimethylchroman-7-yl)vinyl)-8 ,8,1 la-trimethyl-2,7,7a,8,9,10,l 1,1 la-octahydropyrano[3,2-c]xanthen-9-yl formate, -(4): (7aR,9R,llaR)-5-((E)-2-(5-hydroxy-2,2-diméthylchroman-7-yl)vinyl)-8,8,1 la-triméthyl-2,7,7a,8,9,10,l 1,1 la-octahydropyrano[3,2-c]xanthèn-9-ol, -(5): (2R,4aR,9aR)-7-((E)-2-(5-hydroxy-2,2-diméthylchroman-7-yl)vinyl)-5-méthoxy-1,1,4a-triméthyl-2,3,4,4a,9,9a-hexahydro- lH-xanthèn-2-yl formate, -(6): (2R,4aR,9aR)-7-((E)-2-(5-hydroxy-2,2-diméthylchroman-7-yl)vinyl)-5-méthoxy-l,l,4a-triméthyl-2,3,4,4a,9,9a-hexahydro-lH-xanthèn-2-ol, -(7): (2S,3R,4aR,9aR)-7-((E)-2-(5-hydroxy-2,2-diméthylchroman-7-yl)vinyl)-5-méthoxy-l,l,4a-triméthyl-2,3,4,4a,9,9a-hexahydro-lH-xanthène-2,3- diyl diformate, -(8): (2S,3R,4aR,9aR)-7-((E)-2-(5-hydroxy-2,2-diméthylchroman-7-yl)vinyl) -5-méthoxy-l,l,4a-triméthyl-2,3,4,4a,9,9a-hexaliydro-lH-xarithèrie-2,3-diol, -(9): (2R,4aR,9aR)-5-hydroxy-7-(2-(5-hydroxy-2,2-dimethylchroman-7-yl)et hyl)-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydro- lH-xanthèn-2-yl formate, - (10): (2R,4aR,9aR)-7-(2-(5-hydroxy-2,2-diméthylchroman-7-yl)éthyl)-l,l,4a-triméthyl-2,3,4,4a,9,9a-hexahydro-lH-xanthène-2,5-diol, -(H): (2R,4aR,9aR)-7-(2-(5-hydroxy-2,2-diméthylchroman-7-yl)éthyl)-5-mét hoxy-l,l,4a-triméthyl-2,3,4,4a,9,9a-hexahydro-lH-xanthèn-2-yl formate, - (12) : (2R,4aR,9aR)-7-(2-(5-hydroxy-2,2-diméthylchroman-7-yl)éthyl)-5-mét hoxy-l,l,4a-triméthyl-2,3,4,4a,9,9a-hexahydro-lH-xanthèn-2-ol, -(13): (2R,4aR,9aR)-7-((E)-2-(5-(((2-chloroacetyl)carbamoyl)oxy)-2,2-diméth ylchroman-7-yl)vinyl)-5-méthoxy-l,l,4a-triméthyl-2,3,4,4a,9,9a-hexahy dro-lH-xanthèn-2-yl formate, - (14) : Ethyl 6-(((((2R,4aR,9aR)-7-((E)-2-(5-(((6-éthoxy-6-oxohexyl)carbamoyl)oxy) -2,2-diméthylchroman-7-yl) vinyl)-2-(formyloxy)-1,1,4a-triméthyl-2,3,4, 4a,9,9a-hexahydro-lH-xanthèn-5-yl)oxy)carbonyl)amino)hexanoate, - (15) : Ethyl 4-((((2R,4aR,9aR)-7-((E)-2-(5-(((4-ethoxy-4-oxobutyl)carbamoyl)oxy) -2,2-dimethylchroman-7-yl) vinyl)-2-(formyloxy)-1,4,4-a-trimé 4a,9,9a-hexahydro-lH-xanthene-5-yl)oxy)carbonyl)amino)butanoate, -(16): (2R,4aR,9aR)-7-((E)-2-(5-((((2-chloroacetyl)carbamoyl)oxy)-2,2-dimeth ylchroman-7-yl)vinyl)-5-hydroxy-l,l,4a-trimethyl-2,3-droèa-nhex-9,9, format, -(17): (2R,4aR,9aR)-l,l,4a-trimethyl-7-((E)-4-(3-methylbut-2-en-l-yl)-3,5-bis (prop-2-yn-l-yloxy)styryl)-2,3,4,4a,9,9a-hexathohydrodine-l-lH- -(18): (2R,4aR,9aR)-7-((E)-3-hydroxy-4-(3-methylbut-2-en-l-yl)-5-(prop-2-yn -l-yloxy)styryl)-l,l,4a-trimethyl-5-(prop-2-yn-l-a,3hydroxy,9,4)-2 lH-xanthene-2-ol, -(19): (2R,4aR,9aR)-7-((E)-3-hydroxy-4-(3-methylbut-2-en-l-yl)-5-(prop-2-yn -l-yloxy)styryl)-l,l,4a-trimethyl-2,3,4,4a-9,9,9a-diol,2hydro-hexatho,5 -(20): 5-((E)-2-((2R,4aR,9aR)-2-hydroxy-1,1,4a-trimethyl-5-(prop-2-yn-1 -ylo xy)-2,3,4,4a,9,9a-hexahydro-lH-xanthen-7-thyl)(32-mél)-2 -yl)benzene-1,3-diol, - (21): (2R,4aR,9aR)-l,l,4a-trimethyl-7-((E)-4-(3-methylbut-2-en-l-yl)-3,5-bis (prop-2-yn-l-yloxy)styryl)-5-(prop-2-yn-l-yloxy,9)-a 2,3,4a lH-xanthene-2-ol, -(22): 5-((E)-2-((7aR,9R,llaR)-9-hydroxy-8,8,lla-trimethyl-2,7,7a,8,9,10,ll, lla-octahydropyrano[3,2-c]xanthen-5-yl)vinyl)-2-(3)-benzèl-diylbut-2 -(23): 5-((E)-2-((2R,4aR,9aR)-2-acetoxy-5-methoxy-l,l,4a-trimethyl-2,3,4,4a, 9,9a-hexahydro-lH-xanthene-7-yl)vinyl)-2-(3-ethyl,nethyl-phyl-2-2 diacetate, -(24): (2R,4aR,9aR)-6-allyl-7-((E)-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)st yryl)-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH,-2,5-xanthene-5) 5-((E)-2-((2R,4aR,9aR)-5-(allyloxy)-2-hydroxy-l,l,4a-trimethyl-2,3,4,4 a,9,9a-hexahydro-lH-xanthen-7-yl)vinyl)-2-(3-methylbut-2-en-l-yl)ben zene-l,3-diol, -(26): (2R,4aR,9aR)-6-allyl-7-((E)-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)st yryl)-5-hydroxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-2-yl acetate, -(27): (2R,4aR,9aR)-5-(allyloxy)-7-((E)-3,5-dihydroxy-4-(3-methylbut-2-en-l -yl)styryl)-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-2-yl acetate, -(28): (2R,4aR,9aR)-7-((E)-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-hydroxy-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-2-yl formate, -(29): (2S,3R,4aR,9aR)-7-((E)-2,6-dibromo-3,5-dihydroxy-4-(3-methylbut-2-e nl-yl)styryl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthene-2,3-diol, -(30): (2S,3R,4aR,9aR)-7-((E)-2-bromo-3,5-dihydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthene-2,3-diol, -(31): (2R,4aR,9aR)-7-((E)-3-Hydroxy-4-(3-methylbut-2-en-l-yl)-5-(prop-2-y nl-yloxy)styryl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-2-ol, -(32): (2S,3R,4aR,9aR)-7-((E)-3-Hydroxy-4-(3-methylbut-2-en-l-yl)-5-(prop-2-yn-1 -yloxy)styryl)-5-methoxy-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahyd ro-lH-xanthene-2,3-diol, - (33): Methyl 2-(4,5-dimethoxy-2-nitrophenyl)-2-(5-((E)-2-((2R,4aR)-2-hydroxy-5-m ethoxy-1,1,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-7-yl)vinyl )-2-(3-methylbut-2-en-l-yl)-3-(prop-2-yn-l-yloxy)phenoxy)acetate, - (34): Methyl 2-(5-((E)-2-((2S,3R,4aR)-2,3-dihydroxy-5-methoxy-l,l,4a-trimethyl-2, 3,4,4a,9,9a-hexahydro-lH-xanthene-7-yl)vinyl)-2--(2-yl-methyl)vinyl )-3-(prop-2-yn-l-yloxy)phenoxy)-2-(4,5-dimethoxy-2-nitrophenyl)aceta for, - (35) : Acid 2-(5-((E)-2-((2S,3R,4aR)-2,3-Dihydroxy-5-methoxy-l,l,4a-trimethyl-2, 3,4,4a,9,9a-hexahydro-lH-xanthene-7-yl)vinyl)-2--(3-yl-methyl)vinyl )-3-(prop-2-yn-l-yloxy)phenoxy)-2-(4,5-dimethoxy-2-nitrophenyl)aceti que, -(36): (2R,4aR,9aR)-5-methoxy-1,1,4a-trimethyl-7-((E)-4-(3-methylbut-2-en-1 -yl)-3,5-bis(prop-2-yn-l-yloxy)styryl)-2,3,4,4a-Hxanthoxy-9,9a-he hen-2-ol, -(37): (2S,3R,4aR,9aR)-5-Methoxy-1,1,4a-trimethyl-7-((E)-4-(3-methylbut-2-en-l-yl)-3 ,5-bis(prop-2-yn-l-yloxy)styryl)-2,3,4,4a,9,9a-hexahydro-lH-xanthène-2,3-diol, -(38): (2R,4aR,9aR)-7-((E)-3-Hydroxy-4-(3-methylbut-2-en-l-yl)-5-(pent-4-y nl-yloxy)styryl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4-a-hexathol-9,9,9 -(39): (2R,4aR,9aR)-5-Methoxy-1,1,4a-trimethyl-7-((E)-4-(3-methylbut-2-en-l-yl)-3,5-bis(pent-4-yn-l-yloxy)styryl)-2,3,4,4a-Hxaol,9,hydroèn-hel-he -(40): (2R,4aR,9aR)-7-((E)-3-Hydroxy-4-(3-methylbut-2-en-l-yl)-5-(2-(prop-2-yn-l-yloxy)ethoxy)styryl)-5-methoxy-l,l,4a-trimethyl,9o-ah ex,9,4,4 lH-xanthene-2-ol, - (41): (2R,4aR,9aR)-5-Methoxy-1,1,4a-trimethyl-7-((E)-4-(3-methylbut-2-en-l-yl)-3,5-bis(2-(prop-2-yn-l-yloxy)ethoxy)styryl)-2,3,4,4,4-a lH-xanthene-2-ol, -(42): (2R,4aR,9aR)-7-((E)-3-hydroxy-4-(3-methylbut-2-en-l-yl)-5-(2-(2-(pro p-2-yn-l-yloxy)ethoxy)ethoxy)styryl)-5-methoxy-l,l,4a-trimethyl,4 ,4a,9,9a-hexahydro-lH-xanthene-2-ol, -(43): (2R,4aR,9aR)-5-Methoxy-1,1,4a-trimethyl-7-((E)-4-(3-methylbut-2-en-l-yl)-3,5-bis(2-(2-(prop-2-yn-l-yloxy)ethoxy)ethoxy)styryl)-2,3,4,4a,9, 9a-hexahydro-lH-xanthen-2-ol, - (44): Methyl 2-(5-((E)-2-((2S,3R,4aR)-2,3-dihydroxy-5-methoxy-l,l,4a-trimethyl-2, 3,4,4a,9,9a-hexahydro-lH-xanthen-7-yl)vinyl)-3-hydroxy-2-(3-methylb ut-2-en-l-yl)phenoxy)-2-(4,5-dimethoxy-2-nitrophenyl)acetate, - (45): Acid 2-(5-((E)-2-((2S,3R,4aR)-2,3-Dihydroxy-5-methoxy-l,l,4a-trimethyl-2, 3,4,4a,9,9a-hexahydro-lH-xanthen-7-yl)vinyl)-3-hydroxy-2-(3-methylb ut-2-en-l-yl)phenoxy)-2-(4,5-dimethoxy-2-nitrophenyl)acetic acid, -(46): (2S,3R,4aR)-7-((E)-3-((4,5-Dimethoxy-2-nitrobenzyl)oxy)-5-hydroxy-4 -(3-methylbut-2-en-1 -yl)styryl)-5-methoxy-1,1,4a-trimethyl-2,3,4,4a,9,9 a-hexahydro-lH-xanthene-2,3-diol, - (47): Dimethyl 2,2' -((5-((E)-2-((2S,3R,4aR,9aR)-2,3-dihydroxy-5-methoxy-1,1,4a-trim ethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-7-yl)vinyl)-2-(3-methylbut-2 -en-l-yl)-l,3-phenylene)bis(oxy))bis(2-(4,5-dimethoxy-2-nitrophenyl)ac etate, - (48): Acid 2,2'-((5-((E)-2-((2S,3R,4aR,9aR)-2,3-Dihydroxy-5-methoxy-1,1,4a-trim ethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-7-yl)vinyl)-2-(3-methylbut-2 -en-l-yl)-l,3-phenylene)bis(oxy))bis(2-(4,5-dimethoxy-2-nitrophenyl)ac etic - (49): Acid 2-(3-((l-(2-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethoxy)ethyl)-lH-l,2,3-triazol-4-yl)methoxy)-5-((E)-2-((2S,3R,4aR)-2,3-dihydroxy-5-methoxy-l, l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-7-yl)vinyl)-2-(3-m ethylbut-2-en-l-yl)phenoxy)-2-(4,5-dimethoxy-2-nitrophenyl)acetic acid, -(50): (2S,3R,4aR)-7-((E)-3-((l-(2-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethoxy)ethyl)-lH-l,2,3-triazol-4-yl)methoxy)-5-hydroxy-4-(3-methylbut-2-en-l -yl)styryl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xan thene-2,3-diol, -(51): (2R,4aR,9aR)-7-((E)-3-(3-(l-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethyl)-l Hl,2,3-triazol-4-yl)propoxy)-5-hydroxy-4-(3-methylbut-2-en-l-yl)styr yl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-2-ol, -(52): (2R,4aR,9aR)-7-((E)-3-(2-((l-(2-(2-(2-((6-Chlorohexyl)oxy)ethoxy)etho xy)ethyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)-5-hydroxy-4-(3-methyl lbut-2-en-l-yl)styryl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahy dro- lH-xanthen-2-ol, -(53): (2R,4aR,9aR)-7-((E)-3-(2-((l-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)-5-hydroxy-4-(3-methylbut-2-en-l-yl)styryl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xa nthen-2-ol, -(54): (2R,4aR,9aR)-7-((E)-3-(2-(2-((l-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-lH-l,2,3-triazol-4-yl)methoxy)ethoxy)ethoxy)-5-hydroxy-4-(3-methyl lbut-2-en-l-yl)styryl)-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahy dro- lH-xanthen-2-ol, -(55): (2R,4aS,9aS)-7-((E)-3-((l-(2-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethoxy)ethyl)-lH-l,2,3-triazol-4-yl)methoxy)-5-hydroxy-4-(3-methylbut-2-en-l -yl)styryl)-5-methoxy-1,1,4a-trimethyl-1,2,3,4,4a,9,9a, 10-octahydroanth racèn-2-ol, -(56): (2R,4aR,9aR)-7-((E)-3-((l-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethyl)-lH -l,2,3-triazol-4-yl)methoxy)-5-hydroxy-4-(3-methylbut-2-en-l-yl)styryl )-5-methoxy-l,l,4a-trimethyl-2,3,4,4a,9,9a-hexahydro-lH-xanthen-2-ol, and more particularly chosen from compounds (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (16), (24), (26), (29), (30), (50), (55) and (56).
15. A synthetic process for the preparation of a compound of formula (Ia”) (there"), in which R1 and R6 are as defined in claim 1, 2 and 8 and at least one of R8 and R9 represents a -OCORh group as defined in claim 1, and in particular a -OCHO group or a -OCOCH3 group, and in which R2 is a hydrogen atom, or any of its pharmaceutically acceptable salts, comprising at least one step of intramolecular cyclization of the geranyl chain into pyran, of a compound of general formula (II), accompanied by the esterification of the secondary alcohol of the hexahydroxanthene unit (II) , in which R1, R6 and R8 are as defined above, or a compound of formula (Ibiv)
16. (Ibiv) in which R1, R2, R4, R6, R8 and R9 are as defined above, in particular in the presence of a catalyst, in particular in the presence of a palladium catalyst and in particular in the presence of a base which may be chosen from sodium acetate, sodium formate or sodium tetraborate and mixtures thereof, preferably sodium acetate, optionally followed by a step of saponification of the ester function of the hexahydroxanthene unit, to lead to the compounds of general formula (Ia”), in which at least one of the groups R1, R6, R8 or R9 is a hydroxy group. Intermediate compounds of formula (III)
17.
18. in which Rh, R9 and R6 are as defined in claim 1. Pharmaceutical composition comprising at least one compound of formula (I) as defined in any one of claims 1 to 13, at least one compound as defined in claim 14, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, the mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures, and at least one pharmaceutically acceptable excipient. Compound of formula (I) as defined in claims 1 to 13 or at least one compound as defined in claim 14, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, the mixtures of its ste- reisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures or pharmaceutical composition according to claim 17 for its use as a medicament.
19. Compound of formula (I) as defined in claims 1 to 13 or at least one compound as defined in claim 14, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, the mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures or pharmaceutical composition according to claim 17, for its use as an inhibitor of oxysterol binding protein 1 (OSBP).
20. Compound of formula (I) as defined in claims 1 to 13 or at least one compound as defined in claim 14, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, the mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures or pharmaceutical composition according to claim 17, for use according to claim 19 for the prevention, inhibition and / or treatment of cancers, neurodegenerative diseases, dyslipidemia, hypercholesterolemia, and / or viral diseases.
21. Compound of formula (I) as defined in claims 1 to 13 or at least one compound as defined in claim 14, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, the mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures or pharmaceutical composition according to claim 17, for its use according to the preceding claim, the neurodegenerative diseases being chosen from amyotrophic lateral sclerosis (ALS or Charcot's disease), Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease (Huntington's chorea), and Niemann-Pick type C disease, in particular Alzheimer's disease, Parkinson's disease, Huntington's disease (Huntington's chorea), and Niemann-Pick type C disease.
22. Compound of formula (I) as defined in claims 1 to 13 or at least one compound as defined in claim 14, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures or pharmaceutical composition according to claim 17, for its use according to claim 19, the cancers being chosen from breast cancer, the cancers being chosen from breast cancer including triple negative breast cancer, kidney cancer, head and neck cancer, prostate cancer, colorectal cancer, colon cancer, gallbladder cancer, bile duct cancer (cholangiocarcinoma), gastrointestinal cancer, gastric cancer, hepatocellular carcinoma, lymphoma, lung cancer, small cell lung cancer, non-small cell lung cancer, pancreatic cancer, pancreatic carcinoma, stomach cancer, brain cancer, metastases, leukemia, leukemia acute lymphoblastic T-cell, chronic myeloid leukemia, melanoma,and glioblastoma, especially kidney cancer, triple negative breast cancer, melanoma, leukemia, and glioblastoma.
23. Compound of formula (I) as defined according to any one of claims 1 to 13 or at least one compound as defined in claim 14, its pharmaceutically acceptable salts, its hydrates, its solvates, as well as its tautomeric forms, its stereoisomers, the mixtures of its stereoisomers, its pure enantiomers and its racemic or non-racemic mixtures or its mixtures or pharmaceutical composition according to claim 17, for use according to claim 19, the viral diseases being chosen from viral infections caused by RNA viruses, even more particularly infections caused by RNA viruses of classes IV and V of the Baltimore classification, and even more particularly chosen from dengue fever, Zika virus infection, influenza, viral angina, measles, AIDS, Chi-kungunya, yellow fever, poliomyelitis, hepatitis A, hepatitis C, hepatitis E, SARS-CoV virus infection,SARS-CoV-2 virus infection, and rubella, especially dengue, Zika virus infection, Chikungunya, yellow fever, polio, hepatitis A, hepatitis C, hepatitis E, SARS-CoV virus infection, SARS-CoV-2 virus infection and rubella.,
